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The phosphine-triggered organic transformations have become a practical and 
powerful tool in organic chemistry. The unique reactivity of organophosphines, 
compared to their amine counterparts, has led to the discovery of a variety of novel 
reactions. This thesis describes the development of novel threonine-derived phosphine 
organocatalysts and their applications in MoritaBaylisHillman reaction and 
enantioselective [3+2] cycloadditions. 
Chapter 1 presented a brief introduction of nucleophilic phosphine catalysis and 
a series of phosphine-promoted enantioselective organic reactions. Selected examples 
illustrating recent advances in this research field were also presented. 
In Chapter 2, a highly enantioselective MoritaBaylisHillman (MBH) reaction 
of acrylates with aromatic aldehydes using L-threonine-derived bifunctional 
phosphinethiourea catalysts was described. The mechanistic aspects of the reaction 
were also discussed. 
In Chapter 3, the development of a new family of dipeptide-based chiral 
phosphines was presented. Such catalysts were applied to the asymmetric [3+2] 
cycloaddition of allenoates to -substituted acrylates, yielding functionalized 
cyclopentenes with quaternary stereogenic centers in high yields and with excellent 
enantioselectivities. 
In Chapter 4, acrylamides derived from 3,5-dimethyl-1H-pyrazole were utilized 
in the asymmetric [3+2] cycloaddition with the allenoate catalyzed by dipeptide-
derived phosphines.  
In Chapter 5, a highly enantioselective [3+2] annulation of aliphatic or aromatic 
imines with allenoates was realized by employing threonine-based dipeptidic 
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phosphines as catalysts. Highly enantioselective 2-alkyl/aryl-substituted 3-pyrrolines 
could be generated in short reaction times and with low catalyst loadings. Moreover, 
synthetic value of this method was demonstrated by using imineallene annulation as 
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Chapter 1 Nucleophilic Phosphine Organocatalysis 
 
1.1 Introduction 
Nucleophilic catalysis refers to the acceleration of chemical reaction by utilizing 
a nucleophilic compound, which is involved in the rapid formation of a low-energy 
covalent intermediate, and does not end up in the reaction product. The nucleophilic 
catalyst enhances the reactivity of a reactant through donation of its electron pair to an 
electrophile reactant other than a proton. Moreover, nucleophilicity of a nucleophilic 
catalyst is closely related to the polarizability of the nucleophilic atom, and is also 
very sensitive to steric hindrance.  
Nucleophilic catalysis plays an important role in organic synthesis. Numerous 
Lewis bases, such as tertiary phosphines, pyridines, 4-dimethylaminopyridine 
(DMAP), N-heterocyclic carbenes (NHCs), have been employed as nucleophilic 
catalysts in a wide array of organic reactions. These compounds accelerate a broad 
spectrum of reactions, including rearrangement of O-acylated enolates,1 isomerization 
of alkynes to dienes,2 acylation of alcohols by anhydrides3 and addition of alcohols to 
ketones.4  
Organophosphorus compounds have been widely used in synthetic organic 
chemistry for more than a century. The well-known applications include Wittig 
reaction, Mitsunobu and Staudinger reactions, furthermore, phosphines are commonly 
employed ligands in transition metal-mediated processes.5 However, the most 
significant important developments in nucleophilic phosphine catalysis only emerged 
in the last two decades. The triphenylphosphine and its derivatives, which are 
commercially available or easily accessible, can be directly used as organocatalysts in 




groups.6 As compared to similarly substituted amines, phosphines are generally less 
basic and more nucleophilic, which consequently contribute to their divergent 
catalytic behaviors and unique properties in organic processes. The reaction cycles of 
phosphine-promoted processes start from the formation of the phosphonium ylide-
type intermediates through donation of the non-bonded phosphorus lone pair of 
electrons to eletronphilic species, such as activated alkynes and olefins.  The resultant 
ylide intermediates undergo subsequent coupling reactions with the other reaction 
partners, such as olefins, imines and aldehydes, affording a variety of highly 
functionalized molecular frameworks. The relevant examples are 
MoritaBaylisHillman-type reactions,7 the isomerization of alkynes to dienes,8 the 
nucleophilic additions of alkynes,9 the Rauhut-Currier reactions10 and the 



















































Scheme 1.1 Selective examples of phosphine-promoted organic reactions 
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The catalytic ability of organophosphorus compounds can be attributed primarily 
to their pronounced nucleophilicity and the exceptional stability of the phosphonium 
enolate zwitterions. There are several important features of phosphine organocatalysis: 
(1) the nucleophilicity of phosphines are easily tunable by simply varying the 
substitutents (alkyl or aryl) on the phosphorus atom; (2) modification of chiral 
phosphine backbones could result in asymmetric induction; (3) the availability of 
many known phosphine ligands makes the catalyst development more readily; (4) 
most phosphine compounds are not only cheap and stable, but also completely free 
from contamination as compared with some metal catalysts, which is an especially 
attractive feature for industrial synthesis.12 
Asymmetric organocatalysis has been growing rapidly in the past decade, and 
has been established as an important tool in the preparation of chiral molecules. 
Despite the importance of tertiary phosphines in organocatalysis, it was only till the 
late 1990s that Vedejs and co-workers reported the first enantioselective example 
utilizing phosphine- catalysts,13 in which they showed the effectiveness of cyclic 
phosphines in the asymmetric acylations. Shortly after, Zhang et al. disclosed the 
highly enantioselective  [3+2] cycloaddition between allenoates and acrylates 
catalyzed by a bicyclic chiral phosphine.14 Since then, phosphine-mediated 
nucleophilic catalysis has attracted much attention from synthetic community and 
became an intensively investigated research area. In the following sections, recent 
development in this field will be discussed in detail. 
 
1.2 Phosphine-Promoted Enantioselective Organic Reactions 
In this section, several types of asymmetric organic reactions promoted by chiral 




allowed the discovery of the Michael-type addition of activated alkenes and alkynes, 
enantioselective nucleophilic additions at the - or -position of unsaturated carbonyl 
compounds, as well as novel [3+2] and [4+2] cyclizations of electron-deficient allenes 
and alkynes. Additionally, the divergent phosphine catalyst has also made the 
acylation of secondary alcohol occurred in an enantioselective fashion.   
 
1.2.1 Morita–Baylis–Hillman (MBH) Reactions 
The origin of MoritaBaylisHillman (MBH) reaction dates back to 1968, when 
Morita and coworkers demonstrated that the reaction of acrylonitrile or methyl 
acrylate with various aldehydes under the catalytic influence of 
tricyclohexylphosphine (PCy3) led to densely functionalized products (Scheme 1.2).15 
In 1972, Baylis and Hillman disclosed a German patent describing the tertiary 
bicyclic amine-catalyzed CC bond formation of aldehydes (aliphatic, aromatic and 
,-unsaturated) with activated alkenes (acrylic esters, acrylonitriles, vinyl ketones, 




Scheme 1.2 Reactions embodied in patents by Morita, Baylis andHillman 
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The applications of the MBH reaction were very limited in the early days due to 
the low reaction rates and conversions, as well as the highly substrate-dependent 
nature of the MBH reaction. An important improvement in reaction efficiency was 
achieved by Kawanisi and coworkers by using cocatalysts tributylphosphine and 
triethylaluminum to promote the MBH reaction between ,-unsaturated carbonyl 
compounds and aldehydes.17 Even though the tertiary amine-catalyzed MBH reaction 
dominated in the 1980s, the value of phosphine-mediated MBH reaction were later 
recognized.18 
The intramolecular variant of the MBH reaction, which is an excellent strategy 
for the construction of the cyclic framework, has seen significant progress since the 
first report by Frater et al. in 1992.19 Further investigations resulted in the synthesis of 














n = 1, 2; X = S, O 33%-83% yield
n
 
Scheme 1.3 Interamolecular MoritaBalysiHillman reaction 
 
      The MBH reaction formally comprises a sequence of Michael addition, aldol 
reaction and -elimination, and the commonly accepted mechanism of MBH reaction 




addition of the nucleophilic catalyst to the ,-unsaturated carbonyl compound 1-8, 
generating the zwitterionic enolate 1-11 (step 1), which subsequently intercept the 
aldehyde or the acylimine 1-9 to afford the second zwitterionic intermediate 1-12 
(step 2). Following a proton migration from the -carbon atom to the -
alkoxide/amide (step 3), -elimination of the catalyst affords the MBH adduct 1-10 
(step 4).21 The detailed mechanistic studies were carried out and reported by the 
groups of Aggarwal22 and McQuade 23 in the past few years. 
 
 
Scheme 1.4 Proposed mechanism for the MBH reaction 
 
      Following the initial report by Morita, many new phosphine catalysts, including 
chiral ones, have been developed and widely applied in the enantioselective 
condensation of electron-deficient olefins with aldehydes and ketones in both inter- 
and intramolecular MBH reactions. The first significant advance in enantioselective 
variant was reported by Soai and co-workers in 1998.24 The intermolecular MBH 
reaction between methyl acrylate and pyrimidine-5-carbaldehyde could proceeded 
smoothly in the presence of 20 mol% (S)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl 
[(S)-BINAP] 1-16 (Scheme 1.5). The corresponding MBH adduct 1-17 was obtained 
Chapter 1 Nucleophilic Phosphine Organocatalysis 
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with up to 44% ee value. Later, a chiral hydroxyl phospholane 1-20 was prepared and 
used as a catalyst for the coupling of 4-pyridinecarboaldehyde and methyl acrylate. 
However, only 17% enantiomeric excess was obtained (Scheme 1.6).25  
 
 
Scheme 1.5 (S)-BINAP-catalyzed MBH reaction 
 
.  
Scheme 1.6 Phosphine-catalyzed asymmetric MBH reaction 
 
In 2003, Schaus and coworkers reported the successful use of chiral BINOL-
derived Brønsted acids 1-24 catalysts in coordination with triethylphosphine (1 eq.) in 
the asymmetric MBH reactions of cyclohexenone 1-22 with aldehydes 1-23 (Scheme 
1.7).26 Good to excellent enantioselectivities were achieved with aliphatic aldehydes, 
while the conjugated aldehydes such as benzaldehyde and cinnamaldehyde led to 




Brønsted acid was suggested to stabilize the phosphonium enolate formed in the 
Michael addition of triethylphosphine to cyclohexenone, while the hydrogen-bonding 
interaction between Lewis catalyst and reactant played an important role in the 
subsequent enantio-determining addition to the aldehyde. Catalysts with two 
hydrogen bonding partners are necessary for the higher level of enantioselectivity as 
the mono-O-methylated Lewis acid catalyst resulted in diminished catalytic activity, 























Y = CH3 or CF3
1-24  
Scheme 1.7 Brønsted-acid-catalyzed asymmetric MBH reactions 
 
Recently, a series of novel chiral bifunctional phosphine catalysts (1-291-31) 
were designed and synthesized by the Shi group. Lewis base catalyst 1-31 proved to 
be the most effective for the asymmetric MBH reaction of aldehydes with methyl 
vinyl ketone (MVK) and ethyl vinyl ketone (EVK), affording the corresponding 
products in good yields with moderate ee’s (Scheme 1.8).27 Wu and coworkers later 
reported that trans-2-amino-1-(diphenylphosphino)-cyclohexane-derived 
phosphino(thio)ureas 1-35 were highly effective for the MBH reaction between 
various aromatic aldehydes and MVK leading to the MBH adducts with excellent 
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enantiomeric excesses under mild conditions in relative short reaction time  (Scheme 
1.9).28 Further exploration was reported by the same group utilizing the L-valine-
derived phosphinothioureas (1-37, Scheme 1.9) in the reaction of aromatic aldehydes 
with acrylates. It was found that reaction with electron-rich arylaldehyde turned out to 
be more difficult resulted in complex reaction mixtures.29 
 
       
OH
PR1R2
R1 = Ph, Bu
R2 = Et, iPr, Bu, Cy, iBu
OH
PPhBu


















R3 = alkyl, aryl R4 = Me, Et 29-55% ee
 
Scheme 1.8 Bifunctional chiral phosphine-catalyzed asymmetric MBH reaction 









































As a modification to the traditional MBH reaction, the aza-
MortiaBaylisHillman (aza-MBH) reaction pioneered by Perlmutter and Teo30 
involves the coupling of electron-deficient alkenes with more reactive imines.31 The 
first phosphine catalyzed enantioselective variant was demonstrated by Shi in 2003. 
The best results were obtained using bifunctional phosphine catalyst 1-34 in the 
reaction of Ts-imines with activated alkenes.32 Products 1-41 were generally obtained 
with good to excellent enantioselectivity (Scheme 1.10). The mechanistic studies 
indicated the bifunctional activation mode of the catalyst the phosphine acting as a 
Lewis base to initiate the reaction, whereas the phenol serving as a Brønsted acid to 


















R1 = Ts, Ms, SES, 4-ClC6H4SO2




Scheme 1.10 Catalytic asymmetric aza-MBH reaction 
 
Over the past few years, various organophosphine catalysts have been developed 
and employed in aza-MBH reactions. These include phosphine bearing multiple 
phenol moieties, such as compound 1-4233, 1-43,34 and 1-44,35 phosphineamide 1-
45,36  phosphinesulfonamide 1-46,37 and phosphinethiourea 1-47 (scheme 1.11).37 
Aromatic imines and vinyl ketones are the most commonly explored substrates. 
Excellent enantioselectivities have been achieved in these and analogous aza-MBH 






Scheme 1.11 Selective phosphine catalysts in the aza-MBH reactions 
 
Our research group recently introduced a novel class of amino acid derived 
bifunctional phosphinesulfonamide catalysts 1-51 (Scheme 1.12).38 We 
demonstrated that these phosphine catalysts were highly effective for the 
enantioselective aza-MBH reactions of N-(p-methoxybenzene-sulfonyl)imines with 
acrylates. Excellent chemical yields (76-96%) and very high enantioselectivities (88-
97%) were attainable with 20 mol% phosphine catalyst 1-52 in a wide range of 
aromatic imines within 48 hours. Further mechanistic studies and the experimental 
observations suggested that the hydrogen bonding donor moiety of Brønsted acidic 
sulfonamide in the catalyst contributed significantly to the aza-MBH reaction and was 
crucial for the asymmetric induction. Employing N-methylated sulfonamide 
phosphine 1-53 as reaction catalyst resulted in the dramatically decreased 











R1 = TBS, TDS,
TBDPS, TIPS, TMS
















O 20 mol% 1-52






Scheme 1.12 Phosphinesulfonamide mediated enantioselective Aza-MBH 
reactions 
 
1.2.2 [3+2] Cycloaddition Reactions of Activated Allenes and Alkynes 
In 1995, Lu’s pioneering work on [3+2] cycloadditions of allenoates with ,-
unsaturated carbonyl compounds has established a novel synthetic approach to 
functionalized five-membered carbocycles from readily available starting materials.39  
It was found that the treatment of 2,3-butadienoate 1-54 with triphenyphosphine or 
more reactive tributylphosphine in the presence of the activated olefins such as ethyl 
acrylate 1-55 afforded the corresponding cycloadducts with good regioselectivity (～
4:1) and isolated combined yield (Scheme 1.13). Further attempted cycloaddition with 
diethyl fumarate 1-57 and diethyl maleate 1-59 succeeded with furnishing the single 
product trans-1-1-58 and cis-1-60 respectively (Scheme 1.14). In addition to allenoate 
esters, alkynyl esters were also shown to be suitable substrates for this annulation in 
the presence of 10 mol% tributylphosphine, while triphenylphosphine failed to 
catalyze the reaction even at a higher temperature (135 oC) for a long time (24 h) due 
to the respective weaker catalytic activity. 
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Scheme 1.13 [3+2] Cycloaddition between allenoate and ethyl acrylate 
 
 










The proposed mechanism for the [3+2] cycloaddition reaction stems from 
nucleophilic addition of the phosphine to the -carbon of the allenoate 1-54 (Scheme 
1.15). The generated zwitterionic enolate 1-61 or 1-61 will react with activated 
alkene to yield the cyclic intermediate 1-62 and 1-62, which are in equilibrium with 
1-63 and 1-63respectively. Following proton transfer and elimination, the 
regioisomeric cyclopentenes 1-64 and 1-64are formed 
The first enantioselective [3+2] cycloaddition of allenes with olefins was 
reported by Zhang shortly after Lu’s original disclosure.40 In this work, a variety of 
chiral mono- and bisphosphines were explored in the annulations between allenoates 
and acrylate substrates. Structurally rigid P-chiral phosphabicyclo[2.2.1]heptane 
catalyst 1-66 led to the formation of single regioisomer 1-67 in 88% yield and 93% ee 
in the reaction system of ethyl 2,3-butadienoate 1-54 with isobutyl acrylate 1-65 
(Scheme 1.16). Although high level of enantioselectivity was achieved in most cases, 




Scheme 1.16 Enantioselective [3+2] cycloaddition with acrylate 
 
Following Zhang’s work, Fu and coworkers revealed their findings with 
binaphthyl-based C2-symmetric chiral phosphine 1-69 in cyclizations reactions with 
allenoates 1-54 (Scheme 1.17).41 The scope of activated olefins was broadened to 
Chapter 1 Nucleophilic Phosphine Organocatalysis 
15 
 
include -substituted enones 1-68, and functionalized spirocyclic products 1-70 were 
obtained in high regioselectivity (up to > 20 :1) and enantiocontrol (up to 90% ee). 
 
 
Scheme 1.17 Enantioselective [3+2] cycloadditions with chalcones 
 
Subsequently, Cowen and Miller demonstrated that amino acid-derived chiral 
phosphineamide 1-74 could effectively induce the enantioselective variant of [3+2] 
cycloaddition of allenoate esters 1-73 with acyclic and cyclic enones 1-72 (Scheme 
1.18).42 Under optimized reaction conditions, this simple peptide-like chiral 
phosphine gave the products 1-75 as only -isomer in up to 95% isolated yield and 
93% ee. Notably, this reaction provides a new methodology for efficient construction 
of chiral cyclic and acyclic exomethylenes, even though a full equivalent of catalyst 
loading is required in the case of less reactive chalcones as coupling partners. A six-
membered cyclic transition state was considered, in which an intermolecular 
hydrogen bonding interactions were assumed to exist between the zwitterionic enolate 
intermediate and the NH group of the amide moiety in phosphine catalyst. 
Presumably due to the steric shielding of phenyl rings on the catalyst, the substrate 









































Scheme 1.18 Asymmetric [3+2] cycloaddition of allenoates and enones 
promoted by phosphineamide catalyst 
 
A report further expanding the range of chiral phosphines for enantioselective 
cycloadditon processes to the ferrocenophane derivatives was disclosed by Marinetti 
and coworkers in 2008.43 In their approach, a new class of chiral phosphines based on 
a planar chiral 2-phospha[3]ferrocenophane scaffold was synthesized and examined in 
the asymmetric [3+2] annulation of  ethyl 2,3-butadienoate with ,-unsaturated 
esters and ketones (Scheme 1.19). Two regioisomeric cycloadducts 1-77 and 1-77 
could be obtained from reactions of 1-54 with 1-68 in high yields (63-87%), regio- 
(up to >20 : 1), and enantioselectivities (87-96% ee). It should be noted that catalyst 
1-76 displays good good air-stability and ease of handling, even though the P-center is 
trialkylated. 
 





Scheme 1.19 2-Phospha[3]ferrocenophane-promoted enantioselective [3+2] 
cycloadditions of allenoates with ketones 
 
Usually, alkynes are regarded as less reactive coupling partners as compared to 
allenes containing the same electron-withdrawing substitutes. Loh et al. recently 
reported the direct applicability of 3-butynoates 1-78 in the [3+2] cycloaddition 
reaction of a series of electron-deficient enones 1-79 (Scheme 1.20).44 Commercially 
available chiral phosphine, (R,R)-DIPAMP 1-80 showed the best efficiency for the 
cycloaddition reaction, affording various cyclopentene derivatives 1-81 with high 
optical purities (81-99% ee). However, their methodology suffers from the high price 

















(R, R)-DIPAMP (10 mol%)











Very recently, the Zhao group extended the enantioselective [3+2] cycloaddition 
scope to the dual activated olefins 1-82.45 The cyclization reactions were performed 
well with allenoates and a variety of ,-disubstituted alkene in the presence of  
bifunctional N-acyl aminophosphine catalyst 1-83 (Scheme 1.21). The good 
accessibility of the catalyst, high yields (79-99%), good to excellent 
enantioselectivities (80-96%), and mild reaction conditions made their methodology a 
valuable complement to currently existing methods for accessing synthetically useful 
multifunctionalized chiral cyclopentenes. 
 
 
Scheme 1.21 Enantioselective [3+2] cycloadditions of ethyl 2,3-butadienoate 
with N-acyl aminophosphine catalyst 
 
The dipolarophiles in the phosphine-promoted [3+2] cycloadditions are not 
limited to electron-deficient olefins, as activated aldimines were also found to be 
competent coupling partners in these types of transformations. Again, Lu and 
coworkers pioneered this subfield establishing that N-tosylimines participated in 
formal [3+2] cyclization reactions with 2,3-butadienoates catalyzed by 
triphenylphosphine to afford pyrrolines 1-87 in good to excellent yield (83-98%) 
(Scheme 1.22).46 Subsequent transformation of the cycloaddition products produced 
the pyrroles 1-88 in moderate to good yields in two steps. 





Scheme 1.22 Formal [3+2] cycloaddition with Ts-imines 
 
Lu’s methodologies involving phosphine-promoted annulations of allenoates to 
activated aldimines provide a potentially convenient, nevertheless underdeveloped 
tool for the synthesis of five-membered multi-functionalized pyrrolines and 
derivatives, which are useful intermediates for the synthesis of natural products46b and 
pharmaceutically relevant compounds47. Due to its significant synthetic potential, the 
development of an enantioselective variant by using chiral phosphines catalysts would 
be an important objective. The first example of the asymmetric cycloaddition between 
allenoate and imine was not reported until 2006. Marinetti and coworkers 
demonstrated the potential utility of readily available chiral phosphine ligands in the 
enantioselective synthesis of 2-aryl-3-pyrrolines via the [3+2] cyclizations of imines 
with allenic esters.48 The corresponding cyclization adducts 2-naphthyl-substituted 
pyrrolinic esters 1-91 were obtained in moderate to good yields with ee values 
ranging from 46% to 60% in the presence of phosphine (R,R)-Et-FerroTANE 1-92 
and coupling partners 1-89 and 1-90 (Scheme 1.23). Scherer and Gladysz later 
reported similar ee values in analogous systems using rhenium phosphine catalyst 1-
93. Although high chemical yields were achieved, the enantiomeric excesses were 
























up to 60% ee







Scheme 1.23 Phosphine-promoted enantioselective [3+2] cycloaddition 
 
The breakthrough came when Jacobsen introduced phosphinothiourea catalysis of 
imineallene cyclization; by utilizing diphenylphosphinoyl (DPP) imines 1-94,50 
substituted 2-aryl-2,5-dihydropyrroles 1-96 were formed in good yields and with 
excellent enantioselectivities (Scheme 1.24). Catalyst 1-95 bearing an alanine unit 
gave the best results in the reaction system containing substoichiometric triethylamine 
(Et3N; 5 mol%) and water (20 mol%). The existence of additives (Et3N and H2O) in 
the reaction medium resulted in significantly increased reaction rates, which 
presumably is due to the beneficial effect on proton transfer and catalyst regeneration 
steps in the reaction mechanism—a hypothesis supported experimentally and 
computationally by the study from other groups.30,51 





















































Scheme 1.24 Asymmetric [3+2] cycloadditions of allenoates and imines  
promoted by phosphinethiourea catalysts 
 
In a plausible mechanism, it was suggested that the thiourea moiety is 
responsible for the activation of phosphonyl imines through hydrogen bonding 
interaction. The generated zwitterionic enolate may then attack the imine from the Re 
face in an intramolecular manner resulting in the observed enantiomer of the 
cycloadduct.  
 
1.3 [4+2] Cycloaddition Reactions of Electron-Deficient Allenoates 
The phosphine-promoted reaction between allenes and activated imines, which 
usually affords the [3+2] adducts, may follow a different reaction pathway, whereby 
an alkyl group replaces the hydrogen at the -position of the starting allenic ester. In 
such a case, a formal [4+2] cycloaddition process takes place, leading to a highly 
functionalized piperidine, which is prevalent structural motif in bioactive molecules 
and natural products. 




first time. In their work, the tetrahydropyridine derivatives 1-98 were obtained from 
reactions of allenoate 1-97 with Ts-imine 1-85 in excellent yields with complete 
regioselectivity and high diastereoselectivities (Scheme 1.25).52 The potential utility 
of this [4+2] annulation was demonstrated subsequently by the same group for the 




Scheme 1.25 Enantioselective [4+2] cyclizations between -substituted allenic 
esters and N-tosyl-substituted imines 
 
A very successful asymmetric variant was later described by Wurz and Fu in 
2005.54 Several known chiral phosphine ligands were examined in the formal [4+2] 
cycloadditions of Ts-imines to -substituted allenic esters (Scheme 1.26). BINEPINE    
1-100 was found to be the most effective catalyst providing six-membered nitrogen 
heterocycles 1-101 with excellent diastereo- (up to 96:4) and enantioselectivity (up to 
99%). A facile transformation of the [4+2] cycloadduct afforded a framework 
common to an array of important natural products 1-102. 
 
This recent study opens up promising and interesting perspectives in the field of 
enantioselective [4+2] cycloaddition reaction by using phosphine catalysts. Further 
progress is expected in the near future. 
 
 

























Me R = Boc
1-102  
Scheme 1.26 Enantioselective [4+2] cyclizations promoted by BINEPINE 
 
1.2.4 Nucleophilic Addition of Electron-Deficient Substrates 
In the mid-1990s, Lu’s group and Trost’s group independently developed a series 
of new synthetic reactions derived from nucleophilic addition of tertiary phosphines 
to electron-deficient allenoates or alkynes.55,56 Trost first reported the phosphine-
promoted -addition of nucleophiles to 2-alkynoates (Scheme 1.27). Treatment of 
dimethyl malonate 1-103 with methyl 2,3-butadienoate 1-54 in the presence of 5 
mol% triphenylphosphine in benzene at room temperature afforded the product 1-104 
in 65% isolated yield.57 On the basis of this work, Lu studied the similar addition of 
carbon and oxygen nucleophiles to the allenoates.58 When alcohols were used as 
nucleophiles in the -addition, a catalytic amount of an acid (e.g. acetic acid) as a 
cocatalyst was essential for prohibiting the formation of Michael adduct 1-107. 
Moreover, the more nucleophilic tributylphosphine was required for the reaction 












Scheme 1.28 Phosphine-catalyzed -addition of allenoate with nuclephiles 
 
Based on Lu and Trost’ discovery, the potential for asymmetric synthesis was 
demonstrated later by Zhang and coworkers.59 It was shown that ethyl 2,3-
butadienoate reacts with a variety of carbon acids 1-110 to yield -addition products 
1-112 in moderate enantioselectivity under the conditions of phosphine catalysis 
(Scheme 1.29). Bicyclic phosphine 1-111 was found to be the optimal catalyst giving 
the products with enantiomeric excesses of up to 81%. The additive of a sodium 
acetate-acetic acid buffer could enhance the enantioselectivity considerablely at the 
expense of slowing the reaction rate significantly. 
 




Scheme 1.29 Chiral phosphine-catalyzed asymmetric nucleophilic addition 
 
Another report further attempted the same reaction of allenic esters with cyclic 
-keto esters was disclosed by Pietrusiewicz and coworker in 2004. However, their 
novel bicyclic phosphine 1-113 (Scheme 1.29) was unable to improve the 
enantioselectivity; only a maximum 51% ee was obtained.60 
A major advance in the development of highly enantioselective nucleophilic 
addition was reported by Chung and Fu in 2009.61 Spirocyclic monophosphine 1-115, 
which had previously proved effective as a chiral ligand in transition-metal chemistry, 
was utilized as a catalyst in the synthesis of an array of oxygen heterocycles 1-114 
from hydroxy-2-alkynoates 1-110. The nuclephilic addition adducts—
tetrahydrofurans and tetrahydropyrans, were obtained in good yields and high 
enantiomeric excesses in the presence of phosphine 1-115 and benzoic acid as 
reaction additive (Scheme 1.30). Significantly, this reaction has been used not only to 







Scheme 1.30 Enantioselective cyclization of hydroxy-substituted 2-alkynoates 
 
1.2.5 Alcohols Acylation and Kinetic Resolution 
Nucleophiles as well as bases are known to catalyze the acylation of alcohols by 
acid anhydrides. Significant catalysis was therefore anticipated with tributylphosphine, 
a weak base but a potent nucleophile. In 1993, Vedejs and coworkers surprisingly 
found that addition of catalytic n-Bu3P to the solution of cyclohexanol in 
dichloromethane containing 3 equivalence of acid anhydride resulted in the formation 
of cyclohexyl acetate with 88% conversion.62 The reaction rates of alcohol acetylation 
or benzoylation using Bu3P were remarkably fast, with efficiency similar to those of 
DMAP catalyst.63 The reagents Bz2O/PBu3 and Ac2O/PBu3 acylated typical alcohol 
substrates including menthol, tertiary alcohols and hindered phenols. A likely 
mechanistic pathway involves a tight ion pair [Bu3PCOR][RCO2] transition state, 
derived from a P-acylphosphonium carboxylate intermediate. 
Following the discovery of phosphine-catalyzed alcohol acylations with acid 
anhydrides, Vedejs and coworkers reported the first examples of enantioselective acyl 
transfer reactions catalyzed by a chiral phosphine.64 It was showed that trans-2,5-
dimethyl-1-phenylphospholane 1-118 could activate m-chlorobenzoic anhydride for 
the chlorobenzoylation of alcohols 1-117 with significant enantioselectivity (Scheme 
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1.31). However, the reaction was very slow and required two weeks to reach 25% 
conversion to 1-119 at room temperature using 15 mol% of the phosphine catalyst. 
Many prior attempts had been made subsequently to develop more efficient chiral 
nucleophilic acylation phosphine catalysts, including a variety of mono- and 
disubstituted phospholanes. Among them, bicyclic derivative 1-121 based on the 2-
phosphabicyclo-[3.3.0]octane (PBO) skeleton appeared to be remarkably more 
reactive, giving the acylation products 1-122 with impressive levels of 












R = Me: 34% ee at 51% conversion























R = Me, nBu,
iPr, iBu, tBu  
 
Scheme 1.31 Chiral phosphines as enantioselective acylating catalysts 
 
Because PBO catalysts are rather air-sensitive, an improvement was made later 
by using the air-stable, easy-to-handle phosphonium tetrafluoroborate salts as 




releases the free phosphine catalyst in typical acylation experiments. Precatalyst 1-
123 gave products with enantioselectivities comparable to those with PBO 1-124 for 


















Scheme 1.32 PBO Derived chiral phosphine salts 
 
Much progress has been made in the kinetic resolution of aryl-substituted and 
allylic secondary alcohols using specifically designed phosphine catalysts, however, 
the desymmetrization of diols had not been explored until the year of 2004. Vedejs et 
al. described the chiral phosphine-promoted desymmetrization of meso-hydrobenzoin 
for the first time.67 Catalyst 1-126 offered the best efficiency in terms of reactivity and 
enantioselectivity in the benzoylation reaction, affording product dibenzoate 1-127 



























Scheme 1.33 Chiral phosphine-promoted desymmetrization of meso-hydrobenzoin 
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1.2.6 Allylic Substitutions and [3+2] Cyclizaitons of MBH Adducts   
The Morita–Baylis–Hillman (MBH) reaction provides a convenient and atom- 
economic synthetic method for the synthesis of -methylene--hydroxy-carbonyl 
compounds, which have proven to be versatile and valuable synthetic intermediates in 
organic transformations. The MBH adducts have been widely used in organic 
synthesis, including tertiary amines and metal catalyzed amination and allylic 
alkylation of MBH adducts, as well as their application in natural products 
synthesis.68 
In 2004, Krische and co-workers demonstrated the first examples of chiral 
phosphine catalyzed allylic amination of MBH acetates. With (R)-Cl-MeO-BIPHEP       
1-131 as the catalyst, the substitution of 4-nitrophenyl-substituted allylic acetate 1-
129 with phthalimide 1-130 furnished the corresponding product 1-132 in 80% 
isolated yield and 56% enantiomeric excess (Scheme 1.34).69 Hou70 and Shi71 later 
attempted the same reaction by using phosphine 1-133 and 1-134, but only moderate 
































Striking improvement in enantioselectivity became possible when Shi et al. 
introduced the multifunctional chiral phosphine 1-137 in the nucleophilic 
substitutions of MBH acetates 1-135 with 2-trimethylsilyloxy furan 1-136.72 -
Butenolides 1-138 were obtained with high syn-diastereoselectivity and excellent 
enantiomeric excesses for a range of substrates (Scheme 1.35). 
 
 
Scheme 1.35 Substitution of MBH acetates with 2-(trimethylsiloxy)furan 
 
In addition to the allylic substitution, Lu and coworkers reported that the simple 
allylic compounds, which can be easily obtained by a one-step transformation of the 
MBH product, underwent readily formal [3+2] and [3+6] cycloaddition reactions with 
electron-deficient olefins in good to excellent yields in the presence of 10 mol% 
PPh3.73  On the basis of these findings, Tang and Zhou recently demonstrated a 
catalytic asymmetric version of the intramolecular [3+2] annulations using a modified 
allylic phosphonium ylide.74 It was found that the spirobiindane-based chiral 
phosphine 1-140 could be an excellent organocatalyst, leading to the formation of 
benzobicyclo [4.3.0] compounds with high diastereo- and enantioselectivities 
(Scheme 1.36). Further transformations of these products provided a direct and 
practical access to the sprio-, heterocyclic derivatives with four contiguous 





Scheme 1.36 Synthesis of functionalized benzobicyclo-[4.3.0] compounds 





















up to 91% yield







R1 =OMe, Me PG = CONHPh, Boc
R2 = COMe, COOMe, COOtBu, COOPh





Scheme 1.37 Phosphine-promoted [3+2] cycloadditions with allylic compounds 
 
Very recently, Barbas and coworkers observed that in the presence of 10 mol% 
chiral phosphine (+)-Ph-BPE, the [3+2] cycloaddition reaction between 
methyleneindolinones 1-143 and allylic compounds 1-144 could afford complex 
spirocyclopentaneoxindoles with excellent enantioselectivity (up to 99% ee) and 




construction of spirocyclopenteneoxindole derivatives containing three chiral centers 
from simple starting materials under mild conditions. 
Almost at the same time, our group reported the same type of [3+2] cycloaddition 
process between the MBH carbonates and isatin-derived tetrasubstituted alkenes.76 
Novel threonine-derived phosphine thiourea 1-149 was found to be the optimal 
catalyst, providing biologically important 3-spirocyclopentene-2-oxindoles containing 
two contiguous quaternary centers with excellent regio- and enantioselectivities. A 
variety of different isatin-derived ,-dicyanoalkenes were explored as coupling 
partners in this novel [3+2] annulation reactions (Scheme 1.38). It should be noted 
that the addition of 3Å molecular sieves to the reaction mixture significantly enhanced 
the reaction rate and afforded the final cycloaddition product with a better 
enantioselectivity meanwhile.  
 
 
Scheme 1.38 Asymmetric [3+2] annulations of MBH adducts with isatin-derived 
activated alkenes 
 
1.2.7 Other Reactions 
Enantioselective variants of the organocatalytic dimerization of ketenes have met, 
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so far, with limited examples. Only one report showed that chiral phosphine (R,R) 
BINAPHANE 1-152 could be used as a catalyst to afford the dimeric product of 
















1-153Z : E > 39 : 1
65%, 80% ee  
Scheme 1.39 Enantioselective dimerization of a ketene 
 
The enantioselective ring opening of aziridines with hydrogen chloride, was 
recently described by Mita and Jacobsen (Scheme 1.40).78 A broad range of cyclic as 
well as acyclic substrates underwent clean addition in the presence of 
phosphinethiourea  1-155 to afford the corresponding -chlorobenzamide derivatives 
in high yields and with high enantioselectivities. A proposed transition state model 
was suggested, the phosphorus functionality of the bifunctional catalyst was assumed 
to activate hydrogen chloride by deprotonation, and the hydrogen bonding formation 
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1-15691-99%, 70-92% ee  
Scheme 1.40 Phosphinethiourea-promoted enantioselective ring opening of 
aziridines 
 
1.3 Project objectives 
The phosphine-triggered organic transformations have become a practical and 
powerful tool in organic chemistry. The unique reactivity of organophosphines 
compared to their amine counterparts has led to the discovery of a variety of novel 
reactions, such as [3+2] and [4+2] cyclizations, Michael and nucleophilic additions of 
activated allenes and alkynes. Over the past few years, many chiral mono- and 
bifuctional phosphine catalysts have been developed and proved to be efficient in a 
wide range of enantioselective variants. These catalytic methodologies allow easy 
access to some sprio-, heterocyclic and polycyclic compounds from readily available 
materials. 
Although great progress has been made in the field of phosphine catalysis, in 
general, phosphine-catalyzed reactions suffer from the large catalyst loading, poor 
regioselectivities and enantioselectivities. Furthermore, phosphine catalysts are 
usually air-sensitive, particularly when substituted by the alkyl groups. In light of this, 
how to increase the air-stability and catalytic efficiency, and how to develop highly 
enantioselective catalytic processes will be the aim of further investigations. 
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Moreover, phosphine catalysis may complement the amino catalysis well in 
asymmetric synthesis. 
The aim of this project is to design and synthesize novel bifunctional or 
multifunctional phosphine catalysts derived from amino acid scaffolds, and to employ 
them in the enantioselective MBH reactions and [3+2] cycloadditions. We are also 
interested in applying the newly developed methodologies to the synthesis of 
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Chapter 2 Enantioselective MoritaBaylisHillman  




Trivalent phosphines, traditionally utilized as ligands in the transition metal 
mediated processes, have recently emerged as versatile Lewis base catalysts in 
synthetic organic chemistry.6,12,56c,79 As a significant complement to the amine-based 
catalysts, phosphines often display remarkable and unique properties in the 
nucleophilic catalysis due to their weaker basicity and stronger nucleophilicity. 
Comparing to the extensive studies carried out on phosphine-triggered organic 
transformations, the development of efficient and versatile chiral phosphine catalysts 
and their applications in enantioselective organic reactions remain to be a less-
explored research area.40-45,80 As our continuous efforts toward the evolution of amino 
acid-derived organic catalysts for enantioselective organic transformations,81 we 
recently embarked on an exciting journey of exploring novel bifunctional chiral 
phosphines derived from amino acid structural scaffolds (Scheme 2.1). We showed 
that novel bifunctional phosphinesulfonamide catalysts could efficiently promote the 
enantioselective aza-MoritaBaylisHillman (aza-MBH) reaction N-(p-methoxy- 
benzene-sulfonyl)imines with acrylates, affording corresponding adducts in excellent 
chemical yields and with very high enantioselectivities (Scheme 2.1, Chapter 2; 
Scheme 1.12, Chapter 1).38 It is thus highly desirable to further extend the utility of 














Primary amino acid-derived bifunctional phosphines






































Scheme 2.1 Applications of amino acid-derived bifunctional phosphines in the 
(aza)-MBH reactions 
 
The MBH reaction is one of the most valuable carboncarbon bond-forming 
reactions, which provides easy access to heavily functionalized and synthetic uesful 
MBH adducts from readily available activated olefins and aldehydes.82 In the past 
decade, the development of enantioselective versions of the MBH reactions has 
received increasing attention from the synthetic community. Among the activated 
alkenes suitable for the MBH reactions, enones are most commonly employed; a 
number of elegant asymmetric MBH reactions between enones and aldehydes have 
been developed in the past few years.83 On the other hand, the examples using 
acrylates as a reaction partner in highly enantioselective MBH reactions are very 
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limited.84 In 1999, Hatakeyama and co-workers disclosed a highly enantioselective 
MBH reaction between hexafluoroisopropyl acrylate (HFIPA) and aldehydes, 
catalyzed by a novel quinine-derived -isocupreidine (β-ICD).85 Although HFIPA had 
to be employed, and the chemical yields were modest in many cases (Scheme 2.2), 
nevertheless, the Hatakeyama method represented a breakthrough in the field; highly 
enantioselective MBH reaction of acrylates was shown to be feasible.86  Recently, 
there were a few reports on organocatalytic enantioselective MBH reactions between 
aldehydes and acrylates.28,87 Those methods, however, suffered from limited substrate 
scope, moderate yields or low enantioselectivities. There clearly exists a need for an 
enantioselective MBH reaction in which simple acrylates can be used directly.  
 
 
Scheme 2.2 β-ICD-Catalyzed MBH reaction 
 
Herein, we describe the development of amino acid-derived phosphinethiourea 
catalysts, and their applications in enantioselective MBH reaction between aromatic 
aldehydes and simple acrylates. The corresponding MBH adducts were obtained with 
with up to 90% ee. Moreover, to gain mechanistic insights into the reaction, effects of 






2.2 Results and Discussion 
2.2.1 Catalysts Design and Synthesis 
Amino acids serve as an excellent starting point for derivatizing various 
bifunctional chiral phosphine catalysts. The phosphine group in the catalysts is 
derived from the carboxylic acid via simple functional group transformations. 
Moreover, the presence of a neighbouring primary alkyl carbon makes the phosphorus 
center highly nucleophilic, as we demonstrated in our previous reports.38 By installing 
different Brønsted acid moieties at the amino sites, and selecting valine or threonine 
as the chiral backbone, a number of bifunctional phosphine catalysts (2-5a2-9d) 
were prepared (Scheme 2.3). We chose to prepare L-threonine-based phosphine 
catalysts, since the effectiveness of the threonine motif in stereochemical control has 
been amply demonstrated by us.38,81b-d The isopropyl group in valine serves as a 
convenient gauge for evaluating steric effects in the asymmetric induction, and the 








2-5a: R = Ts
2-5b: R = Ms 2-6
2-7a: R1 = Bn, R2 = H





















2-9a: R = TBS; 2-9b: R = TDS
2-9c: R = TBDPS; 2-9d: R = TIPS
2-8a: R = Ph; 2-8b: R = 3,5-CF3-Ph
2-8c: R = 4-CF3-Ph; 2-8d: R = 4-NO2-Ph
2-8e: R = 4-OMe-Ph; 2-8f: R = 4-F-Ph
2-8g: R = 4-Cl-Ph; 2-8h: R = 4-Br-Ph




Scheme 2.3 Amino acid-derived bifunctional phosphines 
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Preparation of bifunctional phosphinethiourea catalysts from L-threonine is 
illustrated in Scheme 2.4. Following the literature procedure,88 threonine was 
protected as an oxazolidine 2-10. The hydroxy group was converted to a mesylate, 
and a substitution reaction with NaPPh2 introduced the phosphine moiety in the 
catalyst. Acidic treatment yielded phosphine 2-12 with the free amino group, which 
smoothly reacted with thioisocynate to afford the advanced intermediate 2-13. Finally, 
silylation gave phosphinethiourea catalysts 2-9a to 2-9d. It is noteworthy that the 
above phosphine catalysts and phosphorus-containing synthetic intermediates are 



































2-9a: R = TBS (92%); 2-9b: R = TDS (81%)
2-9c: R = TBDPS (61%); 2-9d: R = TIPS (73%)
F
 
Scheme 2.4 Preparation of L-threonine-derived phosphinethiourea catalysts 
 
2.2.2 Reaction Optimization 
The MBH reaction between p-nitrobenzaldehyde and methyl acrylate was chosen 
as a model reaction to evaluate the effectiveness of our phosphine catalysts (Table 
2.1). L-Valine-based bifunctional phosphines with different Brønsted acid moieties 
were tested first to establish the influence of Brønsted acids on the reaction. 




enantioselectivity was disappointing (entries 12). Phosphine 2-6 containing a Boc 
group led to the formation of the desired product with moderate ee (entry 3). 
Dipeptide-derived phosphinethioureas  2-7a and 2-7b turned out to be quite good 
catalysts, and the MBH adducts were formed in high yields and with good 
enantioselectivities (entries 45). The thiourea moieties in the catalysts seemed 
important in the asymmetric induction, thus, a number of phosphines bearing different 
aryl thioureas (catalysts 2-8a2-9j) were next prepared and screened (entries 615), 
and it was found the p-F-phenyl-thiourea moiety was most efficient in chiral induction 
(entry 11, 85% yield, 83% ee). Having established the importance of steric effects in 
asymmetric induction with valine-derived phosphines, we then focused on 
derivatization of phosphinethiourea catalysts (9a9d) based on threonine backbone.  
Very similar reactivities and selectivities were observed with different silyloxy groups 
(entries 1619), catalyst with the TBS group (29a) was chosen for further studies as 
it gave slightly better results than other silyloxy-containing catalysts, and its 
preparation was more economical.  
 




Entry Catalyst Yield (%)b ee (%)c 
1 2-5a 88 40 
2 2-5b 92 37 
3 2-6 67 53 
4 2-7a 85 79 
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5 2-7b 70 72 
6 2-8a 89 80 
7 2-8b 90 76 
8 2-8c 83 80 
9 2-8d 80 77 
10 2-8e 84 77 
11 2-8f 85 83 
12 2-8g 88 79 
13 2-8h 91 78 
14 2-8i 78 77 
15 2-8j 81 69 
16 2-9a 90 85 
17 2-9b 78 85 
18 2-9c 88 84 
19 2-9d 79 84 
a The reaction was performed with 2-14a (0.1 mmol),  2-15a (0.15 mmol) and the catalyst 
(0.01 mmol) in anhydrous THF (0.2 mL) under N2 at room temperature for 24 h. b Isolated 
yield. c Determined by HPLC analysis on a chiral stationary phase. 
 
 
The influence of different solvents on 2-9a-catalyzed MBH reaction was next 
investigated, and the results are summarized in Table 2.2.  1,4-Dioxane was found to 
be a suitable solvent, offering slightly inferior results to those obtained with THF 
(entry 2). All the other common organic solvents were shown to be unsuitable, 
affording products in low yields and with poor enantioselectivities (entries 38). The 
protic solvent, e.g. methanol, proved to be an extremely poor medium, and the desired 
MBH adduct was obtained in 36% yield and with only 13% ee (entry 9). This result 
seemed to suggest hydrogen bonding interactions might be very important in 
stereochemical control, as methanol likely disrupted such key interactions. When a 
THF/water solvent pair was employed, a very low yield and poor enantioselectivity 




the solvent. Under the optimized reaction conditions in which molecular sieves were 
added, the MBH adduct was obtained in 92% yield and 87% ee (entry 12). 
 
Table 2.2 Solvent screening for 2-9a-catalyzed MBH reactiona 
 
 
Entry Solvent Yield (%)b ee (%)c 
1 THF 90 85 
2 1,4-Dioxane 88 82 
3 Toluene 49 65 
4 CH2Cl2 45 42 
5 Ether 48 61 
6 CH3CN 25 45 
7 DMSO 24 45 
8 DMF 32 51 
9 MeOH 36 13 
10 THF/H2O (4/1) 15 39 
11d THF 85 87 
12e THF 92 87 
13f THF 84 86 
a The reaction was performed with 2-14a (0.1 mmol), 2-15a (0.15 mmol) and 2-9a (0.01 
mmol) in anhydrous THF (0.2 mL) under N2 at room temperature for 24 h.  b Isolated 
yield. c Determined by HPLC analysis on a chiral stationary phase. d 0.4 mL THF was 
used. e 4Å molecular sieves were added. f  The reaction was performed at 10 oC for 72 h. 
 
 
2.2.3 Substrate Scope 
With the best catalyst and the most appropriate solvent in hand, we next 
examined different acrylates in 2-9a-catalyzed MBH reaction (Table 2.3). Simple 
alkyl acrylates gave best results, excellent yields and enantioselectivities were 
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attainable (entries 14); the enantioselectivity seemed to be dependent on the steric 
hindrance of the ester group, and the most sterically hindered t-butyl acrylate led to 
decreased enantioselectivity comparing with less hindered acrylates. The aryl 
acrylates, on the other hand, were found to be unsuitable for the reaction (entries 
56). 
 




Entry R Yield (%)b ee (%)c 
1 Me 92 87 
2 Et 92 85 
3 Bn 94 84 
4 t-Bu 84 82 
5 Ph trace -d 
6 1-naphthyl 32 11 
a The reaction was performed with 2-14a (0.1 mmol), 2-15 (0.15 mmol) and 2-9a (10 
mol %) in anhydrous THF (0.4 mL) containing 4Å molecular sieves (50 mg) under N2 
at room temperature for 24 h. b Isolated yield. c Determined by HPLC analysis on a 
chiral stationary phase. d Not determined. 
 
 
The substrate scope for 2-9a-catalyzed MBH reactions was next investigated 
(Table 2.4). The reaction is applicable to aromatic aldehydes with various electron-
withdrawing groups at differernt positions of the aryl ring, and high yields and 
enantioselectivities were generally attainable (entries 17). In contrast to the related 
examples in the literature in which virtually only electron-poor aldehydes could be 




reaction worked well for the halogenated aromatic aldehydes and benzaldehyde, and 
consistent high enantioselectivities were achieved (entries 813). Moreover, electron-
rich aromatic aldehydes could be employed as well, and the reactions proceeded with 
good enantioselectivities, even though the chemical yields were poor (entries 1415). 
In addition, aromatic aldehydes bearing naphthyl or heterocyclic rings were also 
found to be suitable (entries 1618). However, aliphatic aldehydes could not be 
efficiently activated in our system. It should be noted that only the desired MBH 
adducts were observed in 2-9a-catalyzed MBH reactions, undesired dioxanones1 were 
not observed under our reaction conditions.  
 
Table 2.4 Substrate scope of 2-9a-catalyzed MBH reactiona 
 
Entry x t (h) Product (R) Yield (%)b ee (%)c 
1 10 24 2-16b (3-NO2-Ph) 84 85 
2 10 24 2-16c (2-NO2-Ph) 91 69 
3 10 36 2-16d (4-CN-Ph) 92 87 
4 10 36 2-16e (3-CN-Ph) 89 85 
5 10 40 2-16f (4-CF3-Ph) 80 87 
6 10 40 2-16g (3,5-CF3-Ph) 74 84 
7 10 40 2-16h (3-NO2-2-Cl-Ph) 89 85 
8 20 60 2-16i (4-F-Ph) 72 81 
9 20 60 2-16j (4-Cl-Ph) 67 84 
10 20 60 2-16k (3-Cl-Ph) 63 82 
11 20 60 2-16l (4-Br-Ph) 73 83 
12 20 60 2-16m (3-Br-Ph) 77 84 
13 20 72 2-16n (Ph) 43 80 
14 20 96 2-16o (4-Me-Ph) 25 76 
15 20 96 2-16p (3-Me-Ph) 27 77 
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16 20 72 2-16q (2-naphthyl) 53 90 
17 20 72 2-16r (3-pyridine) 87 84 
18 20 72 2-16s (2-thiophenyl) 52 70 
19 20 96 2-16t (CH2Ph) -d - 
a The reaction was performed with 2-14 (0.1 mmol), 2-15a (0.15 mmol for entries 17 and 0.2 
mmol for entries 819) and 2-9a in anhydrous THF (0.4 mL for entries 112 and 0.2 mL for 
entries 1319) containing 4Å molecular sieves under N2 at room temperature. b Isolated yield.   




2.2.4 Additives Effects and Plausible Reaction Mechanism 
Given the widespread uses of thiourea as the hydrogen bonding catalyst in 
asymmetric catalysis,89 a mechanistic proposal involving hydrogen bonding 
interactions between the bifunctional phosphines and the substrate/intermediates 
seems to be plausible. We focused on the potential roles that thiourea moiety might 
have played in our catalytic systems. Toward this end, the effects of adding various 
external proton donors on 2-9a-catalyzed MBH reaction were next investigated (Table 
2.5). The presence of methanol slightly decreased the enantioselectivity of the 
reaction (entry 2). The addition of thiourea 2-17, which mimics the thiourea moiety in 
catalyst 2-9a, did not have much influence on the stereoselectivity of the reaction, 
even in a large excess (entries 36). However, the addition of a stronger hydrogen 
bond donor, phenol or 2-naphthol, clearly lowered the enantioselectivity of the 
reaction (entries 78). Interestingly, inclusion of a strong acid in the reaction system, 
e.g. benzoic acid, virtually had no effect on the enantioselectivity, but resulted in a 
dramatically decreased chemical yield (entry 9). On the other hand, adding excess 














Entry Additive Yield (%)b ee (%)c 
1 none 92 87 
2 MeOH (10 mol%) 93 84 
3 2-17 (10 mol%) 90 85 
4 2-17 (20 mol%) 89 85 
5 2-17 (50 mol%) 86 84 
6 2-17 (100 mol%) 81 83 
7 PhOH (10 mol%) 84 77 
8 2-Naphthol (10 mol%) 88 74 
9 PhCOOH (10 mol%) 37 85 
10 PhCOOH (20 mol%) -d - 
11 TFA (10 mol%) -d - 
a The reaction was performed with 2-14a (0.1 mmol), 2-15a (0.15 mmol) and 2-9a (0.01 
mmol) in anhydrous THF (0.2 mL) under N2 at room temperature for 24 h.  b Isolated yield.  
c Determined by HPLC analysis on a chiral stationary phase. d Not determined.  
 
 
Based on the above additive studies, as well as recent elegant mechanistic 
investigations on the (aza)-MBH reactions,90 we propose the mechanism of 2-9a-
catalyzed MBH reaction as shown in Scheme 2.5. The reaction is initiated by a 
reversible conjugate addition of phosphine 2-9a to the acrylate to generate 




































Scheme 2.5 Proposed mechanism for phosphinethiourea promoted MBH Reaction 
 
aldehyde to create intermediate B. The subsequent proton transfer, followed by -
elimination, affords the final MBH adduct and regenerates the phosphine catalyst 2-9a. 
We propose the strong intramolecular hydrogen bonding interactions between 
thiourea and the enolate facilitates the formation of a structurally well-defined 
intermediate A, which reacts with the aldehyde substrate in a highly stereochemically 
selective manner, accounting for the high enantioselectivity observed. This proposal is 
supported by the results obtained with the additive studies. Relatively weak external 
hydrogen bond donors competed unfavourably with the intramolecular thiourea in 
their interactions with the enolate, thus had no significant influence on the 
enantioselectivity (Table 2.5, entries 26). Stronger hydrogen bond donors disrupted 
thioureaenolate interaction more, resulting in decreased enantioselectivity (Table 2.5, 




partially/completely protonate the enolate intermediate A, thus leading to a marked 
decrease in chemical yield or a complete stop of the reaction. Had the external proton 
donors participate in the proton transfer step, a more dramatic decrease in 
enantioselectivity is anticipated, as we had observed in a related study.91 
 
2.3 Conclusions 
In summary, we have designed and prepared a series of phosphinethiourea 
organic catalysts based on the structural scaffolds of natural amino acids. In 
particular,               L-threonine-derived bifunctional phosphine 2-9a was prepared for 
the first time and found to be an effective catalyst for the enantioselective MBH 
reaction of acrylates with aromatic aldehydes. The desired MBH adducts were 
obtained with good to very good enantioselectivities. We studied the influences of 
various additives on 2-9a-catalyzed MBH reaction, and we proposed the hydrogen 
bonding interactions between the thiourea and the phosphonium enolate intermediate 
A are crucial for the high enantioselectivity observed. The reaction described in this 
report provides a general and practical solution to the enantioselective MBH reaction 
of simple acrylates, and is anticipated to find wide applications in organic synthesis in 
the future. 
 
2.4 Experimental section 
2.4.1 Material and General Methods 
All the starting materials were obtained from commercial sources and used 
without further purification unless otherwise stated. Toluene, THF and diethyl ether 
were dried and distilled from sodium benzophenone ketyl prior to use. CHCl3 and 
CH2Cl2 were distilled from CaH2 prior to use. Dioxane was dried and distilled from 
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Na prior to use. All the solvents used in reactions involving phosphorus-containing 
compounds were de-gassed by N2. 1H and 13C NMR spectra were recorded on a 
Bruker ACF300 or AMX500 (500 MHz) spectrometer. Chemical shifts were reported 
in parts per million (ppm), and the residual solvent peak was used as an internal 
reference: proton (chloroform δ 7.26), carbon (chloroform δ 77.0). Multiplicity was 
indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd 
(doublet of doublet), br s (broad singlet). Coupling constants were reported in Hertz 
(Hz). All high resolution mass spectra were obtained on a Finnigan/MAT 95XL-T 
spectrometer. For thin layer chromatography (TLC), Merck pre-coated TLC plates 
(Merck 60 F254) were used, and compoundswere visualized with a UVlight at 254 
nm. Further visualizationwas achieved by staining with iodine, or ceric ammonium 
molybdate followed by heating on a hot plate. Flash chromatographic separationswere 
performed on Merck 60 (0.040–0.063 mm) mesh silica gel. The enantiomeric 
excesses of products were determined by HPLC analysis on a chiral stationary phase. 
The absolute configuration of 2-16a was assigned by comparing its specific 
rotation with that of known compound reported in the literature.86b The configurations 
of other MBH adducts were assigned by analogy. 
 
2.4.2 Catalysts Preparation  
(S)-tert-Butyl 1-(diphenylphosphino)-3-methylbutan-2-ylcarbamate (2-6) 
 
 
To a solution of (S)-1-(diphenylphosphino)-3-methylbutan-2-amine92 (150 mg, 




(Boc)2O (143 mg, 0.66 mmol). The reaction mixture was stirred at room temperature 
for 2 hrs, solvent was then removed under reduced pressure, and the residue was 
directly purified by column chromatography on silica gel (hexane/ethyl acetate = 15:1 
to 10: 1) to afford catalyst 2-6 as a white solid (171 mg, 84% yield). 
1H NMR (300 MHz, CDCl3) δ 7.44-7.32 (m, 10H), 4.40-4.38 (m, 1H), 3.59 (br, 1H), 
2.30-2.12 (m, 2H), 1.93-1.87 (m, 1H), 1.43 (s, 9H), 0.88 (d, J = 4.4 Hz, 3H), 0.86 (d, 
J = 4.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 115.3, 146.8, 138.9, 138.8, 138.5, 
133.1, 132.9, 132.8, 132.7, 128.7, 128.5, 128.5, 128.5, 128.5, 128.4, 85.2, 78.8, 53.6 
(d), 32.5, 28.4, 27.4, 18.9, 17.6; 31P NMR (121 MHz, CDCl3) δ -22.2; HRMS (ESI) 






To a solution of isothiocyanide 2-2250 (82 mg, 0.33 mmol) in CH2Cl2 (1 mL) 
under N2 was added (S)-1 (diphenylphosphino)-3-methylbutan-2-amine (81.4 mg, 0.3 
mmol). The mixture was stirred at room temperature for 24 h, the solvent was then 
removed under reduced pressure, and the residue was directly subjected to column 
chromatographic separation on silica gel (hexane/ethyl acetate = 15:1  to 8: 1) to 
afford catalyst 2-7a as a white solid (135 mg, 79% yield). 
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1H NMR (500 MHz, CDCl3) δ 7.44-7.40 (m, 4H), 7.31-7.24 (m, 11H), 6.84 (br, 1H), 
4.81 (s, 1H), 4.46-4.42 (m, 3H), 2.40-2.36 (m, 1H), 2.28-2.13 (m, 1H), 2.07 (s, 1H), 
2.03-1.98 (m, 1H), 0.98-0.89 (m, 6H), 0.83(s, 6H); 13C NMR (125 MHz, CDCl3) δ 
137.3, 132.8 (dd), 128.6, 128.4 (d), 127.4, 64.1, 57.6 (d), 43.5, 31.9 (d), 30.9, 19.4, 
18.8, 18.1; 31P NMR (121 MHz, CDCl3) δ -23.1; HRMS (ESI) m/z calcd for 






Catalyst 2-7b was prepared from N-Boc-L-Valine, following the same procedure 
described for the synthesis of 2-7a. 
A white solid (67% yield); 1H NMR (500 MHz, CDCl3) δ 7.71 (br, 1H), 7.41-7.27(m, 
18H), 7.25 (d, J = 5.1 Hz, 2H), 5.80 (br, 1H), 4.72 (s, 4H), 4.38 (d, J = 13.8 Hz, 1H), 
2.38-2.35 (m, 1H), 2.34-2.22 (m, 2H), 2.14-1.97 (m, 1H), 0.98 (d, J = 6.3 Hz, 3H), 
0.88 (d, J = 7.0 Hz, 3H), 0.81 (d, J = 5.7 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 
138.9, 136.3 (d), 132.9 (dd), 132.8, 128.6 (d), 128.3 (d), 127.9 (d), 127.4, 57.3 (d), 
50.5, 47.9, 31.9 (dd), 19.6 (d), 18.8, 17.9; 31P NMR (202 MHz, CDCl3) δ -23.4; 











To a solution of (S)-1-(diphenylphosphino)-3-methylbutan-2-amine (81 mg, 0.30 
mmol) in CH2Cl2 (2 mL) under N2 was added isothiocyanate (1.1 eq., 0.33 mmol), 
and the reaction mixture was stirred at room temperature for 24 hrs. Solvent was then 
removed under reduced pressure, and the residue was directly subjected to column 
chromatographic separation on silica gel (hexane/ethyl acetate = 12:1 to 8: 1) to 





A white solid (86% yield); 1H NMR (300 MHz, CDCl3) δ 8.05 (br, 1H), 7.42-7.16(m, 
13H), 7.00 (d, J = 10.3 Hz, 4H), 5.92 (d, J = 11.4 Hz, 1H), 4.50 (br, 1H), 2.36-2.30 (m, 
1H), 2.24-2.17 (m, 1H), 2.09-2.00 (m, 1H), 0.80 (d, J = 9.0 Hz, 3H), 0.75 (d, J = 9.0 
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 180.1, 135.9, 132.9 (d), 132.7 (d), 130.1, 
128.5 (dd), 127.1, 125.2, 58.5 (d), 31.7 (d), 31.2 (d), 18.8, 17.9; 31P NMR (121 MHz, 
CDCl3) δ -23.9; HRMS (ESI) m/z calcd for C24H28N2PS [M+H] + = 407.1711, found = 
407.1711. 
 






A white solid (86% yield); 1H NMR (500 MHz, CDCl3) δ 8.23 (br, 1H), 7.66 (d, J = 
12.6 Hz, 6H), 7.44 (t, J = 2.9 Hz, 4H), 7.42-7.29 (m, 6H), 6.22 (br, 1H), 4.62(br, 1H), 
2.54-2.52 (m, 1H), 2.51-2.49 (m, 1H), 2.34-2.16 (m, 1H), 0.95 (t, J = 7.8 Hz, 6H); 31P 
NMR (202 MHz, CDCl3) δ -23.2; HRMS (ESI) m/z calcd for C26H26F6N2PS [M+H]+ 
= 543.1459, found = 543.1459. The characterization data were in agreement with the 
values reported in the literature.28 
 
(S)-1-(1-(Diphenylphosphino)-3-methylbutan-2-yl)-3-(4 (trifluoromethyl) phenyl) 
thiou- rea  (2-8c) 
 
A white solid (81% yield); 1H NMR (500 MHz, CDCl3) δ 8.59 (br, 1H), 7.58 (d, J = 
8.2 Hz, 2H), 7.47-7.41 (m, 4H), 7.31(d, J = 3.8 Hz, 6H), 7.22 (d, J = 7.6 Hz, 2H), 6.19 
(br, 1H), 4.64 (br, 1H), 2.50-2.46 (m, 1H), 2.32-2.27 (m, 1H), 2.19-2.15 (m, 1H), 0.91 
(t, J = 7.3 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 179.6, 139.8, 137.9, 132.8 (d), 
132.6, 128.8 (d), 128.5 (dd), 127.9, 127.7, 128.2, 126.9, 124.8, 123.6, 122.7, 58.7 (d), 
31.9, 30.8 (d), 18.5 (d); 31P NMR (202 MHz, CDCl3) δ -24.1; HRMS (ESI) m/z calcd 








A white solid (86% yield); 1H NMR (300 MHz, CDCl3) δ 8.76 (br, 1H), 8.14-8.11 (m, 
2H), 7.46-7.30 (m, 12H), 6.49 (br, 1H), 4.62 (br, 1H), 2.55-2.53 (m, 1H), 2.50-2.48 
(m, 1H), 2.35-2.15 (m, 1H), 0.95 (s, 3H), 0.93 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
179.4, 143.9, 143.3, 138.0 (d), 137.4, 132.7 (d), 128.8 (dd), 125.3, 122.1, 58.6 (d), 
32.0, 30.7, 18.5; 31P NMR (121 MHz, CDCl3) δ -23.7; HRMS (ESI) m/z calcd for 






A white solid (75% yield); 1H NMR (300 MHz, CDCl3) δ 7.60 (br, 1H), 7.48-7.41 (m, 
4H), 7.36-7.31 (m, 6H), 7.00-6.96 (m, 2H), 6.89-6.84 (m, 2H), 5.78 (d, J = 8.2 Hz, 
1H), 4.55 (br, 1H), 3.80 (s, 3H), 2.44-2.37 (m, 1H), 2.29-2.21 (m, 1H), 2.16-2.05 (m, 
1H), 0.86 (d, J = 6.7 Hz, 3H), 0.80 (d, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
180.7, 158.8, 132.9 (d), 132.6 (d), 128.6, 128.3 (dd), 127.68, 115.1, 58.3 (d), 55.4, 
31.7 (d), 31.2 (d), 18.8, 17.9, 31P NMR (121 MHz, CDCl3) δ -24.1; HRMS (ESI) m/z 
calcd for C25H30N2O3PS [M+H] + = 437.1816, found = 437.1811. 
 
 







A white solid (91% yield); 1H NMR (300 MHz, CDCl3) δ 8.05 (br, 1H), 7.46-7.40 (m, 
4H), 7.32-7.31(m, 6H), 7.04 (d, J = 6.8 Hz, 4H), 5.83 (d, J = 5.9 Hz, 1H), 4.57 (br, 
1H), 2.47-2.44 (m, 1H), 2.42-2.40 (m, 1H), 2.28-2.04 (m, 1H), 0.86 (d, J = 6.8 Hz, 
3H), 0.83 (d, J = 6.8 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 180.3, 162.9, 159.6, 
138.1, 132.9 (d), 132.6 (d), 131.8, 128.7, 128.5 (dd), 127.7, 127.6, 117.0, 116.7, 
58.44(d), 31.8 (d), 31.1 (d), 18.7, 18.1; 31P NMR (121 MHz, CDCl3) δ -24.3; HRMS 
(ESI) m/z calcd for C24H27FN2PS [M+H] + = 425.1617, found = 425.1624. 
 




A white solid (81% yield); 1H NMR (500 MHz, CDCl3) δ 8.20 (br, 1H), 7.46-7.41 (m, 
4H), 7.32-7.29 (m, 7H), 7.02 (d, J = 8.2 Hz, 2H), 5.95 (br, 1H), 4.60 (br, 1H), 2.47-
2.45 (m, 1H), 2.44-2.42 (m, 1H), 2.28-2.11 (m, 1H), 0.88 (d, J = 6.3 Hz, 3H), 0.85 (d, 
J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 179.9, 138.2 (d), 132.8 (d), 132.5 
(dd), 130.1, 128.8 (d), 128.5 (d), 128.5, 126.3, 58.5 (d), 31.8 (d), 31.0 (d), 18.7, 18.2; 
31P NMR (202 MHz, CDCl3) δ -24.2; HRMS (ESI) m/z calcd for C24H27ClN2PS 








A white solid (75% yield); 1H NMR (500 MHz, CDCl3) δ 8.07 (br, 1H), 7.41-7.36 (m, 
6H), 7.27-7.25 (m, 6H), 6.90 (d, J = 8.2 Hz, 2H), 5.90 (br, 1H), 4.54 (br, 1H), 2.42-
2.38 (m, 1H), 2.23-2.18 (m, 1H), 2.10-2.07 (m, 1H), 0.84 (d, J = 7.0 Hz, 3H), 0.81 (d, 
J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 179.9, 138.2 (d), 135.1, 132.8 (dd), 
128.8 (d), 128.5 (d), 126.5, 120.2, 58.6 (d), 31.85 (d), 30.9 (d), 18.7, 18.3; 31P NMR 
(202 MHz, CDCl3) δ -24.2; HRMS (ESI) m/z calcd for C24H27BrN2PS [M+H] + = 





A white solid (79% yield); 1H NMR (300 MHz, CDCl3) δ 8.05 (br, 1H), 7.41-7.34 (m, 
4H), 7.33-7.17 (m, 7H), 6.88-6.74 (m, 3H), 6.02 (d, J = 11.6 Hz, 1H), 4.52 (br, 1H), 
2.40-2.38 (m, 1H), 2.36-2.34 (m, 1H), 2.23-2.02 (m, 1H), 0.86 (d, J = 2.9 Hz, 3H), 
0.82 (d, J = 2.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 179.7, 164.8, 161.5, 138.1 (d), 
137.8 (d), 132.8 (dd), 131.1 (d), 128.7, 128.5 (dd), 119.9 (d), 113.5 (d), 111.8 (d), 
58.6 (d), 31.8 (d), 31.0 (d), 18.7, 18.2; 31P NMR (121 MHz, CDCl3) δ -24.1; HRMS 
(ESI) m/z calcd for C24H27FN2PS [M+H] + = 425.1617, found = 425.1621. 
 
 







A white solid (82% yield); 1H NMR (500 MHz, CDCl3) δ 7.63 (br, 1H), 7.49-7.40 (m, 
4H), 7.33-7.21 (m, 8H), 7.16-7.10 (m, 2H), 6.05 (br, 1H), 4.60 (br, 1H), 2.42-2.39 (m, 
1H), 2.38-2.32 (m, 1H), 2.31-2.13 (m, 1H), 0.90 (d, J = 7.0 Hz, 3H), 0.86 (d, J = 7.0 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 180.3, 156.9, 154.9, 138.0 (d), 132.8 (d), 
132.7 (d), 128.7, 128.4 (dd), 128.1 (d), 126.7, 124.9, 116.8 (d), 58.6 (d), 31.6, 31.1 (d), 
18.7, 17.9; 31P NMR (202 MHz, CDCl3) δ -24.1; HRMS (ESI) m/z calcd for 
C24H27FN2PS [M+H] + = 425.1617, found = 425.1617. 
 
 (4S,5R)-tert-Butyl-2,2,5-trimethyl-4-((methylsulfonyloxy) methyl)oxazolidine-3-





To a solution of alcohol 2-1088(2.33 g, 9.5 mmol) in CH2Cl2 (30 mL) at 0 oC  
was added  Et3N (3.30 mL, 23.7 mmol), followed by dropwise addition of 
MeSO2Cl (970 μL, 12.50 mmol) over 10 minutes. The reaction mixture was stirred 
at room temperature for 3 hours. The mixture was then washed with water, and the 
aqueous layer was back extracted with CH2Cl2 several times (3 x 10 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated. 
Purification by silica gel column chromatography (hexanes/ethyl acetate = 10:1 to 




1H NMR (500 MHz, DMSO, 50 oC) δ 4.43 (br, 1H), 4.34-4.31 (m, 1H), 4.15-4.12 
(m, 1H), 3.62-3.59 (m, 1H), 3.17 (s, 3H), 1.54 (s, 3H), 1.44 (s, 9H), 1.41 (s, 3H), 
1.29 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, DMSO, 50 oC ) δ 150.8, 93.3, 79.5, 
78.9, 72.2, 66.6, 61.2, 36.6, 27.7, 25.6, 19.1; HRMS (ESI) m/z calcd for 
C13H26NO6S  [M+H]+ = 324.1403, found = 324.1400. 
 
(2R,3S)-3-Amino-4-(diphenylphosphino)butan-2-ol (2-12)  
 
 
To a solution of 2-11 (2.6 g, 8.0 mmol) in anhydrous THF (20 mL) under N2 
at 0 oC was slowly added a solution of NaPPh2 in THF/dioxane (0.2 M in 
THF/dioxane, 52.0 mL, 10.40 mmol). The resulting mixture was stirred at 0 oC for 
2 hrs. The reaction was then quenched by adding H2O (25 mL), and the mixture 
was extracted with ethyl acetate (3 × 30 mL). The combined organic extracts were 
washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. A THF 
solution of HCl (4 M, 25 ml) was added to the residue, and the resulting mixture 
was stirred for 1h. The pH value of the mixture was adjusted to 10 by slow 
addition of 2 M aqueous NaOH solution at 0 oC. The mixture was then extracted 
with ethyl acetate several times (3 x 30 mL), and the combined organic layers 
were washed with brine and dried over Na2SO4. Purification by column 
chromatography (hexane/ethyl acetate = 5:1 to 1:1, hexanes containing 5% Et3N) 
afforded 2-12 as a white solid (1.7 g, 78%).  
1H NMR (500 MHz, CDCl3) δ 7.49-7.30 (m, 10H), 3.59-3.54 (m, 1H), 2.61-2.55 
(m, 1H), 2.42 (t, J = 3.5 Hz, 1H), 2.40-2.25 (m, 3H), 2.05-1.99 (m, 1H), 1.14 (d, J 
Chapter 2 MoritaBaylisHillman Reaction 
61 
 
= 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 138.8 (dd), 132.7 (dd), 129.1, 128.6 
(dd), 71.0 (d), 56.7 (d), 34.6 (d), 20.0; 31P NMR (121.5 MHz, CDCl3) δ -22.3 (s); 





To a solution of 2-12 (0.81 g, 3.0 mmol) in CH2Cl2 (5 mL) under N2 was 
added 4-fluorophenyl isothiocyanate (0.51 g, 3.3 mmol), and the reaction mixture 
was  stirred at room temperature for 2 h. The mixture was concentrated in vacuo, 
and the residue was directly purified by column chromatography (hexane/ethyl 
acetate = 15:1 to 5:1) to afford 2-13 as a white solid (1.14 g, 90% yield).  
1H NMR (300 MHz, CDCl3) δ 8.19 (s, 1H), 7.51-7.41 (m, 4H), 7.33-7.29 (m, 6H), 
7.10-6.98 (m, 4H), 6.47 (d, J = 7.7 Hz, 1H), 4.60 (br, 1H), 4.21-4.19 (m, 1H), 
2.49-2.47 (m, 2H), 1.14 (d, J = 6.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 180.5, 
161.0 (d),  137.8 (d), 137.2 (d), 132.8 (d), 132.6 (d), 132.1, 128.8 (d), 128.6 (d), 
128.5 (d), 127.1 (d), 127.1, 116.7 (d), 68.9 (d), 58.1 (d), 31.6 (d), 20.7; 31P NMR 
(121 MHz, CDCl3) δ -23.9; HRMS (ESI) m/z calcd for C23H25FN2OPS [M+H]+ = 








     To the solution of thiourea 2-13 (0.50 g, 1.17 mmol) in anhydrous CH2Cl2 (5 
mL) at 0 oC was added DIPEA (0.61 mL, 3.51 mmol), followed by slow addition 
of TBSOTf (0.11 mL, 0.69 mmol). The resulting mixture was allowed to warm to 
room temperature and continued stirring for an additional hour. The reaction was 
quenched with the addition of saturated aqueous NaHCO3 (10 mL), and then 
extracted with CH2Cl2 (2×20 mL). The combined organic extracts were washed 
with brine, and dried over Na2SO4. Purification by column chromatography 
(hexane/ethyl acetate = 10:1) afforded 2-9a (0.58 g, 92% yield) as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.93 (br, 1H), 7.70-7.64 (m, 2H), 7.40-7.35 (m, 
5H), 7.29-7.23 (m, 3H), 7.15-7.09 (m, 2H), 7.07-7.02 (m, 2H), 6.37 (d, J = 8.9 Hz, 
1H), 4.45 (s, 1H), 4.35 (d, J = 5.7 Hz, 1H), 2.66 (dd, J = 4.4 Hz, 8.8 Hz, 1H), 
2.04-2.00 (m, 1H), 1.09 (d, J = 6.3 Hz, 3H), 0.69 (s, 9H), 0.04 (s, 3H), 0.02 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 180.4, 161.4 (d), 139.1, 139.0,  137.0, 136.9, 
133.2(d), 132.8, 132.7, 131.9, 128.8, 128.5, 128.5, 128.4, 128.3,  127.9 (d), 117.0 
(d), 68.5 (d),-4.6, 58.6 (d), 31.9 (d), 21.5, 17.6, -4.3, -4.6; 31P NMR (121 MHz, 
CDCl3) δ -22.60; HRMS (ESI) m/z calcd for C29H39FN2OPSSi [M+H]+ = 










To a solution of 2-13 (57.5 mg, 0.14 mmol) in THF (1 mL) at 0 oC was added 
NaH (22.4 mg, 0.60 mmol, 60% (w/w) in mineral oil). The mixture was stirred at 0 
oC for 20 minutes, followed by the addition of tert-butyldimethylsilyl chloride 
(32.5 mg, 0.18 mmol). The mixture was then allowed to warm to room 
temperature and the stirring was continued for 2 hours. The reaction was quenched 
by the addition of water (2 mL), and the mixture was extracted with EtOAc several 
times (3 x 5 mL). The combined organic extracts were washed with brine, dried 
over Na2SO4, and concentrated. The residue was purified by column 
chromatography (hexane/ethyl acetate = 10:1 to 5:1) to afford 2-9b as a white 
solid (64.5 mg, 81% yield).  
1H NMR (300 MHz, CDCl3) δ 7.89 (br, 1H), 7.70-7.65 (m, 2H), 7.40-7.26 (m, 
8H), 7.15-7.03 (m, 4H), 6.31 (s, 1H), 4.47 (s, 1H), 4.32 (d, J = 6.0 Hz, 1H), 2.68-
2.65 (m, 1H), 2.10-2.03 (m, 1H), 1.45-1.36 (m, 1H), 1.09 (d, J = 6.2 Hz, 3H), 0.69 
(d, J = 6.9 Hz, 6H), 0.64 (d, J = 2.0 Hz, 6H), 0.08 (d, J = 6.9 Hz, 6H); 13C NMR 
(75 MHz, CDCl3) δ 180.5, 161.0 (d), 133.3, 133.1, 132.8, 132.6, 131.9, 128.9, 
128.5, 128.6, 128.4, 128.3, 128.0 (d), 117.0 (d), 68.7 (d), 58.6 (d), 33.8, 31.7 (d), 
24.6, 20.1, 18.4, 18.4, 2.4, 2.2, -2.4, -2.4; 31P NMR (121 MHz, CDCl3) δ -24.2; 










Following the procedure described for the preparation of 2-9b, catalyst 2-9c 
(61% yield) was prepared similarly.  
A white solid; 1H NMR (300 MHz, CDCl3) δ 7.78 (br, 1H), 7.58-7.51 (m, 4H), 
7.49-7.40 (m, 4H), 7.36-7.30 (m, 7H), 7.28-7.26 (m, 5H), 7.19-7.14 (m, 2H), 7.07-
7.01 (m, 2H), 6.47 (d, J = 8.8 Hz, 1H), 4.49 (s, 1H), 4.28-4.23 (m, 1H), 2.66-2.60 
(m, 1H), 2.17-2.10 (m, 1H), 0.96 (d, J = 4.5 Hz, 3H), 0.89 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 180.7, 161.5 (d), 137.5, 135.9, 135.8, 134.8, 133.5, 133.3, 133.0, 
132.8, 132.8, 132.6, 129.9, 129.8, 129.6, 128.8, 128.5, 128.4, 128.3, 128.3, 128.1 
(d), 127.7, 127.5, 117.1 (d), 70.7 (d), 58.8 (d), 32.5 (d), 29.7, 26.9, 21.4, 19.2; 31P 
NMR (121 MHz, CDCl3) δ -23.8; HRMS (ESI) m/z calcd for C39H43FN2OPSSi 
[M+H]+ = 665.2587, found = 665.2592. 
 
1-((2S,3R)-1-(Diphenylphosphino)-3-((triisopropylsilyl)oxy)butan-2-yl)-3-(4-
fluoro- phenyl)thiourea (2-9d)  
 
 
Following the procedure described for the preparation of 2-9b, catalyst 2-9d 
(73% yield) was prepared similarly. A white solid.  
1H NMR (300 MHz, CDCl3) δ 7.83 (br, 1H), 7.53-7.48 (m, 2H), 7.27-7.12 (m, 
8H), 7.00-6.92 (m, 2H), 6.90-6.87 (m, 2H), 6.25 (d, J = 8.5 Hz, 1H), 4.34 (d, J = 
5.7 Hz, 2H), 2.58-2.51 (m, 1H), 2.06 (t, J = 10.5 Hz, 1H), 1.01 (d, J = 6.2 Hz, 3H), 
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0.80 (br, 21H); 13C NMR (75 MHz, CDCl3) δ 180.5, 161.5 (d), 139.0, 137.5, 
137.3, 133.2, 132.9, 132.9, 132.6, 131.8, 128.7, 128.5, 128.4, 128.4, 128.3, 128.1 
(d), 116.9 (d), 69.2 (d), 58.9 (d), 32.1 (d), 18.1, 18.1, 12.5; 31P NMR (121 MHz, 
CDCl3) δ -23.7; HRMS (ESI) m/z calcd for C32H45FN2OPSSi [M+H]+ =583.2665, 
found = 583.2746. 
 
2.4.3 Representative Procedure for MBH Reactions 
To a flame-dried round bottom flask with a magnetic stirring bar under N2 were 
added methyl acrylate 2-15a (14 ml, 0.15 mmol), anhydrous THF (0.4 mL), 2-9a (5.4 
mg, 0.01 mmol) and 4 Å molecular sieves (50 mg). The resulting mixture was stirred 
for 2 min, followed by the addition of p-nitrobenzaldehyde 2-14a (15.1 mg, 0.1 
mmol). The flask was then sealed, and the mixture was stirred at room temperature for 
24 h. The reaction mixture was filtered (to remove molecular sieves) and concentrated 
under reduced pressure, and the residue was purified by column chromatography on 
silica gel (hexane/EtOAc = 10 : 1 to 1 : 1) to afford 2-16a (21.8 mg, 92%) as a yellow 
solid. 
 
2.4.4 Analytical Data of MBH Products 
(R)-Methyl 2-(hydroxy(4-nitrophenyl)methyl)acrylate (2-16a) 
 
 
A yellow solid; [α]27D = -83.4 (c 1.00, MeOH), (lit.85: [α]25D = -86.6 (c, 0.54, MeOH)); 




(s, 1H), 5.87 (s, 1H), 5.29 (d, J = 5.1 Hz, 1H), 3.74 (s, 3H), 3.32 (d, J = 5.7 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ 166.4, 148.6, 147.5, 140.9, 127.3, 127.2, 123.6, 72.75, 
52.19; HRMS (ESI) m/z calcd for C11H12NO5 [M+H]+ = 238.0715, found = 238.0705; 
the ee value was 87%, tR (minor) = 25.2 min, tR (major) = 33.6 min (Chiralcel IC-H, λ 
= 254 nm, 10% iPrOH/hexanes, flow rate = 0.5 mL/min). 
 







A yellow solid; [α]27D = -2.7 (c 0.85, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.13-
8.15 (m, 1H), 7.74 (d, J = 7.6 Hz, 1H), 7.52 (t, J = 7.9 Hz, 1H), 6.41 (s, 1H), 5.90 (s, 
1H), 5.64 (d, J = 5.1 Hz, 1H), 3.74 (s, 3H), 3.32 (d, J = 5.7 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ 166.4, 148.4, 143.6, 140.9, 132.6, 129.3, 127.2, 122.8, 121.5, 72.6, 52. 
2; HRMS (ESI) m/z calcd for C11H12NO5 [M+H]+ = 238.0715, found = 238.0706; The 
ee value was 85%, tR (minor) = 13.4 min, tR (major) = 16.1 min (Chiralcel IC-H, λ = 
254 nm, 10% iPrOH/hexanes, flow rate = 1.0 mL/min). 
 




A yellow solid; [α]27D = -16.9 (c 0.80, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.95 
(dd, J = 1.3 Hz, 8.2 Hz), 7.74-7.76 (m, 1H), 7.64 (d, J = 7.3 Hz, 1H), 7.44-7.48 (m, 
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(125 MHz, CDCl3) δ 166.4, 148.3, 140.7, 136.1, 133.4, 128.9, 128.7, 126.5, 124.6, 
67.7, 52.1; HRMS (ESI) m/z calcd for C11H12NO5 [M+H]+ = 238.0715, found = 
238.0712; The ee value was 69%, tR (minor) = 14.4 min, tR (major) = 16.9 min 
(Chiralcel OD-H, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1.0 mL/min). 
 
 (R)-Methyl 2-((4-cyanophenyl)(hydroxy)methyl)acrylate (2-16d) 
 
 
A colorless oil; [α]27D = -4.4 (c 0.85, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.63 (d, 
J = 8.2 Hz, 2H), 7.51 (d, J = 8.2 Hz, 2H), 6.37 (s, 1H), 5.85 (s, 1H), 5.58 (d, J = 4.4 
Hz, 1H), 3.73 (s, 3H), 3.29 (d, J = 5.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.4, 
146.6, 141.0, 132.2, 127.2, 127.1, 118.7, 111.6, 72.8, 52.1; HRMS (ESI) m/z calcd for 
C12H12NO3 [M+H]+ = 218.0817, found = 218.0816; The ee value was 87%, tR (minor) 
= 16.3 min, tR (major) = 22.0 min (Chiralcel IC-H, λ = 254 nm, 10% iPrOH/hexanes, 
flow rate = 1.0 mL/min). 
 
(R)-Methyl 2-((3-cyanophenyl)(hydroxy)methyl)acrylate (2-16e) 
 
 
A colorless oil; [α]27D = +11.5 (c 0.87, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.69 (s, 
1H), 7.63 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 7.6 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 6.39 
(s, 1H), 5.86 (s, 1H), 5.56 (d, J = 5.7 Hz, 1H), 3.74 (s, 3H), 3.28 (d, J = 6.3 Hz, 1H); 




118.7, 112.5, 72.5, 52.1; HRMS (ESI) m/z calcd for C12H12NO3 [M+H]+ = 218.0817, 
found = 218.0824; The ee value was 85%, tR (minor) = 17.1 min, tR (major) = 24.4 
min (Chiralcel IC-H, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1.0 mL/min). 
 
(R)-Methyl 2-(hydroxy(4-(trifluoromethyl)phenyl)methyl)acrylate (2-16f) 
 
 
A colorless oil; [α]27D = -4.3 (c 0.71, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.60 (d, 
J = 8.2 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 6.36 (s, 1H), 5.84 (s, 1H), 5.59 (d, J = 5.7 
Hz, 1H), 3.73 (s, 3H), 3.27 (br, 1H); 13C NMR (125 MHz, CDCl3) δ 166.5, 145.3, 
141.4, 129.9 (q), 126.8, 126.8, 125.4 (q), 125.2, 123.0, 72.9, 52.1; HRMS (ESI) m/z 
calcd for C12H12F3O3 [M+H]+ = 261.0714, found = 261.0717; The ee value was 87%, 
tR (minor) = 12.9 min, tR (major) = 20.4 min (Chiralcel IC-H, λ = 254 nm, 5% 
iPrOH/hexanes, flow rate = 0.5 mL/min). 
 
(R)-Methyl 2-((3,5-bis(trifluoromethyl)phenyl)(hydroxy)methyl)acrylate (2-16g) 
 
 
A colorless oil; [α]27D = 20.9 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.86 (s, 
2H), 7.80 (s, 1H), 6.24 (s, 1H), 5.88 (s, 1H), 5.65 (s, 1H), 3.76 (s, 3H), 3.34 (br, 1H); 
13C NMR (125 MHz, CDCl3) δ 166.3, 144.0, 140.8, 132.1, 131.6, 127.5, 126.8, 124.4, 
122.2, 121.8, 121.7, 121.7, 72.5, 52.3; HRMS (ESI) m/z calcd for C13H11F6O3 [M+H]+ 
= 329.0612, found = 329.0620; The ee value was 84%, tR (minor) = 12.7 min, tR 
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(major) = 10.7 min (Chiralcel OD-H, λ = 254 nm, 5% iPrOH/hexanes, flow rate = 0.5 
mL/min). 
 
(R)-Methyl 2-((4-chloro-3-nitrophenyl)(hydroxy)methyl)acrylate (2-16h) 
 
 
A colorless oil; [α]27D = -7.7 (c 1.10, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.89 (d, 
J = 1.9 Hz, 1H), 7.49-7.55 (m, 2H), 6.39 (s, 1H), 5.91 (s, 1H), 5.56 (s, 1H), 3.74 (s, 
3H), 3.43 (br, 1H); 13C NMR (125 MHz, CDCl3) δ 166.2, 147.8, 142.1, 140.7, 131.7, 
131.1, 127.3, 126.0, 123.6, 71.9, 52.2; HRMS (ESI) m/z calcd for C11H11ClNO5 
[M+H]+ = 272.0326, found = 272.0329; The ee value was 85%, tR (minor) = 19.0 min, 
tR (major) = 23.4 min (Chiralcel IC-H, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 
0.5 mL/min). 
 








A colorless oil; [α]27D = -20.0 (c 0.50, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.33-
7.36 (m, 2H), 7.02 (t, J = 8.8 Hz, 2H), 6.33 (s, 1H), 5.82 (s, 1H), 5.54 (d, J = 5.1 Hz, 
1H), 3.73 (s, 3H), 3.06 (d, J = 5.1 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.7, 
163.3, 161.4, 141.9, 137.0 (d), 128.3 (d), 126.1, 115.3 (d), 72.6, 52.9; HRMS (ESI) 




81%, tR (minor) = 13.9 min, tR (major) = 24.2 min (Chiralcel IC-H, λ = 254 nm, 10% 
iPrOH/hexanes, flow rate = 0.5 mL/min). 
 
(R)-Methyl 2-((4-chlorophenyl)(hydroxy)methyl)acrylate (2-16j) 
 
 
A colorless oil; [α]27D = -22.4 (c 1.31, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.30 (m, 
4H), 6.32 (s, 1H), 5.83 (s, 1H), 5.51 (d, J = 5.0 Hz, 1H), 3.71 (s, 3H), 3.23 (d, J = 5.1 
Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.6, 141.6, 139.8, 133.5, 128.5, 127.9, 
126.2, 72.5, 51.9; (ESI) m/z calcd for C11H12ClO3 [M+H]+ = 227.0475, found = 
227.0480; The ee value was 84%, tR (minor) = 13.6 min, tR (major) = 21.0 min 
(Chiralcel IC-H, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 0.5 mL/min). 
 







A colorless oil; [α]27D = -6.6 (c 0.63, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.55 (dd, 
J = 1.9 Hz, 7.6 Hz, 1H), 7.22-7.36 (m, 3H), 6.33 (s, 1H), 5.98 (s, 1H), 5.58 (s, 1H), 
3.77 (s, 3H), 3.33 (br, 1H); 13C NMR (125 MHz, CDCl3) δ 166.9, 140.6, 138.2, 132.8, 
129.4, 129.0, 128.1, 127.0, 126.9, 69.3, 52.1; HRMS (ESI) m/z calcd for C11H11ClO3 
[M+H]+ = 227.0475, found = 227.0476; The ee value was 82%, tR (minor) = 20.5 min, 
tR (major) = 31.1 min (Chiralcel IC-H, λ = 254 nm, 5% iPrOH/hexanes, flow rate = 
0.5 mL/min). 
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(R)-Methyl 2-((4-bromophenyl)(hydroxy)methyl)acrylate (2-16l) 
 
 
A colorless oil; [α]27D = +7.9 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.84 (d, J 
= 8.2 Hz, 2H), 7.45 (dd, J = 2.6 Hz, 8.9 Hz, 2H), 6.33 (s, 1H), 5.82 (s, 1H), 5.49 (d, J 
= 5.1 Hz, 1H), 3.71 (s, 3H), 3.22 (d, J = 5.1 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 
166.5, 141.6, 140.3, 131.5, 128.3, 126.3, 121.7, 72.6, 51.9; (ESI) m/z calcd for 
C11H12BrO3 [M+H]+ = 270.9970, found = 270.9961; The ee value was 83%, tR (minor) 
= 14.2 min, tR (major) = 21.8 min (Chiralcel IC-H, λ = 254 nm, 10% iPrOH/hexanes, 
flow rate = 0.5 mL/min). 
 







A colorless oil; [α]27D = -14.9 (c 0.80, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.52 (s, 
1H), 7.40 (d, J = 8.2 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 7.20 (t, J = 8.2 Hz, 1H), 6.35 
(s, 1H), 5.84 (s, 1H), 5.50 (s, 1H), 3.73 (s, 3H), 3.22 (br, 1H); 13C NMR (125 MHz, 
CDCl3) δ 166.5, 143.6, 141.4, 130.8, 129.9, 129.6, 126.6, 125.2, 122.5, 72.6, 52.0; 
HRMS (ESI) m/z calcd for C11H12BrO3 [M+H]+ = 270.9949, found = 270.9952; The 
ee value was 84%, tR (minor) = 14.6 min, tR (major) = 20.7 min (Chiralcel IC-H, λ = 






(R)-Methyl 2-(hydroxy(phenyl)methyl)acrylate (2-16n)  
 
 
A colorless oil; [α]27D = -94.3 (c 0.42, MeOH), (lit.85: [α]28D = -109.3 (c, 0.54, 
MeOH)); 1H NMR (500 MHz, CDCl3) δ 7.32-7.38 (m, 4H), 7.26-7.29 (m, 1H), 6.33 
(s, 1H), 5.84 (s, 1H), 5.56 (s, 1H), 3.71 (s, 3H), 3.15 (br, 1H); 13C NMR (125 MHz, 
CDCl3) δ 166.8, 142.0, 141.3, 128.4, 127.8, 126.6, 126.1, 73.2, 51.9; HRMS (ESI) 
m/z calcd for C11H13O3 [M+H]+ = 193.0865, found = 193.0866; The ee value was 80%, 
tR (minor) = 14.8 min, tR (major) = 29.1 min (Chiralcel IC-H, λ = 254 nm, 5% 
iPrOH/hexanes, flow rate = 1.0 mL/min). 
 







A colorless oil; [α]27D = -57.4 (c 0.52, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.26 (d, 
J = 6.6 Hz, 2H), 7.15 (d, J = 8.2 Hz, 2H), 6.33 (s, 1H), 5.85 (d, J = 1.3 Hz, 1H), 5.53 
(s, 1H), 3.71 (s, 3H), 2.99 (br, 1H), 2.34 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 166.7, 
142.1, 138.3, 137.5, 129.1, 126.5, 125.8, 73.0, 51.9, 21.1;  HRMS (ESI) m/z calcd for 
C12H15O3 [M+H]+ = 207.1021, found = 207.1022; The ee value was 76%, tR (minor) = 
21.6 min, tR (major) = 37.5 min (Chiralcel IC-H, λ = 254 nm, 10% iPrOH/hexanes, 
flow rate = 0.5 mL/min). 
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A colorless oil; [α]27D = -46.7 (c 0.45, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.15-
7.26 (m, 3H), 7.10 (d, J = 6.9 Hz, 2H), 6.34 (s, 1H), 5.85 (s, 1H), 5.53 (s, 1H), 3.72 (s, 
3H), 3.05 (br, 1H), 2.35 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 166.7, 141.9, 141.2, 
138.0, 128.5, 128.3, 127.2, 125.9, 123.6, 73.2, 51.9, 21.4; HRMS (ESI) m/z calcd for 
C12H15O3 [M+H]+ = 207.1021, found = 207.1015; The ee value was 77%, tR (minor) = 
9.9 min, tR (major) = 17.3 min (Chiralcel IC-H, λ = 254 nm, 10% iPrOH/hexanes, 
flow rate = 1.0 mL/min). 
 
(R)-Methyl 2-(hydroxy(naphthalen-2-yl)methyl)acrylate (2-16q) 
 
 
A white solid; [α]27D = -12.6 (c 0.43, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.82-
7.86 (m, 4H), 7.48 (d, J = 7.6 Hz, 3H), 6.38 (s, 1H), 5.88 (s, 1H), 5.75 (d, J = 3.2 Hz, 
1H), 3.72 (s, 3H), 3.15 (d, J = 5.1 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.8, 
141.9, 138.6, 133.2, 133.0, 128.2, 128.1, 127.6, 126.4, 126.1, 126.0, 125.5, 124.6, 
73.4, 52.9; HRMS (ESI) m/z calcd for C15H15O3  [M+H]+ = 243.1021, found = 
243.1021; the ee value was 90%, tR (minor) = 13.0 min, tR (major) = 18.6 min 






(R)-Methyl 2-(hydroxy(pyridin-3-yl)methyl)acrylate (2-16r) 
 
 
A colorless oil; [α]27D = -44.5 (c 1.2, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.41 (d, 
J = 4.4 Hz, 1H), 7.71-7.73 (m, 1H), 7.23-7.26 (m ,1H), 6.37 (s, 1H), 5.95 (s, 1H), 5.59 
(m, 1H), 3.70 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.3, 148.6, 148.3, 141.6, 
137.4, 134.5, 126.2, 123.4, 70.7, 51.9; HRMS (ESI) m/z calcd for C10H12NO3 [M+H]+ 
= 194.0817,  found = 194.0813; the ee value was 84%, tR (minor) = 12.0 min, tR 
(major) = 19.2 min (Chiralcel IC-H, λ = 254 nm, 30% iPrOH/hexanes, flow rate = 1.0 
mL/min). 
 
(S)-Methyl 2-(hydroxy(thiophen-2-yl)methyl)acrylate (2-16s) 
 
 
A colorless oil; [α]27D = +46.7 (c 0.5, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.24-
7.26 (m, 1H), 6.94 (m, 2H), 6.35 (s, 1H), 5.95 (s, 1H), 5.76 (d, J = 6.3 Hz, 1H), 3.74 
(s, 3H), 3.44 (br, 1H); 13C NMR (125 MHz, CDCl3) δ 166.5, 145.7, 141.3, 126.8, 
126.1, 125.2, 124.7, 69.6, 51.9; HRMS (ESI) m/z calcd for C9H11O3S [M+H]+ = 
199.0429, found = 199.0427; The ee value was 70%, tR (minor) = 11.6 min, tR (major) 
= 17.1 min (Chiralcel IC-H, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1.0 
mL/min). 
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Chapter 3 Enantioselective [3+2] Cycloaddition of Allenes to 
Acrylates Catalyzed by Dipeptide-Derived Phosphines: 
Facile Creation of Functionalized Cyclopentenes Containing 
Quaternary Stereogenic Centers 
 
3.1 Introduction 
Functionalized five-membered carbocycles are structural motifs often found in 
natural products and medicinally important agents.93 Among the known synthetic 
methods, phosphine-catalyzed [3+2] cycloaddition, developed by Lu in 1995,39,94 is 
considered to be one of the most efficient synthetic approaches. By employing 
electron-deficient olefins and imines, cyclopentenes and pyrrolidines can be prepared 
via phosphine-catalyzed cycloadditions, respectively.6,12,56c,79 The first asymmetric 
[3+2] cycloaddition between allenoates and acrylates catalyzed by a bicyclic chiral 
phosphine was reported by Zhang in 1997.40 Recently, enantioselective cyclizations of 
allenoates and enones were achieved by Fu41 and Miller,42 utilizing a binaphthyl-
based C2-symmetric chiral phosphine and a multifunctional phosphine-containing -
amino acid, respectively. Jacobsen designed a series of bifunctional 
phosphinethiourea catalysts and applied them to the enantioselective imineallene 
annulations.50 Planar chiral 2-phospha[3]ferrocenophanes, introduced by Marinetti, 
were shown to promote enantioselective [3+2] additions of allenic esters and 
phosphonates with enones.43,95 Very recently, Loh discovered that commercially 
available chiral phosphines could promote the cycloaddition of 3-butynoates to 
enones.44 Zhao reported  bifunctional N-acyl amino phosphines were effective 
catalysts for the asymmetric [3+2] cycloadditions of allenoates and activated olefins.45 




of phosphine-mediated processes, the design and development of chiral phosphine 
catalysts are still under-explored. When the phosphine-catalyzed [3 + 2] cyclizations 
are concerned, acrylates remain as elusive substrates;40,43 thus an enantioselective 
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Scheme 3.1 Cyclopentane structures with a quaternary carbon 
 
Creation of quaternary stereocenters is a challenging task in organic synthesis,96 
and we recently became interested in devising organocatalytic methods to access 
molecules with chiral quaternary centers.97 Five-membered carbocycles with a 
quaternary stereogenic center are interesting substructures often found in many 
natural products and bioactive molecules (Scheme 3.1),98 we envisioned that 
phosphine-catalyzed [3+2] annulations between -substituted acrylates and allenes 
may be utilized to construct such five-memebered ring systems.  Our group has been 
actively investigating asymmetric organic transformations that can be promoted by 
organocatalysts derived from primary amino acids in the past few years,81,98 thus we 
have keen interest in deriving versatile amino acid-based novel phosphines. To ensure 
effective chiral communications with the substrates, and to make the catalysts readily 
accessible, we chose dipeptide99 as the basic chiral backbone for our catalyst 
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development (Scheme 3.2). The carboxylic acid group can be easily converted to a 
phosphine, which is expected to be highly nucleophilic as the phosphorus atom is 
connected to a primary carbon. The substrate-interacting chiral pocket derived from 
the dipeptide is highly tunable by simply varying the amino acid side chains. Herein, 
we describe the first enantioselective [3+2] cycloaddition between -substituted 
acrylates and allenoates mediated by dipeptide-based novel phosphine catalysts, 
creating chiral cyclopentenes containing a quaternary stereogenic center. 
 
 
Scheme 3.2 Phosphine catalysts based on dipeptides 
 
3.2 Results and Discussion 
3.2.1 Reaction Optimization 
We began our investigation by selecting [3+2] cycloaddition between 2-phenyl-
substituted acrylate 5a and benzyl allenoate 6a as a model reaction (Table 3.1). It 
should be noted that employment of -substituted acrylates in asymmetric [3+2] 
cycloadditions is virtually unexplored.39,100 For the design of effective catalysts, given 
our success in threonine-based catalytic systems,38,81 we chose threonine as the first 
amino acid residue, and a number of dipeptide-derived phosphines 3-13-4 were 






Scheme 3.3 Amino acid-based phosphine catalysts  
 
dipeptide catalyst to adopt a relatively rigid conformation, favoring its interactions 
with substrates. L-Threonine-derived phosphine 3-1 led to the formation of -
selective product with low ee (entry 1). On the other hand, dipeptide-based 
phosphines turned out to be more effective. L-Thr-L-Val-derived 3-2 led to 
substantially improved results, moderate ee was attainable (entry 2). Combining L-Thr 
and D-Val yielded a better catalytic system, and the ee value was further improved to 
60% (entry 3). Employment of sulfonamide as Brønsted acid moiety in the catalyst 
did not offer better results (entry 4). L-Thr-D-Val-derived phosphinethiourea catalyst 
3-3d was also prepared and examined in the cyclization, and the reaction was 
completed only after 24 hrs. The cycloaddition products were obtained in 85% yield, 
with an  to ratio of 90:10, and -28% ee for the -isomer. Higher -selectivity was 
achieved by utilizing an even more sterically hindered carbamate (entry 6). The 
catalyst structures were further tuned by engaging tert-leucine as the second amino 
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acid residue and varying the siloxy groups on the OH of threonine. To make the 
catalyst more economical, D-Thr-L-tert-Leu dipeptidic backbone was selected for 
structural elaborations. Finally, O-TBDPS-D-Thr-L-tert-Leu-derived 3-4c was found 
to be the best catalyst, affording the desired adduct 3-7a in 96% yield, with an  to  
ratio of 95:5 and 78% ee (entry 9). 
 
Table 3.1 [3+2] Cycloaddition of allenoates with acrylates catalyzed by different 
amino acid-based phosphinesa 
 
 
Entry Catalyst 3-7a:3-7b Yield (%)c ee (%)d 
1 3-1 83:17 88 -36 
2 3-2 84:16 90 -52 
3 3-3a 89:11 96 -60 
4 3-3b 74:26 90 -57 
5 3-3c 92:8 93 -61 
6e 3-3d 90:10 85 -28 
7 3-4a 93:7 93 63 
8 3-4b 94:6 95 74 
9 3-4c 95:5 96 78 
a Reactions were conducted with 3-5a (0.05 mmol), 3-6a (0.075 mmol) and the catalyst (10 
mol%) in toluene (0.5 mL) at room temperature. b Determined by 1H NMR analysis of the 
crude reaction mixture. c Isolated yield. d The ee value of the major stereroisomer, 
determined by HPLC analysis on a chiral stationary phase.  
 
 
Having identified the best catalyst 3-4c, we then focused on tuning the ester 
moieties in acrylates and allenoates (Table 3.2). The tert-butyl ester proved to be 




improved to 96:4, and ee of the major isomer reached 84% (entries 15). Among the 
different acrylate esters, 9-phenanthryl acrylate was found to be the best, and its 
cycloaddition with tert-butyl allenoate led to the formation of only -isomer in 95% 
yield and 91% ee (entry 11). 
 




Entry R1/R2  : γb Yield (%)c ee (%)d 
1 2-Napthyl/Et 94:4 91 74 
2 2-Napthyl/Bn 95:5 96 78 
3 2-Napthyl/9-CH2An 93:7 87 76 
4 2-Napthyl/t-Bu 96:4 94 84 
5 2-Natphyl/Ph 89:11 95 84 
6 i-Pr/t-Bu 97:3 72 24 
7 Bn/t-Bu 94:6 68 20 
8 Ph/t-Bu 97:3 92 76 
9 2,6-CH3Ph/t-Bu 98:2 94 72 
10 1-Napthyl/t-Bu 98:2 93 81 
11 9-Phenanthryl/t-Bu >99: 1 95 91 
12 9-Anthryl/t-Bu >99 : 1 95 80 
a Unless otherwise specified, reactions were conducted with 3-5 (0.05 mmol), 3-6 (0.075 mmol) 
and 3-4c (10 mol%) in toluene (0.5 mL) at room temperature. b Determined by 1H NMR 
analysis of the crude reaction mixture. c Isolated yield. d  The ee value of the major 




Performing reaction in different solvents and lowering the reaction temperature 
did not result in further improvement (Table 3.3). Toluene still turned out to be the 
best solvent, offering the corresponding [3+2] adduct in 95% yield with 91% ee (entry 
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1). All the other common organic solvents were shown to be unsuitable, affording 
products in low yields and with poor enantioselectivities. The protic solvent, e.g. 
methanol, proved to extremely poor medium, and no desired product was observed 
under this reaction condition (entry 12). Furthermore, with the decrease of the 
temperature from room temperature to -20 °C, the reaction became much slower and 
the enantioselectivity was not improved at all; only 84% yield was obtained (entry 15). 
 
Table 3.3 Solvents screening for 3-4c-promoted [3+2] cycloadditiona  
       
 
 
Entry Solvent t (h) Yield (%)b ee (%)c 
1 toluene 0.5 95 91 
2 1,2-dichlorobenzene 0.5 90 77 
3 PhBr 0.5 91 82 
4 benzene 0.5 94 88 
5 xylene 0.5 89 88 
6 4-fluorotoluene 0.5 94 74 
7 CH2Cl2 0.5 92 70 
8 CHCl3 2 81 76 
9 THF 0.5 93 67 
10 Et2O 0.5 95 87 
11 CNCH3 6 53 12 
12 MeOH 6 -d -d 
13 DMF 6 21 13 
14e toluene 1.2 95 89 
15f toluene 5 84 88 
a Unless otherwise specified, reactions were conducted with 3-5a (0.05 mmol), 3-6b (0.075 
mmol) and  3-4c (10 mol%) in solvent (0.5 mL) at room temperature. b Isolated yield.  c  The ee 
value of the major stereoisomer, determined by HPLC analysis on a chiral stationary phase.  













Additionally, the molecular sieves (MS) were revealed to be useless in 
improving the asymmetric induction (entry 24, Table 3.4). To make the 
methodology more practical, catalyst loading was further decreased. With 5 mol% 3-
4c, the [3+2] cycloaddition could be completed with half an hour, furnishing -isomer 
in 95% yield and with 91% ee (entry 7). It should be noted that the catalyst loading 
could go as low as 2 mol%, with marginally reduced yield and enantioselectivity 
(entry 8). 
 







Entry x (mol %) Additive t (h) Yield (%)b ee (%)c 
1 10 none 0.5 95 91 
2 10 3Å MS 0.5 95 91 
3 10 4Å MS 0.5 94 91 
4 10 5Å MS 0.5 94 90 
6 10 H2O 0.5 90 87 
7 5 none 0.5 95 91 
8 2 none 0.5 93 90 
9 1 none 6 56 88 
a Unless otherwise specified, reactions were conducted with 3-5a (0.05 mmol), 3-6b (0.075 
mmol) and  3-4c (10 mol%) in toluene (0.5 mL) at room temperature. b Isolated yield.  c The 
ee value of the major stereoisomer,  determined by HPLC analysis on a chiral stationary 
phase. 
 
3.2.2 Substrate Scope 







3-4c (x mol %) RO2C
CO2tBu CO2tBu
R= 9-phenanthryl
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catalyzed enantioselective [3+2] cycloaddition between allenes and acrylates was 
examined (Table 3.5). Different -aryl-substituted acrylates could be employed, -
isomers were regiospecifically formed, and enantioselectivities were excellent in all 
the examples examined. Reactions of acrylates bearing electronwithdrawing aryl 
substituents proceeded very fast, typically completing in 10 min, while longer 
reaction time was required for the cyclization of the acrylate with electron-rich phenyl 
group at its -position (entry 48). The acrylate with 1- or 2-naphthyl substitution, or 
disubstituted phenyl was well-tolerated for the reaction (entries 1213). However, the 
use of -alkyl substituted acrylate resulted in the formation of the desired product in 
high yield, but only with moderate enantioselectivity (entry 1517), which 
presumably due to the rather flexible conformation of acrylate with a alkyl 
substitution compared to that of other -aryl substituents. The absolute configurations 
of the cycloaddition products were determined on the basis of the X-ray crystal 
structure of 3-7l. 
 
Table 3.5 Enantioselective alleneacrylates [3+2] cycloadditions catalyzed by 3-4ca 
 
 
Entry Product (R1) time  Yield (%)c ee (%)d 
1 3-7b (Ph) 0.5 h 95 91 
2 3-7c (4-ClC6H5) 10 min 96 94 
3 3-7d (4-BrC6H5) 10 min 97 93 
4 3-7e (4-MeC6H5) 3 h 81 90 
5 3-7f (4-OMeC6H5) 24 h 61 87 
6 3-7g (4-t-BuC6H5) 3 h 87 90 




8 3-7i (3-MeC6H5) 3 h 96 88 
9 3-7j (2-NO2C6H5) 0.5 h 96 90 
10 3-7k (2-FC6H5) 0.5 h 95 83 
11 3-7l (3,4-ClC6H4) 0.5 h 94 92 
12 3-7m (1-naphtyl) 0.5 h 96 80 
13 3-7n (2-naphtyl) 0.5 h 92 91 
14 3-7o (9-phenanthryl) 0.5 h 95 82 
15 3-7p (Bn) 5 h 91 68 
16 3-7q (CH3) 20 h 51 51 
17 3-7r (cyclohexyl) 48 h 44 47 
18 3-7s (H) 10 min 96 62 
a Unless otherwise specified, reactions were conducted with 3-5 (0.05 mmol), 3-6b (0.075 
mmol) and  3-4c (5 mol%) in toluene (0.5 mL) at room temperature. b Isolated yield.  




-Substituted acrylate, moreover, could undergo a unique deracemization 
reaction upon cycloaddition with racemic -substituted allenoate (Scheme 3.4). We 
were pleased to find that when (±)-3-6c was exposed to acrylate 3-5a in the presence 
of 5 mol % catalyst 3-4c, a 81% yield of cyclopentene 3-7t was formed within 1 h and 
that the corresponding product exhibited 76% ee. When -phenyl-substituted allenoate 
3-6d was employed, a similar result was observed, although the reaction rate was 
diminished (Scheme 3.4, 67% yield within 10 h, 84% ee). In each of these cases, these 
highly substituted cycloadducts were formed as single regio- and diastereomers via 
chiral phosphine-catalyzed [3+2] cycloaddition. Furthermore, alkynoate 3-8, which is 
generally much less reactive as compared to allenoate, was found to be suitable 
coupling partner, affording product 3-7a in 84% yield with 87% ee in the presence of 
10 mol % catalyst. 
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Scheme 3.4 Phosphine 3-4c-promoted [3+2] cycloaddition involving -
substituted allenoates and alkynoate as reaction substrates 
 
3.2.3 Derivative Synthesis 
The optically enriched functionalized cyclopentenes 3-7 are valuable molecules, 
due to the importance of five-membered ring structures in natural products and 
medicinal chemistry.98 With the established synthetic protocols,101 such structures are 
also attractive synthetic intermediates. As oxindoles are important structural scaffolds 
in pharmaceutical industry,102 synthetic value of the cycloaddition products was 
further demonstrated by converting 3-7j into a spiral oxindole. As illustrated in 
Scheme 3.5, reduction of the nitro group resulted in a spontaneous lactam formation 
and yielded spiral oxindole core 3-9, which was readily transformed to 3-10, an agent 



























Scheme 3.5 Preparation of a spiral oxindole derivative 
 
3.2.4 Plausible Mechanism and Transition State Model 
 
 
Scheme 3.6 Proposed mechanism and transition state model 
 
Mechanism of this reaction has not been rigorously investigated at this stage, 
based on Lu’s initial proposal39 and recent excellent mechanistic studies,104 a 
plausible mechanism and transition state model are presented in Scheme 3.6. We 
propose that the dipeptidic backbone of the catalyst adopts a conformation favoring its 
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hydrogen bonding interactions with the acrylate substrate. The phosphonium enolate 
intermediate, generated from the nucleophilic attack of the phosphine catalyst at the 
allene, approaches the acrylate from its Re face to yield the major stereoisomer. The 
formation of the -regioisomer is suppressed by the unfavorable steric interactions of 
the bulky tert-butyl group with the acrylate substrate and the sterically hindered 
carbamate moiety in the catalyst, which is analogous to Lu’s utilization of tert-butyl 
allenoate in an -selective cycloaddition.  
    
3.3 Conclusions 
In summary, we have developed a new family of dipeptide-based chiral 
phosphines; such phosphine catalysts are highly reactive, and their structures are 
easily tunable. We have also employed -substituted acrylates in the enantioselective 
cycloaddition reactions for the first time. D-Thr-L-tert-Leu-based phosphine 4c 
catalyzed the allene-acrylate [3+2] cyclizations efficiently, affording functionalized 
cyclopentenes containing quaternary stereocenters in a regiospecific and 
enantioselective manner. Detailed mechanistic investigations and applications of this 
class of novel catalysts to other organic transformations are currently ongoing in our 
laboratory. 
 
3.4 Experimental Section 
3.4.1 General Methods 
        1H and 13C NMR spectra were recorded on a Bruker ACF300 or DPX300 (300 
MHz) or AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts 




Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), dd (doublet of doublet), br s (broad singlet). Coupling constants were 
reported in Hertz (Hz). Low resolution mass spectra were obtained on a 
Finnigan/MAT LCQ spectrometer in ESI mode, and a Finnigan/MAT 95XL-T mass 
spectrometer in FAB mode. All high resolution mass spectra were obtained on a 
Finnigan/MAT 95XL-T spectrometer. Flash chromatography separation was 
performed on Merck 60 (0.040 - 0.063 mm) mesh silica gel. The enantiomeric 
excesses of products were determined by HPLC analysis on a chiral stationary phase. 
 





rbam- ate (3-1) 
To a solution of 2-12 (150 mg, 0.55 mmol) in CH2Cl2 (5 mL) at 0 oC was added 
Et3N (153 μL, 1.10 mmol) and (Boc)2O (143 mg, 0.66 mmol) under N2. The reaction 
mixture was allowed to warm to room temperature and stirring was continued for 
additional 2 hrs. After concentration in vacuo, the residue was directly purified by 
column chromatography (hexane:ethyl acetate = 10:1 to 5:1) to afford compound 3-11 
as a white solid (174 mg, 85% yield). To the crude 3-11 (174 mg, 0.46 mmol) in 
anhydrous CH2Cl2 (5 mL) at 0 oC was added triethylamine (95 mL, 0.69 mmol), 
followed by slow addition of TBSOTf (0.16 mL, 0.69 mmol). Then the mixture was 
stirred at room temperature for 1 hr. The reaction was quenched by the addition of 
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CH2Cl2 (2 × 20 mL). The organic extracts were combined and washed with brine, and 
dried over Na2SO4. Purification by column chromatography (hexane: ethyl acetate = 
10:1) afforded catalyst 3-1 (0.197 g, 88% yield) as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.51-7.30 (m, 10H), 4.73 (d, J = 9.5 Hz, 1H), 4.13 (d, J 
= 5.0 Hz, 1H), 3.59-3.43 (m, 1H), 2.36-2.20 (m, 2H), 1.46 (s, 9H), 1.11 (d, J = 6.5 Hz, 
3H), 0.91 (s, 9H), 0.09 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 155.5, 138.8 (d), 132.7 
(dd), 129.3, 128.4 (dd), 78.9, 76.7, 69.4, 53.5 (d), 32.3 (d), 28.5, 25.9, 20.4, 18.0, -4.6; 
31P NMR (202.5 MHz, CDCl3) δ -22.7 (s); HRMS (ESI) m/z calcd for C27H43NO3PSi 






To a stirred solution of N-Boc L-valine (0.176 g, 0.82 mmol) in anhydrous 
CH2Cl2 (5 mL) was added DCC (84 mg, 0.41 mmol), and the resulting mixture was 
stirred at room temperature for 2 hrs. The solution was then cooled down to 0 oC and 
a solution of 2-12 (0.1 g, 0.37 mmol) in CH2Cl2 (1 mL) was added dropwise over 2 
minutes. The reaction mixture was further stirred for 0.5 h at 0 oC and 0.5 h at room 
temperature.  Water (10 mL) was added to quench the reaction, and the resulting 
mixture was extracted with dichloromethane several times (3 x 10 mL). The 
combined organic extracts were dried over sodium sulfate, filtered, concentrated, and 




afford 3-13 (0.138 g, 79%) as a white solid. To a solution of 3-13 in anhydrous 
CH2Cl2 (5 mL) at 0 oC was added TEA (61 μL, 0.44 mmol), followed by addition of 
TBSOTf (0.11 mL, 0.69 mmol) slowly. Then the mixture was allowed to warm to 
room temperature and continued stirring for additional 1 hour. The reaction was 
quenched with saturated aqueous NaHCO3 (10 mL) and extracted with CH2Cl2 (2 × 
20 mL). The combined organic extracts were washed with brine, and dried over 
Na2SO4. Purification by column chromatography (hexane: ethyl acetate = 10:1) 
afforded catalyst 3-2 (0.140 g, 82% yield) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.56-7.28 (m, 10H), 6.33, (s, 1H), 5.03 (s, 1H), 4.32-
4.26 (m, 1H), 3.95-3.75 (m, 2H), 2.38 (dd, J1 = 3.9 Hz, J2 = 10.5 Hz, 1H), 2.20-2.12 
(m, 2H), 1.42 (s, 9H), 1.07 (d, J = 6.0 Hz, 3H), 0.98-0.90 (m, 15H), 0.10 (d, J = 2.1 
Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 170.9, 138.6, 132.9, 132.7 (d), 132.5, 128.4 
(dd), 79.6, 68.2(d), 60.0, 52.3 (d), 31.7 (d), 20.8, 19.2, 17.7 (d), -4.5; 31P NMR (121 
MHz, CDCl3) δ -23.9 (s); HRMS (ESI) m/z calcd for  C32H52N2O4PSi [M+H]+ = 











The catalyst 3-3a was prepared in an overall yield of 66% (2 steps), following 
the procedure described for the preparation of compound 3-2.  
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A white solid; 1H NMR (300 MHz, CDCl3) δ 7.56-7.28 (m, 10H), 6.25, (d, J = 8.4 Hz, 
1H), 4.98 (d, J = 8.1 Hz, 1H), 4.24 (d, J = 6.0 Hz, 1H), 3.90-3.85 (m, 2H), 2.40 (dd, J1 
= 6.6 Hz, J2 = 13.5 Hz, 1H), 2.23-2.11 (m, 2H), 1.44 (s, 9H), 1.07 (d, J = 6.3 Hz, 3H), 
0.96-0.91 (m, 15H), 0.10 (d, J = 2.4 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 170.7, 
155.7, 138.9 (d), 137.4, 132.7 (d), 128.4 (dd), 79.7, 68.5(d), 60.0, 52.3 (d), 31.8 (d), 
28.3, 25.6 (d), 21.0, 19.2, 17.9, 17.6, -4.5; 31P NMR (121 MHz, CDCl3) δ -23.6 (s); 
HRMS (ESI) m/z calcd for C32H52N2O4PSi [M+H]+ = 587.3428, found = 587.3453; 
[α]27D = -21.4 (c 0.30, CHCl3). 
 
(R)-N-((2S,3R)-3-(tert-Butyldimethylsilyloxy)-1-(diphenylphosphino)butan-2-yl)-3-









The catalyst 3-3b was prepared in an overall yield of 70% (2 steps), following the 
procedure described for the preparation of compound 3-2.  
A white solid; 1H NMR (500 MHz, CDCl3) δ 7.89, (d, J = 5.0 Hz, 1H), 7.34-7.25 (m, 
13H), 6.05, (d, J = 8.0 Hz, 1H), 5.38 (d, J = 8.0 Hz, 1H), 4.26 (t, J = 4.5 Hz, 1H), 
3.66-3.60 (m, 1H), 3.45 (dd, J1 = 5.0 Hz, J2 = 8.0 Hz, 1H), 2.05-1.79 (m, 3H), 1.03 (d, 
J = 5.5 Hz, 3H), 0.91-0.85 (m, 15H), 0.11 (d, J = 4.0 Hz, 6H); 13C NMR (125 MHz, 
CDCl3) δ 169.3, 139.7, 132.9, 132.7 (d), 132.6, 129.0, 128.9, 128.6 (dd), 127.2, 67.8 
(d), 62.2, 52.7 (d), 31.9, 28.3, 25.9, 21.1, 19.0, 18.0, 17.4, -4.5; 31P NMR (202 MHz, 
CDCl3) δ -24.1 (s); HRMS (ESI) m/z calcd for C33H48N2O4PSSi [M+H]+ = 627.2836, 

















The catalyst 3-3c was prepared in an overall yield of 67% (2 steps), following 
the procedure described for the preparation of compound 3-2.  
A white solid; 1H NMR (500 MHz, CDCl3) δ 7.53, (t, J = 7.0 Hz, 2H), 7.40-7.28 (m, 
8H), 6.06, (d, J = 7.5 Hz, 1H), 5.39 (d, J = 7.5 Hz, 1H), 4.24 (d, J = 5.5 Hz, 1H), 3.92-
3.85 (m, 2H), 3.42 (dd, J1 = 7.0 Hz, J2 = 13.5 Hz, 1H), 2.18-2.13 (m, 2H), 1.91 (d, J = 
6.0 Hz, 6H), 1.08 (d, J = 6.0 Hz, 3H), 0.96-0.90 (m, 15H), 0.10 (d, J = 4.0 Hz, 6H); 
13C NMR (125 MHz, CDCl3) δ 169.9, 154.0, 138.8 (d), 137.4 (d), 132.7 (d), 128.5 
(dd), 106.4, 88.3, 68.7 (d), 60.4, 52.6 (d), 32.0 (d), 31.0, 25.7 (d), 21.6 (d), 21.0, 19.0, 
18.0, 17.9, -4.5; 31P NMR (121 MHz, CDCl3) δ -23.6 (s); HRMS (ESI) m/z calcd for 
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To a stirred solution of 3-2 (0.052 g, 0.089 mmol) in anhydrous CH2Cl2 (0.5 mL) 
was added TFA (0.1 mL), and the resulting mixture was stirred at room temperature 
for 2 hrs. The reaction was then quenched with saturated aqueous NaHCO3 (10 mL), 
and extracted with CH2Cl2 several times (3 × 10 mL). The combined organic extracts 
were dried over sodium sulfate, filtered and concentrated. To a solution of the above 
residue in anhydrous CH2Cl2 (0.5 mL) at 0 oC was added 3,5-
bis(trifluoromethyl)phenyl isothiocyanate (20 μL, 0.098 mmol), and the mixture was 
stirred at 0 oC for 1 h. Purification by flash column chromatography (hexane/ethyl 
acetate = 15 : 1 to 8 : 1) afforded 3-3d as a white solid (48 mg, 72% yield). 
A white solid; 1H NMR (500 MHz, CDCl3) δ 8.83 (s, 1H), 8.66 (s, 1H), 7.82 (s, 2H), 
7.33 (s, 1H), 7.16-7.07 (m, 10H), 6.64 (d, J = 9.9 Hz, 1H), 4.84 (t, J = 7.6 Hz, 1H), 
4.25 (d, J = 6.3 Hz, 1H), 3.80-3.74 (m, 1H), 2.33 (dd, J1 = 6.3 Hz, J2 = 13.2 Hz, 1H), 
2.26-2.16 (m, 2H), 1.16 (d, J = 7.0 Hz, 3H), 1.11 (t, J = 5.7 Hz, 6H), 0.95 (s, 9H), 
0.11 (d, J = 15.1 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 181.8, 173.4, 139.9, 137.4 
(q), 132.7 (d), 131.9 (d), 131.0 (q), 128.8, 128.4 (d), 128.3 (d), 126.2, 124.5, 124.0, 
121.9, 117.9, 68.6 (d), 65.3, 53.6, 33.1 (d), 30.9, 25.9, 21.7, 19.5 (d), 17.9, -4.2, -4.6; 
31P NMR (121 MHz, CDCl3) δ -23.4 (s); HRMS (ESI) m/z calcd for 















The catalyst 3-4a was prepared in an overall yield of 68% (2 steps), following 
the procedure described for the preparation of compound 3-2.  
A white solid; 1H NMR (500 MHz, CDCl3) δ 7.52, (t, J = 6.5 Hz, 2H), 7.39-7.29 (m, 
8H), 5.99, (d, J = 7.5 Hz, 1H), 5.31 (d, J = 8.0 Hz, 1H), 4.28 (d, J = 6.5 Hz, 1H), 3.88-
3.77 (m, 2H), 2.38 (dd, J1 = 5.0 Hz, J2 = 13.5 Hz, 1H), 2.19-2.14 (m, 1H), 1.44 (s, 9H), 
1.10 (d, J = 5.5 Hz, 3H), 1.00 (s, 9H), 0.89 (s, 9H), 0.09 (s, 6H); 13C NMR (125 MHz, 
CDCl3) δ 170.0, 155.8, 138.8, 137.4 (d), 132.7 (d), 128.6 (dd), 79.5, 68.4 (d), 62.9, 
52.4 (d), 34.6, 32.2 (d), 29.7, 28.3, 26.8, 25.9, 21.5, 18.0, -4.4; 31P NMR (202 MHz, 
CDCl3) δ -23.6 (s); HRMS (ESI) m/z calcd for C33H54N2O4PSi [M+H]+ = 601.3585, 






To a stirred solution of N-Boc-L-lucine (0.379 g, 1.64 mmol) in anhydrous 
CH2Cl2 (8 mL) was added DCC (0.169 mg, 0.82 mmol), and the resulting mixture was 
stirred at room temperature for 2 hrs. The solution was then cooled down to 0 oC, and 
a solution of 3-14 (0.2 g, 0.74 mmol) in CH2Cl2 (2 mL) was added dropwise over 2 
minutes. The reaction mixture was further stirred at 0 oC for 0.5 h and then at room 
temperature for another 0.5 h.  Water (10 mL) was added to quench the reaction, and 
the resulting mixture was extracted with dichloromethane several times (3 x 10 mL). 
The combined organic extracts were dried over sodium sulfate, filtered and 
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concentrated, and the residue was purified by column chromatography (hexane: ethyl 
acetate = 10:1) under N2 to yield the intermediate 3-15 (0.292 g, 81%) as a white solid. 
To a solution of 3-15 in anhydrous DMF (138 L, 1.8 mmol) at room temperature 
under N2 was added imidazole (54.4 mg, 1.2 mmol), followed by TBDPSCl (198 mg, 
0.72 mmol). The resulting mixture was stirred for 24 h, and then quenched by 
additing water (3 mL), and extracted with diethyl ether several times (3 x 3 mL). The 
organic extracts were combined, washed with brine, and dried over Na2SO4. 
Purification by column chromatography (hexane: ethyl acetate = 20:1 to 10:1) 
afforded catalyst 3-4b (0.3 g, 70% yield) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 7.70-7.66, (m, 4H), 7.45-7.27 (m, 16H), 6.09, (d, J = 
8.5 Hz, 1H), 5.34 (d, J = 8.0 Hz, 1H), 4.23 (d, J = 5.5 Hz, 1H), 3.91-3.85 (m, 2H), 
2.38 (dd, J1 = 7.5 Hz, J2 = 14.0 Hz, 1H), 2.24-2.20 (m, 1H), 1.47 (s, 9H), 1.09 (s, 9H), 
1.05 (s, 9H), 0.98 (d, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 171.3, 155.8, 
138.7 (d), 137.8 (d), 135.9 (d), 134.8, 133.8, 133.2, 132.8 (d), 132.6, 129.8(d), 128.5 
(dd), 127.8 (d), 127.5, 79.5, 70.5(d), 63.0, 52.5 (d), 34.6, 32.6 (d), 27.1, 26.8, 21.8, 
21.5, 21.2, 19.4; 31P NMR (202 MHz, CDCl3) δ -23.3 (s); HRMS (ESI) m/z calcd for  
C43H58N2O4PSi [M+H]+ = 725.3898, found = 725.3918; [α]27D = -17.6 (c 0.33, 



















The catalyst 3-4c was prepared in an overall yield of 55% (2 steps), following 
the procedure described for the preparation of compound 3-4b.  
A white solid; 1H NMR (500 MHz, CDCl3) δ 7.71-7.68, (m, 4H), 7.49-7.28 (m, 16H), 
6.00, (d, J = 9.0 Hz, 1H), 5.70 (d, J = 7.5 Hz, 1H), 4.22 (t, J = 6.0 Hz, 1H), 3.92-3.87 
(m, 2H), 2.43 (dd, J1 = 7.5 Hz, J2 = 14.0 Hz, 1H), 2.25-2.20 (m, 1H), 1.95 (s, 9H), 
1.10 (s, 9H), 1.07 (s, 9H), 1.00 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
169.5, 154.1, 138.4 (d), 137.8 (d), 135.9 (d), 133.8, 132.8 (dd), 129.8 (d), 128.5 (dd), 
127.7 (d), 106.4, 88.2, 70.7 (d), 63.2, 52.5 (d), 34.8, 32.6 (d), 27.1, 21.9, 21.6, 21.2, 
19.3; 31P NMR (202 MHz, CDCl3) δ -22.2 (s); HRMS (ESI) m/z calcd for 
C43H55Cl3N2O4PSi [M+H]+ = 827.2729, found = 827.2740; [α]27D = -20.0 (c 0.82, 
CHCl3). 
 
3.4.3 Preparation of -Substituted Acrylates 
 
An aqueous solution of 1 N sodium hydroxide (10 mL) was added to different 
ethyl acrylate105-108 (5 mmol), then the reaction mixture was refluxed for 1 h. After 
cooling down to room temperature, the resulting mixture was extracted with diethyl 
ether several times (2 x 20 mL). The aqueous layer was then acidified with 3 N 
aqueous HCl solutions (pH < 1.0 by litmus paper test), and extracted with ethyl ether 
(3 x 20 mL). The combined organic extracts were dried over sodium sulfate, filtered 
and concentrated. The crude acrylic acids 3-17 (80-95%) were used directly for the 
subsequent reactions without further purification. 
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To a solution of acrylic acid (2 mmol) in CH2Cl2 (5 mL) at 0 oC was added 9-
phenanthrol (1.1 eq, 2.2 mmol), followed by EDC·HCl (1.2 eq, 2.4 mmol), and 
DMAP (0.2 eq, 0.4 mmol). The mixture was allowed to warm up to room temperature 
and continued stirring for 12 hrs. Saturated aqueous solution of NaHCO3 (15 mL) was 
added to quench the reaction, and the resulting mixture was extracted with CH2Cl2 
several times (3 x 15 mL). The combined organic extracts were washed with brine, 
and dried over Na2SO4. Purification by column chromatography (hexane: ethyl 
acetate = 20:1 to 10:1) afforded 3-5 as a white solid or colorless oil in 55-82% yield. 
 
Phenanthren-9-yl 2-phenylacrylate (3-5b) 
 
 
A white solid; 1H NMR (300 MHz, CDCl3) δ 8.76-8.68 (m, 2H), 8.06-8.03 (m, 1H), 
7.93-7.92 (m, 1H), 7.90-7.73 (m, 7H), 7.70-7.42 (m, 3H), 6.88 (d, J = 0.9 Hz, 1H), 
6.26 (d, J = 0.9 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 165.0, 145.1, 140.7, 136.3, 
131.5, 131.4, 128.9, 128.7, 128.5, 128.4, 128.2, 127.2, 127.0, 126.9, 126.5, 126.4, 
122.9, 122.6, 121.8, 117.7; HRMS (ESI) m/z calcd for  C23H16NaO2  [M+Na]+ = 
347.1042, found = 347.1044. 
 






A white solid; 1H NMR (300 MHz, CDCl3) δ 8.75-8.66 (m, 2H), 7.97-7.87 (m, 2H), 
7.74-7.62 (m, 4H), 7.59-7.55 (m, 2H), 7.43-7.40 (m, 2H), 6.87 (s, 1H), 6.23 (s, 1H); 
13C NMR (75 MHz, CDCl3) δ 164.7, 145.0, 139.6, 134.7, 134.6, 131.6, 131.4, 129.8, 
129.2, 129.0, 128.5, 127.3, 127.1, 127.0, 126.5, 126.4, 123.0, 122.7, 121.8, 117.7; 
HRMS (ESI) m/z calcd for C23H15ClNaO2 [M+Na]+ = 381.0653, found = 381.0650. 
 
Phenanthren-9-yl 2-(4-bromophenyl)acrylate (3-5d) 
 
 
A white solid; 1H NMR (300 MHz, CDCl3) δ 8.75-8.67 (m, 2H), 7.80-7.86 (m, 2H), 
7.75-7.49 (m, 9H), 6.87 (d, J = 0.6 Hz, 1H), 6.26 (d, J = 0.6 Hz, 1H); 13C NMR (75 
MHz, CDCl3) δ 164.6, 145.0, 139.7, 135.1, 131.6, 131.4, 130.1, 129.2, 129.0, 128.5, 
127.3, 127.1, 127.0, 126.5, 126.4, 123.0, 122.8, 122.7, 121.8, 117.7;  HRMS (ESI) 
m/z calcd for C23H15BrNaO2 [M+Na]+ = 425.0153, found = 425.0158. 
 




Colorless oil; 1H NMR (300 MHz, CDCl3) δ 8.75-8.67 (m, 2H), 8.01-7.87 (m, 2H), 
7.74-7.53 (m, 7H), 7.26 (d, J = 7.8 Hz, 2H), 6.79 (d, J = 0.9 Hz, 1H), 6.20 (d, J = 0.9 
Hz, 1H), 2.42 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 165.3, 145.1, 140.6, 138.4, 133.4, 
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123.0, 122.6, 121.9, 117.7, 21.2; HRMS (ESI) m/z calcd for C24H18NaO2 [M+Na]+ = 
361.1200, found = 361.1206. 
 





Colorless oil; 1H NMR (500 MHz, CDCl3) δ 8.71 (dd, J1 = 8.0 Hz, J2 = 25.0 Hz, 2H), 
8.00 (d, J = 7.5 Hz, 1H), 7.89 (d, J = 7.5 Hz, 1H), 7.73-7.59 (m, 7H), 6.97 (d, J = 7.8 
Hz, 2H), 6.79 (d, J = 9.0 Hz, 1H), 6.77 (s, 1H), 6.18 (s, 1H), 3.86 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 165.4, 159.9, 145.2, 140.1, 131.6, 131.5, 129.7, 128.9, 128.7, 
128.5, 127.2, 127.0, 126.9, 126.6, 126.4, 123.0, 122.6, 121.9, 117.7, 113.7, 55.3; 
HRMS (ESI) m/z calcd for C24H18NaO3 [M+Na]+ = 377.1148, found = 377.1150. 
 
Phenanthren-9-yl 2-(4-tert-butylphenyl)acrylate (3-5g) 
 
 
Colorless oil; 1H NMR (500 MHz, CDCl3) δ 8.72 (dd, J1 = 8.5 Hz, J2 = 25.0 Hz, 2H), 
8.00 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.73-7.59 (m, 7H), 7.48 (d, J = 7.5 
Hz, 2H), 6.81 (s, 1H), 6.22 (s, 1H), 1.39 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 165.3, 
151.7, 145.2, 140.6, 133.4, 131.7, 131.6, 129.0, 128.6, 128.2, 128.1, 127.2, 127.1, 
127.0, 126.7, 126.5, 125.3, 123.0, 122.7, 122.0, 117.8, 34.7, 31.3;  HRMS (ESI) m/z 
















A white solid; 1H NMR (500 MHz, CDCl3) δ 8.74-8.67 (m, 2H), 7.95-7.71 (m, 2H), 
7.70-7.60 (m, 9H), 6.91 (s, 1H), 6.26 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 164.6, 
154.0, 145.0, 139.9, 138.7, 137.1, 131.7, 131.5, 130.1, 129.9, 129.0, 128.9, 128.5, 
127.2, 127.0, 126.6, 126.5, 126.4, 123.1, 122.7, 121.8, 117.8;  HRMS (ESI) m/z calcd 
for C24H15NNaO2 [M+Na]+ = 372.0094, found = 372.0090. 
 
Phenanthren-9-yl 2-m-tolylacrylate (3-5i) 
 
 
Colorless oil; 1H NMR (500 MHz, CDCl3) δ 8.72 (dd, J1 = 8.0 Hz, J2 = 25.5 Hz, 2H), 
7.99 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.73-7.60 (m, 5H), 7.44 (d, J = 11.0 
Hz, 2H), 7.34 (t, J = 8.0 Hz, 1H), 7.23 (d, J = 8.0 Hz, 2H), 6.82 (s, 1H), 6.21 (s, 1H), 
2.43 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 165.2, 145.1, 140.9, 137.9, 136.3, 131.6, 
131.5, 129.3, 129.2, 128.9, 128.5, 128.4, 128.2, 127.2, 127.1, 126.9, 126.6, 126.4, 
125.6, 123.0, 122.7, 121.9, 117.7, 21.4;  HRMS (ESI) m/z calcd for C27H24NaO2 
[M+Na]+ = 403.1668, found = 403.1662. 
 
Phenanthren-9-yl 2-(2-nitrophenyl)acrylate (3-5j) 




A yellow solid; 1H NMR (500 MHz, CDCl3) δ 8.61 (dd, J1 = 8.0 Hz, J2 = 25.0 Hz, 
2H), 8.18 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 3.0 Hz, 1H), 7.92 (d, J = 3.0 Hz, 1H), 7.87-
7.47 (m, 8H), 6.91 (s, 1H), 6.11 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 163.6, 147.5, 
144.8, 139.5, 135.7, 133.9, 132.5, 132.2, 131.3, 131.2, 130.0, 129.6, 129.2, 128.8, 
128.4, 127.1, 126.9, 126.8, 126.4, 126.2, 124.7, 123.7, 122.8, 121.5, 121.7, 117.6; 
HRMS (ESI) m/z calcd for C23H15NNaO4 [M+Na]+ =  392.0893, found = 392.0894. 
 
Phenanthren-9-yl 2-(2-fluorophenyl)acrylate (3-5k) 
 
1H NMR (500 MHz, CDCl3) δ 8.70 (dd, J1 = 7.5 Hz, J2 = 23.5 Hz, 2H), 7.96 (d, J = 
8.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.71-7.59 (m, 5H), 7.50-7.47 (m, 2H), 7.42-
7.38 (m, 2H), 6.91 (s, 1H), 6.18 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 164.5, 161.1, 
159.1, 145.2, 136.3, 131.6, 131.5, 131.2, 131.0, 130.9, 130.5, 130.4, 129.0, 128.5, 
127.2, 127.0, 126.9, 126.6, 126.4, 124.9, 124.8, 124.2, 124.1, 122.9, 121.6, 122.0, 
117.6, 115.7, 115.6; HRMS (ESI) m/z calcd for  C23H15FNaO2 [M+Na]+ = 365.0954, 
found = 365.0971. 
 





A white solid; 1H NMR (500 MHz, CDCl3) δ 8.72 (dd, J1 = 8.0 Hz, J2 = 27.0 Hz, 2H), 
7.93 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.74-7.61 (m, 6H), 7.51-7.45 (m, 
2H), 6.91 (s, 1H), 6.26 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 144.9, 138.7, 136.1, 
132.8, 132.5, 131.7, 131.4, 130.5, 130.2, 130.0, 129.0, 128.5, 127.9, 127.3, 127.2, 
127.0, 126.6, 126.4, 123.1, 122.7, 121.7, 117.8; HRMS (ESI) m/z calcd for  
C23H14Cl2NaO2 [M+Na]+ = 415.0264, found = 415.0268. 
 
Phenanthren-9-yl 2-(naphthalen-1-yl)acrylate (3-5m) 
 
 
A white solid; 1H NMR (500 MHz, CDCl3) δ 8.64 (dd, J1 = 8.5 Hz, J2 = 15.0 Hz, 2H), 
8.07 (d, J = 9.0 Hz, 1H), 7.96-7.93 (m, 2H), 7.83 (d, J = 9.0 Hz, 1H), 7.65-7.46 (m, 
9H), 7.09 (d, J = 1.3 Hz, 1H), 6.18 (d, J = 1.3 Hz, 1H); 13C NMR (125 MHz, CDCl3) 
δ 165.4, 144.9, 140.5, 134.9, 133.5, 131.9, 131.7, 131.4, 128.9, 128.8, 128.5, 128.4, 
127.2, 127.1, 127.0, 126.7, 126.5, 126.4, 126.1, 125.4, 125.3, 122.8, 122.6, 121.9, 
117.3; HRMS (ESI) m/z calcd for  C23H14Cl2NaO2 [M+Na]+ = 415.0263, found = 
415.0259. 
 
Phenanthren-9-yl 2-(naphthalen-2-yl)acrylate (3-5n) 
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A white solid; 1H NMR (500 MHz, CDCl3) δ 8.75-8.68 (m, 2H), 8.14 (s, 1H), 8.03 (d, 
J = 8.0 Hz, 1H), 7.92-7.83 (m, 2H), 7.76-7.61 (m, 7H), 7.56-7.49 (m, 3H), 6.93 (s, 
1H), 6.36 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 165.2, 145.1, 140.8, 133.7, 133.3, 
133.1, 129.0, 128.5, 128.4, 127.8, 127.6, 127.2, 127.1, 127.0, 126.9, 126.6, 126.5, 
126.4, 126.3, 126.1, 123.0, 122.7, 121.9, 117.8; HRMS (ESI) m/z calcd for  
C23H14Cl2NaO2 [M+Na]+ = 415.0264, found = 415.0270. 
 
Phenanthren-9-yl 2-(phenanthren-9-yl)acrylate (3-5o) 
 
 
1H NMR (300 MHz, CDCl3) δ 8.83-8.80 (m, 2H), 8.76-8.58 (m, 2H), 8.16-8.12 (m, 
1H), 8.00-7.56 (m, 12H), 7.45 (t, J = 8.4 Hz, 1H), 7.13 (d, J = 1.2 Hz, 1H), 6.29 (t, J = 
1.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 165.4, 144.8, 140.7, 133.7, 131.7, 131.3, 
130.9, 130.5, 130.4, 128.8, 128.7, 128.4, 128.1, 127.1, 127.0, 126.9, 126.8, 126.7, 
126.6, 126.4, 126.3, 126.1, 123.1, 122.7, 122.6, 122.5, 121.8, 117.3; HRMS (ESI) m/z 
calcd for  C31H20NaO2 [M+Na]+ = 447.1361, found = 415.0270. 
 






A colorless oil; 1H NMR (300 MHz, CDCl3) δ 8.71 (dd, J1 = 8.5 Hz, J2 = 15.0 Hz, 
2H), 7.86 (d, J = 8.0 Hz, 1H), 7.67-7.54 (m, 6H), 7.43-7.34 (m, 5H), 6.71 (s, 1H), 




131.5, 131.4, 129.1, 128.9, 128.6, 128.4, 128.3, 127.1, 127.0, 126.8, 126.6, 126.5, 
126.4, 122.9, 122.6, 121.9, 117.7;  HRMS (ESI) m/z calcd for C24H18NaO2 [M+Na]+ 
= 361.1200, found = 361.1202. 
 
Phenanthren-9-yl methacrylate (3-5q) 
 
 
1H NMR (300 MHz, CDCl3) δ 8.72 (dd, J1 = 8.0 Hz, J2 = 15.0 Hz, 2H), 7.98 (d, J = 
8.0 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.74-7.58 (m, 5H), 6.58 (d, J = 6.0 Hz, 1H), 
5.90 (d, J = 5.5 Hz, 1H), 2.21-2.20 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 165.8, 
145.1, 135.8, 131.5, 128.9, 128.4, 127.6, 127.0, 126.9, 126.7, 126.4, 122.9, 122.6, 
121.8, 117.7, 18.5; HRMS (ESI) m/z calcd for C18H14NaO2 [M+Na]+ = 285.0851, 
found = 285.0844. 
 
Phenanthren-9-yl 2-cyclohexylacrylate (3-5r) 
 
 
1H NMR (300 MHz, CDCl3) δ 8.70 (dd, J1 = 8.5 Hz, J2 = 15.0 Hz, 2H), 7.94 (d, J = 
8.0 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.72-7.58 (m, 5H), 6.60 (s, 1H), 6.82 (s, 1H), 
2.68 (t, J = 5.0 Hz, 1H), 2.02-1.75 (m, 5H), 1.45-1.20 (m, 5H); 13C NMR (125 MHz, 
CDCl3) δ 165.8, 145.9, 145.3, 131.7, 131.6, 128.9, 128.4, 127.1, 127.0, 126.8, 126.3, 
124.2, 122.9, 122.6, 121.9, 117.4, 39.4, 32.7, 26.6, 26.2; HRMS (ESI) m/z calcd for 
C22H22NaO2 [M+Na]+ = 353.1517, found = 353.1500. 
Chapter 3 [3+2] Cycloaddition of Acrylates with Allenoates 
105 
 




1H NMR (300 MHz, CDCl3) δ 8.71 (dd, J1 = 8.0 Hz, J2 = 15.0 Hz, 2H), 7.97 (d, J = 
8.0 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.73-7.60 (m, 5H), 6.78 (d, J = 6.0 Hz, 1H), 
6.57-6.51 (m, 1H), 6.13 (d, J = 5.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 164.6, 
144.8, 133.1, 131.6, 131.5, 128.9, 128.5, 127.7, 127.2, 127.0, 126.9, 126.5, 122.9, 
122.6, 121.8, 117.7; HRMS (ESI) m/z calcd for C17H12NaO2 [M+Na]+ = 271.0735, 
found = 271.0721. 
 




To a flame-dried round bottle flask with a magnetic stirring bar were added 
catalyst 3-4c (2.1 mg, 0.0025 mmol) and acrylate 3-5 (0.05 mmol) under N2, followed 
by the addition of anhydrous toluene (0.5 mL). Allenoate 3-6b (11 μL, 0.075 mmol) 
was then added, and the reaction mixture was stirred at room temperature for a given 
period (as specified in Table 3.4.  At the end of the reaction, the mixture was 
subjected directly to flash column chromatographic separation using a mixture of 









3.4.5 Analytical Data of [3+2] Adducts 





A white solid; [α]27D = +10.9 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.71 (d, J 
= 13.4 Hz, 1H), 8.66 (d, J = 12.6 Hz, 1H), 7.95 (d, J = 12.9 Hz, 1H), 7.87-7.84 (m, 
1H), 7.72-7.57 (m, 4H), 7.52 (s, 1H), 6.67 (d, J = 3.1 Hz, 1H), 3.45-3.12 (m, 2H), 
2.92-2.73 (m, 2H), 2.19-2.09 (m, 1H), 1.91-1.75 (m, 5H), 1.54 (s, 9H), 1.49-1.18 (m, 
5H); 13C NMR (125 MHz, CDCl3) δ175.3, 164.0, 145.0, 140.0, 136.1, 131.5, 131.4, 
128.7, 128.4, 127.1, 127.0, 126.8, 126.7, 126.3, 122.9, 122.6, 121.7, 117.3, 80.5, 57.6, 
45.7, 39.7, 38.7, 28.2, 28.1, 28.0, 26.5, 26.3; HRMS (ESI) m/z calcd for C31H28NaO4 
[M+Na]+ = 487.1880, found = 487.1891; the ee value was 91%, tR (major) = 28.6 min, 




late  (3-7c) 
 
A white solid; [α]27D = +1.4 (c 0.93, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.66 (d, J 
= 8.2 Hz, 1H), 8.62 (d, J = 8.2 Hz, 1H), 7.81-7.79 (m, 1H), 7.65-7.56 (m, 3H), 7.54-
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3.98 (dd, J = 1.3 Hz, 16.4 Hz, 1H), 3.88 (d, J = 18.3 Hz, 1H), 3.27-3.23 (m, 1H), 
3.10-3.05 (m, 1H), 1.58 (s, 9H); 13C NMR (125 MHz, CDCl3) δ173.5, 163.7, 144.9, 
140.5, 139.7, 136.6, 133.6, 131.5, 131.3, 129.0, 128.9, 128.4, 127.1, 127.0, 126.8, 
126.5, 126.4, 122.9, 122.6, 121.4, 117.3, 80.8, 58.5, 43.0, 41.3, 28.2; HRMS (ESI) 
m/z calcd for  C31H27ClNaO4 [M+ Na]+ = 521.1487, found = 521.1486; the ee value 
was 94%, tR (major) = 21.2 min, tR (minor) = 25.6 min (Chiralcel IB-H, λ = 254 nm, 





A white solid; [α]27D = -6.6 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.66 (d, J = 
8.2 Hz, 1H), 8.62 (d, J = 8.2 Hz, 1H), 7.80 (d, J = 7.6 Hz, 1H), 7.65-7.56 (m, 5H), 
7.47-7.43 (m, 3H), 7.36 (s, 1H), 7.29 (d, J = 8.1 Hz, 1H), 6.82 (s, 1H), 3.96 (dd, J = 
1.3 Hz, 16.4 Hz, 1H), 3.87 (dd, J = 1.3 Hz, 18.3 Hz, 1H), 3.25-3.21 (m, 1H), 3.09-
3.05 (m, 1H), 1.56 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 173.4, 163.7, 144.9, 141.1, 
139.7, 136.6, 132.0, 131.5, 131.3, 128.9, 128.8, 128.4, 127.2, 127.1, 126.8, 126.5, 
126.4, 122.9, 122.6, 121.7, 121.4, 117.3, 80.9, 58.6, 42.9, 41.2, 28.2; HRMS (ESI) 
m/z calcd for C31H27BrO4 [M+ Na]+ = 565.1009, found = 565.1007; the ee value was 
93%, tR (major) = 14.4 min, tR (minor) = 16.7 min (Chiralcel IB-H, λ = 254 nm, 10% 











A white solid; [α]27D = -12.8 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.64 (d, J 
= 8.2 Hz, 1H), 8.62 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.63-7.55 (m, 3H), 
7.47 (d, J = 8.2 Hz, 2H), 7.41-7.37 (m, 2H), 7.31-7.28 (m, 3H), 6.82 (s, 1H), 3.96 (d, 
J = 16.4 Hz, 1H), 3.87 (d, J = 18.3 Hz, 1H), 3.26 (dd, J = 2.5 Hz, 16.4 Hz,1H), 3.10 
(dd, J = 2.5 Hz, 18.3 Hz, 1H), 1.56 (s, 9H); 13C NMR (125 MHz, CDCl3) δ174.1, 
163.9, 145.1, 140.0, 139.1, 137.3, 236.7, 131.5, 131.4, 129.54, 128.9, 128.4, 127.0, 
130.0, 126.9, 126.7, 126.6, 126.4, 122.8, 122,6, 121.7, 117.3, 80.7, 58.7, 43.1, 41.2, 
28.2, 21.0; HRMS (ESI) m/z calcd for C32H30NaO4 [M+ Na]+ = 501.2036, found = 
501.2059; the ee value was 90%, tR (major) = 11.2 min, tR (minor) = 13.5 min 





A white solid; [α]27D = -1.2 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.65 (d, J = 
8.2 Hz, 1H), 8.62 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.63-7.55 (m, 5H), 
7.52-7.49 (m, 1H), 7.44-7.40 (m, 1H), 7.31 (d, J = 8.2 Hz, 1H), 7.01-6.99 (m, 2H), 
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(m, 1H), 3.11-3.07 (m, 1H), 1.56 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 174.1, 163.9, 
159.0, 145.1, 140.0, 136.7, 134.0, 131.5, 131.4, 128.9, 128.4, 128.2, 127.0, 127.0, 
126.7, 126.6, 126.4, 122.8, 122.6, 121.6, 117.3, 114.2, 80.7, 58.4, 55.3, 43.1, 41.3, 
28.2; HRMS (ESI) m/z calcd for C32H30O5 [M+ Na]+ = 517.1985, found = 517.2004; 
the ee value was 87%, tR (major) = 10.7 min, tR (minor) = 12.8 min (Chiralcel IC-H, λ 





A white solid; [α]27D = -12.9 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.65-8.60 
(m, 2H), 7.82-7.79 (m, 1H), 7.64-7.51 (m, 7H), 7.48 (d, J = 15.5 Hz, 1H), 7.39 (s, 1H), 
7.35-7.29 (m, 1H), 7.16-7.14 (m, 1H), 6.82 (d, J = 1.9 Hz, 1H), 3.99-3.86 (m, 2H), 
3.32-3.26 (m, 1H), 3.17-3.10 (m, 1H), 1.56 (s, 9H), 1.40 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 174.0, 163.9, 150.6, 145.0, 140.0, 139.0, 136.7, 131.5, 131.4, 128.9, 128.4, 
127.0, 126.9, 126.7, 126.6, 126.3, 125.8, 122.8, 122.6, 121.6, 117.4, 80.7, 58.6, 43.0, 
41.1, 34.6, 31.4, 28.2; HRMS (ESI) m/z calcd for  C35H36NaO4 [M+ Na]+ = 543.2511, 
found = 543.2506; the ee value was 90%, tR (major) = 13.0 min, tR (minor) = 17.0 min 








A white solid; [α]27D = -15.2 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.67-8.62 
(m, 2H), 7.79-7.78 (d, J = 7.5 Hz, 1H), 7.66-7.58 (m, 7H), 7.48 (d, J = 7.5 Hz, 1H), 
7.45-42 (m, 1H), 7.41 (s, 1H), 7.36 (s, 1H), 6.81(s, 1H), 3.99-3.23 (m, 2H), 3.12 (d, J 
= 2.5 Hz, 1H), 3.08 (d, J = 1.9 Hz, 1H), 1.55 (s, 9H), 1.40 (s, 9H); 13C NMR (125 
MHz, CDCl3) δ 173.2, 163.6, 154.0, 144.9, 144.8, 139.5, 136.6, 136.5, 131.5, 131.3, 
128.9, 128.4, 127.2, 127.1, 127.0, 126.8, 126.5, 126.4, 122.9, 122.6, 121.4, 117.2, 
80.7, 58.6, 43.0, 41.1, 34.6, 31.4, 28.2; HRMS (ESI) m/z calcd for C32H27NaNO4 [M+ 
Na]+ = 512.1832, found = 512.1827; the ee value was 94%, tR (major) = 22.1 min, tR 
(minor) = 17.0 min (Chiralcel AD-H, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 
1.0 mL/min). 
 
(S)-3-tert-Butyl 1-phenanthren-9-yl 1-m-tolylcyclopent-3-ene-1,3-dicarboxylate (3-7i) 
 
A white solid; [α]27D = +5.2 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.65 (d, J 
= 8.2 Hz, 1H), 8.62 (d, J = 8.2 Hz, 1H), 7.80 (d, J = 2.6 Hz, 1H), 7.63-7.56 (m, 3H), 
7.41-7.36 (m, 5H), 7.30 (d, J = 8.2 Hz, 1H), 7.22 (d, J = 7.6 Hz, 1H), 6.83 (s, 1H), 
3.97 (d, J = 16.4 Hz, 1H), 3.89 (d, J = 17.7 Hz, 1H), 3.26-3.20 (m, 1H), 3.15-3.11 (m, 
1H), 2.44 (s, 3H), 1.57 (s, 9H); 13C NMR (125 MHz, CDCl3) δ174.0, 163.9, 145.1, 
141.9, 134.0, 138.6, 136.7, 131.5, 131.4, 128.9, 128.8, 128.4, 128.3, 127.7, 127.1, 
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127.0, 126.8, 126.6, 126.4, 124.0, 122.8, 122.6, 121.7, 117.4, 80.7, 58.9, 43.0, 41.2, 
28.2, 21.6; HRMS (ESI) m/z calcd for C32H30NaO4 [M+ Na]+ = 501.2036, found =  
501.2054; the ee value was 88%, tR (major) = 9.8 min, tR (minor) = 11.9 min 





A yellow solid; [α]27D = -24.5 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.67 (d, 
J = 8.2 Hz, 1H), 8.65 (d, J = 8.2 Hz, 1H), 8.10-8.08 (m, 1H), 7.92-7.90 (m, 1H), 7.85 
(d, J = 7.6 Hz, 1H), 7.72-7.59 (m, 8H), 7.53-7.50 (m, 1H), 6.80 (d, J = 1.9 Hz, 1H), 
3.97 (dd, J = 2.6 Hz, 18.9 Hz, 1H), 3.91-3.86 (m, 1H), 3.53 (d, J = 17.1 Hz, 1H), 3.23 
(d, J = 18.9 Hz, 1H), 1.58 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 172.3, 163.4, 148.2, 
144.6, 139.0, 137.7, 135.5, 133.5, 131.5, 131.4, 128.9, 128.8, 128.7, 128.4, 127.1, 
127.0, 126.8, 126.5, 126.4, 125.7, 122.9, 122.5, 121.4, 117.6, 81.1, 56.7, 45.5, 44.2, 
28.1; HRMS (ESI) m/z calcd for C31H27NaNO6 [M+ Na]+ = 532.1731, found = 
532.1729; the ee value was 90%, tR (major) = 15.6 min, tR (minor) = 22.4 min 








1H NMR (500 MHz, CDCl3) δ 1.54 (s, 9H), 3.13 (dd, J = 1.9 Hz, 18.3 Hz, 1H), 3.40 
(dd, J = 1.9 Hz, 17.0 Hz, 1H), 3.78-3.87 (m, 2H), 6.76 (t, J = 1.9 Hz, 1H), 7.19-7.25 
(m, 2H), 7.35-7.40 (m, 1H), 7.48-7.57 (m, 3H), 7.58-7.66 (m, 4H), 7.83-7.85 (m, 1H), 
8.63 (d, J = 8.2 Hz, 1H), 8.66 (d, J = 8.2 Hz, 1H); HRMS (ESI) m/z calcd for 
C31H27NaFO4 [M+ Na]+ = 505.1795, found = 505.1788; the ee value was 83%, tR 
(major) = 13.3 min, tR (minor) = 18.6 min (Chiralcel IB-H, λ = 254 nm, 10% 










A white solid; [α]27D = +5.5 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.65 (dd, J 
= 8.2 Hz, 20.0 Hz, 2H), 7.80 (d, J = 7.6 Hz, 1H), 7.68-7.54 (m, 5H), 7.49 (t, J = 7.6 
Hz, 1H), 7.43-7.37 (m, 3H), 6.81 (s, 1H), 3.95 (d, J = 16.4 Hz, 1H), 3.86 (d, J = 17.7 
Hz, 1H), 3.21 (dd, J = 1.9 Hz, 16.4 Hz, 1H), 3.07 (dd, J = 1.9 Hz, 18.3 Hz, 1H), .56 (s, 
9H); 13C NMR (125 MHz, CDCl3) δ 173.0, 163.5, 144.8, 142.2, 139.4, 136.6, 133.1, 
132.0, 131.5, 131.2, 130.8, 129.1, 128.9, 128.4, 127.2, 127.1, 126.9, 126.6, 126.4, 
126.3, 123.0, 122.6, 121.3, 117.3, 81.0, 58.4, 43.0, 41.4, 28.2; HRMS (ESI) m/z calcd 
for C31H26Cl2NaO4 [M+ Na]+ = 555.1100, found = 555.1122; the ee value was 92%, tR 
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(major) = 16.5 min, tR (minor) = 21.7 min (Chiralcel IB-H, λ = 254 nm, 10% 







A white solid; [α]27D = +9.4 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.57 (dd, J 
= 3.2 Hz, 8.2 Hz, 2H), 8.21-8.19 (m, 1H), 8.02-7.99 (m, 1H), 7.90 (d, J = 8.2 Hz, 1H), 
7.76-7.71 (m, 2H), 7.60-7.52 (m, 6H), 7.29 (s, 1H), 7.22-7.19 (m, 1H), 7.02 (d, J = 
8.2 Hz, 1H), 6.77 (d, J = 2.5 Hz, 1H), 3.99-3.90 (m, 2H), 3.69 (d, J = 16.4 Hz, 1H), 
3.43 (d, J = 18.9 Hz, 1H), 1.55 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 175.5, 163.8, 
144.9, 139.2, 137.7, 135.7, 134.8, 131.3, 131.3, 131.2, 129.6, 128.8, 128.7, 128.4, 
127.0, 126.9, 126.7, 126.5, 126.4, 126.3, 125.7, 125.3, 124.3, 124.1, 122.6, 122.5, 
121.6, 117.1, 80.8, 57.9, 44.3, 42.6, 28.2; HRMS (ESI) m/z calcd for C35H30NaO4 
[M+ Na]+ = 537.2036, found = 537.2043; the ee value was 80%, tR (major) = 16.2min, 
tR (minor) = 20.0 min (Chiralcel IB-H, λ = 254 nm, 5% iPrOH/hexanes, flow rate = 
1.0 mL/min). 
 










A white solid; [α]27D = -9.8 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.61 (t, J = 
8.8 Hz, 2H), 8.04 (s, 1H), 7.97 (d, J = 8.8 Hz, 1H), 7.93-7.91 (m, 2H), 7.77 (d, J = 7.6 
Hz, 1H), 7.72 (dd, J = 1.9 Hz, 8.2 Hz, 1H), 7.60-7.54 (m, 5H), 7.37 (s, 1H), 7.29-7.23 
(m, 2H), 6.88 (s, 1H), 4.10-3.98 (m, 2H), 3.44-3.41 (m, 1H), 3.28-3.24 (m, 1H), 1.58 
(s, 9H); 13C NMR (125 MHz, CDCl3) δ 173.9, 163.9, 145.1, 139.9, 139.3, 136.7, 
133.3, 132.6, 131.4, 131.3, 128.9, 128.8, 128.4, 128.2, 127.6, 127.0, 127.0, 126.7, 
126.5, 126.5, 126.4, 126.3, 125.6, 125.1, 122.8, 122.6, 121.6, 117.3, 80.8, 59.1, 43.1, 
41.3, 28.2; HRMS (ESI) m/z calcd for C35H30NaO4 [M+ Na]+ = 537.2036, found = 
537.2041; the ee value was 91%, tR (major) = 8.8 min, tR (minor) = 9.7 min (Chiralcel 





A white solid; 1H NMR (500 MHz, CDCl3) δ 1.57 (s, 9H), 3.53 (d, J = 17.8 Hz, 1H), 
3.78 (d, J = 16.9 Hz, 1H), 3.95-4.00 (m, 2H), 6.82 (s, 1H), 7.10 (d, J = 8.2 Hz, 1H), 
7.20 (t, J = 7.6 Hz, 1H), 7.27 (s, 1H), 7.51-7.59 (m, 3H), 7.63-7.71 (m, 2H), 7.98 (d, J 
= 7.0 Hz, 2H), 8.26 (d, J = 8.2 Hz, 1H), 8.56 (d, J = 8.2 Hz, 1H), 8.73 (d, J = 8.2 Hz, 
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1H), 8.88 (d, J = 8.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 28.21, 42.63, 44.32, 
57.78, 80.88, 117.10, 121.66, 122.41, 122.53, 122.62, 123.94, 125.06, 125.28, 126.32, 
126.46, 126.51, 126.89, 126.94, 126.94, 127.01, 127.08, 127.16, 128.39, 128.82, 
129.10, 130.35, 131.27, 131.31, 131.76, 135.65, 135.83, 139.06, 145.00, 163.82, 
175.62; HRMS (ESI) m/z calcd for C39H32NaO4 [M+ Na]+ = 587.2203, found = 
587.2215; the ee value was 82%, tR (minor) = 15.3 min, tR (major) = 26.0 min 
(Chiralcel AD-H, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1.0 mL/min). 
 
(R)-3-tert-Butyl 1-phenanthren-9-yl 1-benzylcyclopent-3-ene-1,3-dicarboxylate (3-7p) 
 
A white solid; [α]27D = +19.2 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.70 (d, J 
= 7.6 Hz, 1H), 8.65 (d, J = 7.6 Hz, 1H), 7.84-7.82 (m, 1H), 7.73 (d, J = 8.2 Hz, 1H), 
7.70-7.59 (m, 3H), 7.55 (t, J = 6.9 Hz, 1H), 7.43 (s, 1H), 7.36-7.31 (m, 5H), 6.70 (t, J 
= 1.9 Hz, 1H), 3.49-3.35 (m, 4H), 3.29 (d, J = 13.9 Hz, 1H), 3.02 (dd, J = 1.9 Hz, 17.0 
Hz, 1H), 2.88 (dd, J = 1.3 Hz, 18.9 Hz, 1H), 1.55 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 174.6, 163.9, 144.9, 139.6, 137.3, 136.1, 131.5, 131.4, 130.7, 129.930.0, 
128.8, 128.5, 128.5, 127.9, 127.1, 127.0, 126.9, 126.5, 126.4, 122.9, 122.6, 121.8, 
117.3, 80.6, 54.9, 44.3, 42.1, 41.6, 28.2; (ESI) m/z calcd for C32H30NaO4 [M+ Na]+ = 
501.2036, found = 501.2040; the ee value was 68%, tR (major) = 22.8 min, tR (minor) 






(S)-3-tert-Butyl 1-phenanthren-9-yl cyclopent-3-ene-1,3-dicarboxylate (3-7s) 
 
 
1H NMR (500 MHz, CDCl3) δ 1.53 (s, 9H), 3.01-3.07 (m, 1H), 3.13-3.20 (m, 3H), 
3.70 (dd, J = 7.6 Hz, 11.4 Hz, 1H), 6.70 (s, 1H), 7.55 (s, 1H), 7.59-7.72 (m, 4H), 7.85 
(d, J = 7.6 Hz, 1H), 7.94 (d, J = 7.6 Hz, 1H), 8.67 (d, J = 8.2 Hz, 1H), 8.72 (d, J = 8.9 
Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 28.16, 35.57, 36.70, 42.01, 80.63, 117.59, 
121.67, 122.64, 123.02, 126.46, 126.50, 126.94, 127.07, 127.13, 127.22, 128.46, 
128.91, 131.46, 131.57, 136.62, 139.90, 144.86, 163.93, 173.63; (ESI) m/z calcd for 
C25H24NaO4 [M+ Na]+ = 411.1576, found = 411.1560; the ee value was 68%, tR 
(major) = 32.0 min, tR (minor) = 47.2 min (Chiralcel IB-H, λ = 254 nm, 10% 
iPrOH/hexanes, flow rate = 1.0 mL/min). 
 














(S)-tert-Butyl 2'-oxospiro[cyclopent[3]ene-1,3'-indoline]-3-carboxylate (3-9) 
To a solution of 3-7j (0.102 g, 0.2 mmol) in MeOH (1.6 mL) and H2O (0.4 mL) 
was added activated Zn dust (0.13 g, 2 mmol) and 7.0 M HCl (0.3 mL), and the 
reaction mixture was brought to reflux for 1 h. The mixture was then filtered through 
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(3 x 10 mL). The combined organic extracts were washed with brine, and dried over 
Na2SO4. Purification by column chromatography (hexane: ethyl acetate = 10:1) 
afforded 3-9 (46.2 mg, 81%) as a yellow oil.  
1H NMR (300 MHz, CDCl3) δ 9.68 (s, 1H), 7.30-7.19 (m, 2H), 7.05-6.95 (m, 2H), 
6.79 (s, 1H), 3.29-3.17 (m, 2H), 2.91-2.76 (m, 2H), 1.53 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 183.8, 163.5, 139.9, 139.5, 136.8, 136.3, 127.9, 122.9, 122.0, 110.0, 80.6, 
52.5, 44.8, 43.5, 28.0; (ESI) m/z calcd for C17H19NaNO3 [M+Na]+ = 308.1257, found 
= 308.1263; [α]27D = -28.2 (c 0.9, CHCl3); the ee value was 90%, tR (major) = 19.5 
min, tR (minor) = 17.9 min (Chiralcel IB-H, λ = 254 nm, 5% iPrOH/hexanes, flow rate 




To a solution of 3-9 (0.1 g, 0.35 mmol) in anhydrous CH2Cl2 (3 mL) was added 
TFA (0.26 mL, 3.5 mmol), and the resulting mixture was then stirred at room 
temperature for 15 hrs. Solvent was removed to afford the crude acid, which was then 
dissolved in anhydrous MeCN (3 mL), the solution was then cooled down to 0 oC, to 
which HOBt (45.5 mg, 0.35 mmol) and N, N-dimethylaminoaniline (53 mg, 0.39 
mmol) were added. The mixture was stirred at 0 oC for 10 min, EDC·HCl (68 mg, 
0.35 mmol) was then introduced. The reaction mixture was allowed to warm up 
slowly to room temperature and stirred for 12 h, and subsequently at 60 oC for 2 h. 
The solvent was removed in vacuo, and the residue was extracted with CH2Cl2 (3 x 10 
mL) and washed successively with H2O and brine. Purification by column 
chromatography (hexane: ethyl acetate = 5:1 to 2:1) afforded oxindole 3-10109 (95 mg, 




1H NMR (500 MHz, DMSO) δ 10.39 (s, 1H), 9.49 (s, 1H), 7.51-7.48 (m, 2H), 7.24 (d, 
J = 7.6 Hz, 1H), 7.20-7.17 (m, 1H), 6.96 (t, J = 7.6 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 
6.70 (dd, J = 2.5 Hz, 6.9 Hz, 3H), 3.07 (d, J = 1.9 Hz), 3.04 (d, J = 2.6 Hz, 1H), 3.00 
(s, 6H), 2.99-2.69 (m, 2H); 13C NMR (125 MHz, DMSO) δ 181.6, 161.9, 147.1, 141.0, 
138.0, 136.5, 134.2, 128.6, 127.8, 122.0, 121.5, 121.4, 112.4, 109.3, 51. 6, 44.5, 43.6, 
40.4; (ESI) m/z calcd for C21H21N3NaO2 [M+Na]+ = 370.1526, found = 370.1524. 
 
3.4.7 X-Ray Crystallographic Analysis and Determination of 
Absolute Configurations of [3+2] Adducts 
The absolute configuration of the product 3-7l (S) was assigned by X-ray 
crystallographic analysis of a single crystal of 3-7l (Figure 3.1). The configurations of 
other [3+2] cycloaddition products were assigned by analogy. 
 
 
Figure 3.1 X-ray structure of 3-7l 
 
Table 3.6 Crystal data and structure refinement for A477 
Identification code  A477 
Empirical formula  C31 H26 Cl2 O4 
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Formula weight  533.42 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 8.3201(4) Å = 90°. 
 b = 15.3584(7) Å = 90°. 
 c = 20.8270(9) Å  = 90°. 
Volume 2661.3(2) Å3 
Z 4 
Density (calculated) 1.331 Mg/m3 
Absorption coefficient 0.279 mm-1 
F(000) 1112 
Crystal size 0.30 x 0.26 x 0.10 mm3 
Theta range for data collection 1.65 to 27.49°. 
Index ranges -10<=h<=10, -19<=k<=19, -20<=l<=27 
Reflections collected 18918 
Independent reflections 6090 [R(int) = 0.0714] 
Completeness to theta = 27.49° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9726 and 0.9209 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6090 / 0 / 337 
Goodness-of-fit on F2 1.031 




R indices (all data) R1 = 0.1294, wR2 = 0.1576 
Absolute structure parameter 0.03(10) 
Largest diff. peak and hole 0.347 and -0.362 e.Å-3 
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Chapter 4 Formation of Functionalized Cyclopentenes via 
Catalytic Asymmetric [3+2] Cycloaddition of Acrylamides with  
An Allenoate Promoted by Dipeptide-Derived Phosphines 
 
4.1 Introduction 
Phosphine-mediated [3+2] cycloaddition between electron-deficient alkenes and 
allenes or alkynes is a powerful approach for the construction of functionalized 
cyclopentenes;6,12,56c,79 these structural motifs are often found in natural products and 
medicinally important agents.110 Significant progress has been made in phosphine-
catalyzed enantioselective [3+2] cycloadditions.40-45 The C2 synthons employed for 
such annulations were mainly enones, and occasionally acylates and imines. To the 
best of our knowledge, the direct application of acrylamides in the phosphine-
catalyzed asymmetric [3+2] cycloaddition has not been reported. Thus, it is highly 
desirable to develop a synthetic variant in which acrylamides can be used directly in 
such a cyclization. We have discussed in Chapter 3 novel types of chiral phosphines 
based on simple dipeptides, and demonstrated that such catalysts could promote 
effectively the enantioselective [3+2] cycloaddition of allenoates with acrylates, 
affording functionalized cyclopentenes in high yields and with excellent 
enantioselectivities. Given the high efficiency and reactivity of our catalysts, we 
reasoned that their application in the catalytic asymmetric [3+2] cycloaddition 
between acrylamides and allenes may be feasible. For the design of an efficient [3+2]-
annulation reaction, the allenoate, tert-butyl buta-2,3-dienoate (4-2) appeared to be an 
excellent reaction component, since its effectiveness in inducing the formation of -
regioisomers was demonstrated in our earlier studies (Chapter 3). For the acrylamide 




pyrazole nitrogen atoms are expected to form hydrogen bonds with hydrogen bond 
donors in the bifunctional phosphine catalysts, reinforcing the hydrogen bonding 
interactions between the carbonyl group and the amide N–H moiety. Moreover, the 
presence of the two methyl groups on the pyrazole ring was anticipated to introduce 
steric hindrance, thus facilitating the formation of sterically less demanding 
regioisomers (Figure 4.1). Herein, we describe the first asymmetric acrylamide–allene 
[3+2] cycloaddition mediated by dipeptide derived bifunctional phosphines; the 
reactions proceed efficiently at room temperature, and functionalized cyclopentenes 
with a quaternary stereogenic center were obtained in high yields and with moderate 
enantioselectivities. 
 
Figure 4.1 Working hypothesis 
 
4.2 Results and Discussion 
4.2.1 Reaction Optimization 
We chose the [3+2] cycloaddition between a-phenyl-substituted acrylamide 4-1a 
and allenoate 4-2 as a model reaction, and investigated the catalytic effects of various 
phosphines derived from amino acids. The results are summarized in Table 4.1. Given 
the success we achieved with threonine-based catalytic systems,98 the threonine core 
was incorporated into our catalytic systems. In all the examples examined, the 
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corresponding -regioisomers were formed exclusively. L-Threonine-derived 
phosphine 4-4 promoted the reaction, but the enantioselectivity was very poor (Table 
4.1, entry 1). Combining L-threonine and D-valine led to a more effective catalytic 
system than that based on L-threonine and L-valine (Table 4.1, entries 2 and 3). The 
thiourea–phosphine catalyst 4-7, however, was found to be an extremely poor catalyst 
(Table 4.1, entry 4). Introduction of a tert-leucine residue rendered further 
improvement; when D-threonine-L-tert-leucine-derived phosphine 4-8 or 4-9 was 
employed the enantioselectivity was improved to 49% (Table 4.1, entries 5 and 6). 
The presence of a carbamate moiety at the terminus of the dipeptide was found to be 
important, since catalyst 4-10 containing the more hindered carbamate group proved 
to be superior, affording the desired cycloaddition product in 86% yield and with 66% 
ee (Table 4.1, entry 7). Carrying out the reaction in different solvents and lowering 
the reaction temperature did not result in any further improvements (Table 4.1, entries 
8–16). It is noteworthy that the dipeptide-based phosphine catalysts described here are 
easily tunable, allowing specific interactions with different substrates. Hence, their 
application in a wide array of asymmetric organic reactions is well anticipated. 
 
Table 4.1 [3+2] Cycloaddition of acrylamide 4-1a with allenoate 4-2 catalyzed by 





















Entry Catalyst Solvent Yield (%)b ee (%)c 
1 4-4 toluene 71 7 
2 4-5 toluene 76 19 
3 4-6 toluene 81 -39 
4d 4-7 toluene 41 -17 
5 4-8 toluene 78 47 
6 4-9 toluene 80 49 
7 4-10 toluene 86 66 
8 4-10 benzene 79 41 
9 4-10 xylene 82 43 
10 4-10 4-fluorotoluene 75 11 
11 4-10 CH2Cl2 73 47 
12 4-10 CHCl3 77 40 
13 4-10 Et2O 80 58 
14 4-10 THF 75 26 
15 4-10 DMF 31 4 
16e 4-10 toluene 80 61 
a Reaction conditions: 4-1a (0.05 mmol), 4-2 (0.075 mmol), catalyst (10 mol%), solvent (0.25 
mL), r.t. b Yield of isolated product. c Determined by HPLC analysis on a chiral stationary 
phase. d The reaction time was 48 h. e The reaction was performed at –20 °C over 60 h. 
 
4.2.2 Substrate Scope 
The scope of the reaction was next investigated (Table 4.2). Different -aryl-
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substituted acrylamides were examined in this cyclization, and -regioisomeric 
products were obtained exclusively in good to excellent yields in each case. 
Satisfactory enantioselectivities were obtained for the pyrazole-derived acrylamides 
with para substituted aryl groups at their a-positions (Table 4.2, entries 2–4). The 
acrylamides containing meta- or ortho-substituted aromatic rings turned out to be less 
suitable substrates (Table 4.2, entries 5 and 6), and moderate enantioselectivity was 
obtained when a naphthyl-substituted acrylamide was employed (Table 4.2, entry 7). 
Moreover, acrylamides with-alkyl substituents could also be used, and up to 61% ee 
was attained (Table 4.2, entries 8 and 9). To account for the observed regiospecific 
formation of the -isomer, we propose that steric hindrance due to the presence of the 
bulky tert-butyl group on the allenoate and the 3,5-dimethylpyrazole moiety make 
formation of the -isomer highly unfavorable (Figure 4.2). 
 
Table 4.2 Asymmetric allene–acrylamide [3+2] cycloadditions catalyzed by 


















Entry product (R) t (h) Yield (%)b ee (%)c 
1 4-3a (Ph) 24 86 66 
2 4-3b (4-BrC6H4) 24 84 60 
3 4-3c (4-ClC6H4) 24 88 60 
4 4-3d (4-PhC6H4) 20 93 62 
5 4-3e (3-ClC6H4) 24 88 44 
6 4-3f (2-FC6H4) 20 91 36 
7 4-3h (2-naphthyl) 24 91 56 




9 4-3j (CH2Ph) 48 81 61 
a Reaction conditions: 4-1 (0.05 mmol), 4-2 (0.075 mmol), catalyst 4-10 (10 mol%), 
toluene (0.25 mL), r.t. b Yield of isolated product. c Determined by HPLC analysis on a 




Figure 4.2 Suppression of formation of the -isomer 
 
4.2.3 Derivative Synthesis 
 
 
Scheme 4.1Derivatization of N-acylpyrazole-containing cyclopentene 
 
The optically-enriched functionalized cyclopentenes resulting from the [3+2] 
cycloadditions are useful synthetic intermediates. In particular, the N-acylpyrazoles 
can be converted readily into various acyl derivatives via reactions with different 
nucleophiles, such as alcohols,112 amines,113 and organometallic reagents.114 When 
cyclopentenes 4-3a was treated with sodium methoxide, the corresponding methyl 
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ester 4-11 was obtained in excellent yield (Scheme 4.1). The absolute configuration of 




In summary, we have utilized 3,5-dimethyl-1H-pyrazolederived acrylamides in 
asymmetric [3+2] cycloadditions with an allenoate for the first time. The annulation 
reaction was promoted effectively by dipeptide-derived phosphines, affording only 
the -regioisomers in excellent yields and moderate enantioselectivities. This is the 
first example in which acrylamides are used directly in phosphine-catalyzed 
asymmetric [3+2]-cycloaddition reactions. We are currently investigating the 
mechanistic aspects of this novel reaction and are developing new catalytic systems to 
further improve the enantioselectivities of the reported reactions. 
 
4.4 Experimental Section 
4.4.1 General Methods 
All starting materials were obtained from commercial sources and were used 
without further purification unless otherwise stated. Toluene, THF and Et2O were 
dried and distilled from sodium benzophenone prior to use. CHCl3 and CH2Cl2 were 
distilled from CaH2 prior to use. All solvents used in reactions involving phosphorus-
containing compounds were degassed using N2. Melting points were determined using 
a Büchi B-540 melting point apparatus. Optical rotations were measured using a Jasco 
DIP-1000 polarimeter. 1H and 13C NMR spectra were recorded on a Bruker ACF300 
or AMX500 (500 MHz) spectrometer. Chemical shifts are reported in parts per 




(CHCl3, δ 7.26), carbon (CHCl3, δ 77.0). Multiplicities are indicated as follows: s 
(singlet), d (doublet), t (triplet), m (multiplet). Coupling constants are reported in 
hertz (Hz). High-resolution mass spectra were obtained on a Finnigan/MAT 95XL-T 
spectrometer. TLC was accomplished using Merck pre-coated TLC plates (Merck 60 
F254), and compounds were made visual with UV light at 254 nm. Flash 
chromatographic separations were performed on Merck 60 (0.040–0.063 mm) mesh 
silica gel. Enantiomeric excesses were determined by HPLC analysis on a chiral 
stationary phase.  
All the -substituted acrylic acids were prepared according to our previous 
reported method.115 Acrylamides 4-1a-g were prepared by reaction of the 
corresponding acids with oxalyl chloride and 3,5-dimethyl-1H-pyrazole in the 
presence of pyridine in CH2Cl2;116 acrylamides 4-1h and 4-1i were prepared using 
EDC·HCl, HOBt and 3,5-dimethyl-1H-pyrazole following the procedures reported in 
the literature.117 
 
4.4.2 Representative Procedure for [3+2] Cycloadditions  
To a flame-dried, round bottom flask were added catalyst 4-10 (4.2 mg, 0.005 
mmol) and acrylamide 4-1 (0.05 mmol) under N2, followed by the addition of 
anhydrous toluene (0.25 mL). Allenoate 4-2 (11 mL, 0.075 mmol) was then added, 
and the mixture stirred at r.t. for a given period as specified in Table 4.2. Following 
completion of the reaction the mixture was subjected directly to flash column 
chromatographic separation using a mixture of hexane–EtOAc as the eluent to afford 
cycloaddition products 4-3. 
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Yield: 15.7 mg (86%); white solid; mp 94.095.0 °C; [α]26D  = –47.2 (c 0.65, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.26-7.17 (m, 4 H), 7.16-7.13 (m, 1 H), 6.61 (t, J = 
1.9 Hz, 1 H), 5.77 (s, 1 H), 3.66-3.58 (m, 2 H), 3.37 (d, J = 16.4 Hz, 1 H), 3.14 (d, J = 
19.0 Hz, 1 H), 2.54 (s, 3 H), 1.98 (s, 3 H), 1.49 (s, 9 H); 13C NMR (125 MHz, CDCl3): 
d = 174.6, 164.1, 150.9, 144.9, 144.6, 139.0, 135.5, 128.2, 126.1, 125.3, 110.2, 80.3, 
60.3, 44.9, 42.7, 28.2, 14.7, 13.7; HRMS (ESI): m/z [M+Na]+ calcd for 
C22H26N2O3Na: 389.1836; found: 389.1848; HPLC: 66% ee (Chiralcel IC-H, 
iPrOH/hexane, 5:95, flow rate = 0.5 mL/min, λ = 254 nm): tR (major) = 14.2 min, tR 
(minor) = 16.4 min. 
 






Yield: 18.7 mg (84%); white solid; mp 114.5–115.0 °C; [α]26D = –54.7 (c 0.70, 
CHCl3). 









6.59 (d, J = 2.6 Hz, 1 H), 5.78 (s, 1 H), 3.64-3.56 (m, 2 H), 3.30 (d, J = 17.1 Hz, 1 H), 
3.08 (d, J = 18.9 Hz, 1 H), 2.52 (s, 3 H), 1.99 (s, 3 H), 1.48 (s, 9 H); 13C NMR (125 
MHz, CDCl3): δ = 173.9, 163.9, 151.3, 144.7, 144.0, 138.8, 135.5, 131.3, 127.2, 
119.9, 110.4, 80.5, 59.9, 44.8, 42.7, 28.1, 14.7, 13.7; HRMS (ESI): m/z [M+Na]+ 
calcd for C22H25BrN2O3Na: 467.0941; found: 467.0922. HPLC: 60% ee (Chiralcel IC-
H, iPrOH /hexane, 3:97, flow rate = 0.5 mL/min, λ = 254 nm): tR (major) = 11.2 min, 
tR (minor) = 12.5 min. 
 








Yield: 17.6 mg (88%); white solid; mp 114.1–114.5 °C; [α]26D = –49.0 (c 1.0, CHCl3). 
1H NMR (300 MHz, CDCl3): δ = 7.23-7.15 (m, 4 H), 6.60 (t, J = 2.0 Hz, 1 H), 5.78 (s, 
1 H), 3.66-3.33 (m, 2 H), 3.27 (d, J = 16.5 Hz, 1H), 3.06 (d, J = 19.4 Hz, 1 H), 2.52 (s, 
3 H), 1.99 (s, 3 H), 1.48 (s, 9 H); 13C NMR (75 MHz, CDCl3): δ = 174.0, 163.9, 
151.3, 144.7, 143.4, 138.8, 135.4, 131.9, 128.3, 126.8, 80.5, 59.8, 44.8, 42.7, 28.1, 
14.7, 13.8; HRMS (ESI): m/z [M+Na]+ calcd for C22H25ClN2O3Na: 423.1446; found: 
423.1448; HPLC: 60% ee (Chiralcel IC-H, iPrOH/hexane, 5:95, flow rate = 0.5 








Yield: 20.7 mg (93%); white solid; mp 135.6–136.0 °C; [α]26D  = –50.0 (c 0.9, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.57 (t, J = 8.2 Hz, 2 H), 7.50 (t, J = 14.5 Hz, 2 H), 
7.42 (t, J = 19.5 Hz, 2 H), 7.39-7.31 (m, 3 H), 6.64 (t, J = 1.9 Hz, 1 H), 5.79 (s, 1 H), 
3.71-3.61 (m, 2 H), 3.42 (d, J = 17.6 Hz, 1 H), 3.21 (d, J = 19.0 Hz, 1 H), 2.56 (s, 3 
H), 2.00 (s, 3 H), 1.50 (s, 9 H); 13C NMR (125 MHz, CDCl3): δ = 174.5, 164.2, 151.1, 
144.7, 144.0, 140.7, 139.1, 138.8, 135.6, 128.7, 127.1, 126.9, 126.8, 125.9, 110.4, 
80.4, 60.1, 45.0, 42.8, 28.2, 14.8, 13.8; HRMS (ESI): m/z [M+Na]+ calcd for 
C28H30N2O3Na: 465.2149; found: 465.2149; HPLC: 62% ee (Chiralcel IC-H, 
iPrOH/hexane, 5:95, flow rate = 0.5 mL/min, λ = 254 nm): tR (major) = 12.3 min, tR 





Yield: 17.6 mg (88%); white solid; mp 98.8–99.5 °C; [α]26D = –13.7 (c 0.9, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.26-7.25 (m, 1 H), 7.18-7.09 (m, 3 H), 6.60 (s, 1 
H), 5.79 (s, 1 H), 3.64-3.57 (m, 2 H), 3.29 (d, J = 17.7 Hz, 1 H), 3.11 (d, J = 19.6 Hz, 
1 H), 2.54 (s, 3 H), 1.99 (s, 3 H), 1.49 (s, 9 H); 13C NMR (125 MHz, CDCl3): δ = 




110.4, 80.5, 60.1, 44.8, 42.7, 28.1, 14.7, 13.7; HRMS (ESI): m/z [M+Na]+ calcd for 
C22H25ClN2O3Na: 423.1446; found: 423.1450; HPLC: 44% ee (Chiralcel IC-H, 
iPrOH/hexane, 5:95, flow rate = 0.5 mL/min, λ = 254 nm): tR (major) = 10.3 min, tR 










Yield: 17.5 mg (91%); yellow oil; [α]26D = –37.2 (c 1.2, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.39-7.35 (m, 1 H), 7.16-7.07 (m, 2 H), 6.89-6.84 
(m, 1 H), 6.63 (t, J = 1.9 Hz, 1 H), 5.77 (s, 1 H), 3.72-3.57 (m, 2 H), 3.34 (d, J = 17.7 
Hz, 1 H), 3.06 (d, J = 18.9 Hz, 1 H), 2.54 (s, 3 H), 1.91 (s, 3 H), 1.49 (s, 9 H); 13C 
NMR (125 MHz, CDCl3): δ = 173.6, 164.0, 160.6, 158.8, 150.6, 144.4, 138.9, 133.0 
(d, J = 13.7 Hz), 126.8 (d, J = 4.6 Hz), 123.7 (d, J = 2.7 Hz), 115.2 (d, J = 22.8 Hz), 
110.1, 80.5, 56.4, 44.0, 42.1, 28.2, 14.4, 13.6; HRMS (ESI): m/z [M+Na]+ calcd for 
C22H25FN2O3Na: 407.1741; found: 407.1747; HPLC: 36% ee (Chiralcel IC-H, 
iPrOH/hexane, 5:95, flow rate = 0.5 mL/min, λ = 254 nm): tR (major) = 10.9 min, tR 








Yield: 18.9 mg (91%); white solid; mp 153.0–153.8 °C; [α]26D  = –45.9 (c 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.79-7.71 (m, 4 H), 7.45-7.39 (m, 3 H), 6.65 (t, J = 
1.9 Hz, 1 H), 5.75 (s, 1 H), 3.73–3.45 (m, 2 H), 3.47 (d, J = 17.7 Hz, 1 H), 3.27 (d, J = 
19.0 Hz, 1 H), 2.56 (s, 3 H), 1.92 (s, 3 H), 1.49 (s, 9 H); 13C NMR (125 MHz, CDCl3): 
δ = 174.5, 164.1, 151.1, 144.6, 142.2, 139.0, 135.6, 133.4, 132.0, 128.0, 127.9, 127.4, 
125.9, 125.5, 124.2, 123.8, 110.3, 80.4, 60.5, 44.9, 42.8, 28.2, 14.7, 13.7; HRMS 
(ESI): m/z [M+Na]+ calcd for C26H28N2O3Na: 439.1992; found: 439.2003; HPLC: 
56% ee (Chiralcel IC-H, iPrOH/hexane, 5:95, flow rate = 0.5 mL/min, λ = 254 nm): tR 





Yield: 10.8 mg (71%); yellow oil; [α]26D  = +26.0 (c 0.3, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 6.57 (s, 1 H), 5.89 (s, 1 H), 3.30-3.26 (m, 2 H), 3.75 
(d, J = 15.1 Hz, 1 H), 3.63 (d, J = 17.1 Hz, 1 H), 2.51 (s, 3 H), 2.20 (s, 3 H), 1.58 (s, 3 
H), 1.49 (s, 9 H); 13C NMR (125 MHz, CDCl3): δ = 177.1, 164.6, 151.1, 144.8, 139.1, 
135.4, 110.3, 80.2, 51.6, 45.2, 43.5, 28.2, 14.9, 13.9; HRMS (ESI): m/z [M+Na]+ 
calcd for C17H24N2O3Na: 327.1679; found: 327.1683; HPLC: 47% ee (Chiralcel IC-H, 









Yield: 15.4 mg (81%); yellow oil; [α]26D  = –2.2 (c 0.93, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.21-7.16 (m, 3 H), 6.80-6.78 (m, 2 H), 6.57 (d, J = 
2.5 Hz, 1 H), 5.97 (s, 1 H), 3.52 (d, J = 13.3 Hz, 1 H), 3.31 (d, J = 13.4 Hz, 1 H), 
3.27-3.04 (m, 2 H), 2.90 (d, J = 4.4 Hz, 1 H), 2.86 (d, J = 3.1 Hz, 1 H), 2.29 (s, 3 H), 
1.92 (s, 3 H), 1.51 (s, 9 H); 13C NMR (125 MHz, CDCl3): δ = 175.2, 164.4, 151.3, 
144.9, 139.2, 137.7, 135.5, 129.5, 129.1, 128.1, 126.4, 110.4, 80.3, 57.4, 44.6, 42.3, 
41.5, 39.9, 28.2, 14.8, 13.9; HRMS (ESI): m/z [M+Na]+ calcd for C23H28N2O3Na: 
403.1992; found: 403.1995; HPLC: 61% ee (Chiralcel IC-H, iPrOH/hexane, 5:95, 
flow rate = 0.5 mL/min, λ = 254 nm): tR (major) = 11.0 min, tR (minor) = 13.6 min.  
 
3-tert-Butyl 1-Methyl (1S)-1-Phenylcyclopent-3-ene-1,3-dicarboxylate (4-11) 
 
 
To a solution of 4-3a (73 mg, 0.2 mmol) in MeOH (2 mL) at 0 °C was added 
NaOMe (22 mg, 0.4 mmol) and the mixture stirred at r.t. for 1 h. Next, the reaction 
was quenched by the addition of H2O (4 mL), and the resulting mixture was extracted 
with Et2O (2 × 8 mL). The combined organic extracts were washed with brine (6 mL) 
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and dried over Na2SO4. Purification by column chromatography (eluent: 
hexane/EtOAc, 15:1) afforded diester   4-11.  
Yield: 55 mg (91%); white solid; mp 71.072.0 °C; [α]26D = –24.0 (c 0.8, CHCl3) 
{Lit.115 [α]26D  = –35.2 (c 1.0, CHCl3)}; 1H NMR (500 MHz, CDCl3): δ = 7.32-7.29 
(m, 4 H), 7.26-7.23 (m, 1 H), 6.65 (s, 1 H), 3.66 (s, 3 H), 3.65-3.59 (m, 2 H), 3.03 (d, 
J = 14.5 Hz, 1 H), 2.90 (d, J = 14.1 Hz, 1 H), 1.49 (s, 9 H); 13C NMR (125 MHz, 
CDCl3): δ = 175.8, 163.9, 142.9, 139.7, 136.4, 128.5, 126.9, 126.4, 80.5, 58.2, 52.6, 
43.4, 41.6, 28.1; HRMS (ESI): m/z [M+Na]+ calcd for C18H22O4Na: 325.1410; found: 
325.1417. 
 
4.4.4 Determination of Absolute Configurations of the Products 
 
To a solution of compound 3-7b (Table 3.5, Chapter 3)115 (50 mg, 0.11 mmol) in 
MeOH (1 mL) at 0 oC was added sodium methoxide (12 mg, 0.22 mmol), and the 
reaction mixture was allowed to warm to room temperature and stirred for 1 h. The 
reaction was quenched by addition of H2O (2 mL), and the resulting mixture was 
extracted with ethyl ether (2 × 5 mL). The combined organic extracts were washed 
with brine (5 mL), and dried over Na2SO4. Purification by column chromatography 
(hexane/ethyl acetate = 15:1) afforded 4-11 (29 mg, 88% yield) as a white solid. 
[α]26D = ‐35.2 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.32‐7.29 (m, 4H), 
7.26‐7.23 (m, 1H), 6.65 (s, 1H), 3.66 (s, 1H), 3.65‐3.59 (m, 2H), 3.03 (d, J = 14.5 Hz, 




The above‐derived compound 4-11 has same configuration as the 4-11 derived 
from 4-3a, by comparing the optical rotation values. Thus, the configuration of 4-3a 
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Chapter 5 Versatile Enantioselective [3+2] Cyclization between 
Imines and Allenoates Catalyzed by Dipeptide-Based Phosphines 
 
5.1 Introduction 
Optically pure five-membered N-heterocycles are valuable intermediates in 
chemical synthesis, and they are also prevalent structural motifs in bioactive 
molecules and natural products.118 Over the past decade, many synthetic methods 
have been devised for the construction of such ring systems.119 In this context, [3+2] 
cyclization of imines with allenes or alkynes is one of the most straightforward and 
efficient methods for the creation of pyrrolines120 and pyrrolidines,121 which are 
classes of compounds of synthetic and biological importance. In 1997, Lu disclosed 
the [3+2] cycloadditions between imines and alkynes or allenes for the synthesis of 
pyrroline rings.46b However, asymmetric variants of these phosphine-catalyzed [3+2] 
cyclizations only appeared almost a decade later. Marinetti and Gladysz 
independently reported chiral phosphine-triggered asymmetric [3+2] annulations of 
allenes with N-tosyl imines, affording functionalized 3-pyrrolines in moderate 
enantioselectivity.48,49,122 The breakthrough came when Jacobsen introduced 
phosphinothiourea catalysis of imineallene cyclization; by utilizing 
diphenylphosphinoyl (DPP) imines,123 substituted 2-aryl-2,5-dihydropyrroles were 
formed in good yields and with excellent enantioselectivities.50 Despite all the above 
advances, the utilization of aliphatic imines in phosphine-catalyzed [3+2] 
cycloaddition reaction remains elusive. Aliphatic imines are challenging substrates, 
due to their isomerizable nature124 and relative instability. Nonetheless, their synthetic 




cycloaddition reactions of aliphatic imines holds significant synthetic utilities. As 
illustrated in Scheme 5.1, pyrrolidines with 2-alkyl substituents are very common 







































Scheme 5.1 Pyrrolidine-containing bioactive molecules 
 
We recently embarked on an exciting adventure of developing amino acid-based 
bifunctional phosphines and their applications in asymmetric organic 
transformations.81 We showed that highly enantioselective aza-Morita 
BaylisHillman (MBH) and MBH reactions could be realized by using L-threonine-
derived phosphinesulfonamides38 and phosphinethioureas (Chapter 2), respectively. 
We also demonstrated that dipeptide-derived phosphines were powerful catalysts for 
promoting enantioselective [3+2] cycloadditions of allenes to acrylates (Chapter 3) or 
acrylamides (Chapter 4). Very recently, we discovered that L-threonine-derived 
phosphinethioureas were capable of promoting MBH carbonates as C3-synthons in 
the [3+2] cyclization.126 Given the relative instability of aliphatic imines, we reasoned 
highly reactive phosphines are probably necessary for their effective activations in the 
Chapter 5 [3+2] Cycloaddtion of Imines with Allenoates 
139 
 
cycloaddition reaction, since potential decomposition of imines may be avoided. It is 
noteworthy that our amino acid-based phosphines possess remarkably high 
nucleophilicity. We hypothesize employment of highly nucleophilic bifunctional 
phosphines may result in a practical asymmetric [3+2] annulation protocol in which 
alkyl imines can be conveniently utilized (Scheme 5.2).  
 
 
Scheme 5.2 Phosphine-triggered [3+2] cyclization of imines with allenoates 
 
5.2 Results and Discussion 
5.2.1 Reaction Optimization 
The [3+2] cycloaddition between DPP imine 5-1a and tert-butyl allenoate 5-2 
was selected as a model reaction for the initial explorations (Table 5.1). For the 
catalysts, we chose to focus on dipeptide-based bifunctional phosphines, which were 
shown to be highly efficient in our previous studies (Chapter 3).115 To our delight, all 
the phosphines examined displayed remarkable catalytic effects, affording the desired 
3-pyrrolines in just a few minutes. While L-Thr-L-Val-derived phosphine 5-4 induced 
very low enantioselectivity, catalyst 5-5 consisting of L-Thr and D-Val subunits 
turned out to be very effective in asymmetric induction (entries 12), suggesting the 
chirality matching is very important in our catalytic system. The structures of the 




varying the carbamate group on the N-terminal of the dipeptide, and it was discovered 
that O-TBDPS-D-Thr-L-tert-Leu-based 5-7d was the best catalyst (entries 47).  
 





Entry Catalyst Yield (%)b ee (%)c 
1 5-4 88 -11 
2 5-5 91 -88 
3 5-6 86 -82 
4 5-7a 91 92 
5 5-7b 90 85 
6 5-7c 88 89 
7 5-7d 90 92 
a Reactions were performed with 5-1a (0.05 mmol), 5-2 (0.075 mmol) and the catalyst (10 
mol %) in toluene (0.5 mL) at room temperature. b Isolated yield. c The ee value was 
determined by HPLC analysis on a chiral stationary phase.
 
To further improve the enantioselectivity of the reaction, solvent screening was 
performed and summarized in Table 5.2. To our delight, slightly better result was 
achieved when this reaction was carried out in ether at room temperature, offering the 
corresponding [3+2] adduct in 91% yield with 93% ee (entry 7). All the other 
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common solvents were shown to be unsuitable, affording products in low yields and 
with poor enantioselectivities. When the reaction was performed with 10 mol% 5-7d 
in ether, the product 5-3a was obtained in 92% yield and with 94% ee (entry 14). 
 
Table 5.2 Solvents screening for 5-7a-promoted [3+2] cycloadditiona  
 
 
Entry Solvent t (min) Yield (%)b ee (%)c 
1 toluene 3 91 92 
2 benzene 3 90 90 
3 CH2Cl2 3 85 78 
4 CHCl3 3 72 69 
5 DCE 3 77 79 
6 CH3CN 3 70 69 
7 Et2O 3 91 93 
8 THF 3 85 86 
9 dioxane 3 < 20% -d 
10 DME 3 87 91 
11 TBME 3 93 90 
12 CH3OH 3 -e  
13 Toluene/ Et2O 3 90 92 
14f Et2O 3 92 94 
a Reactions were performed with 5-1a (0.05 mmol), 5-2 (0.075 mmol) and 5-7a (10 mol %) in 
corresponding solvent (0.5 mL) at room temperature. b Isolated yield. c The ee value was 
determined by HPLC analysis on a chiral stationary phase. d Not determined. e No reaction. f 
Phosphine 5-7d was used as the catalyst. 
 
The screening indicated that catalyst 5-7d was promising (Table 5.2), so further 
attempts to improve the enantioselectivity were performed by investigations the 




cycloaddition (Table 5.3). The existence of 5 Å molecular sieves had a positive effect 
on the enantioselectivity (entry 4). Furthermore, lowering the temperature to 0 oC 
enhanced the enantioselectivity (entry 7); however, further cooling prolonged the 
reaction time but gave no additional improvement in enantioselectivity. Applying the 
catalyst 5-7d with 5 mol% under the optimized conditions furnished the pyrroline 
product 5-3a in very high yield and excellent enantioselectivity (entry 9). 
 
Table 5.3 The effects of additive, temperature and catalyst loading on 5-7a-promoted 
[3+2] cycloaddition  
 
Entry Additive Temperature t (min) Yield (%)b ee (%)c 
1 none rt 3 92 94 
2 3Å MS rt 10 90 94 
3 4Å MS rt 10 92 94 
4 5Å MS rt 10 91 95 
6 H2O rt 3 84 90 
7 5Å MS 0 oC 20 89 96 
8 5Å MS - 20 oC 60 84 94 
9d 5Å MS 0 oC 30 92 96 
10e 5Å MS 0 oC 45 86 95 
a Reactions were performed with 5-1a (0.05 mmol), 5-2 (0.075 mmol) and 5-7d (10 mol %) 
in ether (0.5 mL) at room temperature. b Isolated yield. c The ee value was determined by 
HPLC analysis on a chiral stationary phase. d Catalyst loading was 5 mol %. e Catalyst 
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5.2.2 Substrate Scope 
Having established the optimal reaction conditions for the preparation of 3-
pyrroline, the substrate scope for 5-7d-catalyzed [3+2] cyclization was then 
investigated (Table 5.4). A wide range of alkyl imines could be employed, and the 
enantioselectivity of the reaction was independent to the alkyl substituents of the 
imines. The reaction was applicable to -methyl-substituted imine, which tends to 
form isomeric enamide readily (entry 1). -Unbranched alkyl imines were found to be 
excellent substrates; not only simple linear alkyl groups of different length were 
applicable, the alkyl imine bearing a phenyl group at the end was also suitable (entries 
27). The reaction also tolerated branched alkyl imines, and the cycloaddition 
proceeded remarkably well with imines bearing s-butyl, isopropyl or cyclohexyl 
group (entries 810). Furthermore, the imine with a vinylic substituent also proved to 
be a suitable substrate. Notably, only 5 mol% catalyst was sufficient to promote the 
allenoateimine cyclizations, affording the 3-pyrrolines in good to excellent yields, 
and with nearly perfect enantioselectivities. Moreover, the reactions were very fast, 
and all the cyclizations could be completed in less than 30 minutes. The absolute 
configuration of [3+2] products were determined by comparing the optical rotation of 
a 5-3j derivative with the value reported in the literature.127 
 
Table 5.4 Enantioselective [3+2] cycloaddition of allenoates with aliphatic DPP-

























Entry R Product Yield (%)b ee (%)c 
1 5-3b 75 95 
2  5-3c 78 96 
3 5-3d 80 97 
4 5-3e 84 97 
5 5-3f 85 97 
6 5-3g 82 96 
7  5-3h 81 95 
8 5-3i 90 95 
9 5-3j 81 99 
10 5-3k 83 99 
11  5-3l 81 96 
a Reactions were performed with 5-1 (0.1 mmol), 5-2 (0.15 mmol)  and 5-7d (0.005 mmol) in 
Et2O (1 mL) containing 5Å molecular sieves at 0 oC for 30 min. b Isolated yield. c The ee value 
was determined by HPLC analysis on a chiral stationary phase. 
 
 
The broad applicability of dipeptide-based phosphine-catalyzed [3+2] annulation 
to various alkyl imines suggested such enantioselective process should be applicable 
to aryl imines. We therefore investigated imineallenoate cyclization employing aryl 
imines (Table 5.5). Under the optimized conditions and in the presence of phosphine 
5-7d, the [3+2] cycloadditions of aryl imines with allenes were completed within one 
hour, and the desired products were obtained in constantly high yields and excellent 
enantioselectivities. The reaction was applicable to aryl imines with different 
electronic nature and substitution patterns on the aromatic rings. 2-Naphthyl and 
heteroaryl imines were also found to be suitable. 
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Table 5.5 Enantioselective [3+2] cycloaddition of allenoates with aromatic imines 





Entry Ar Product Yield (%)b ee (%)c 
1 Ph 5-3m 82 95 
2 4-BrC6H4 5-3n 83 95 
3 3-BrC6H4 5-3o 85 96 
4 4-OMeC6H4 5-3p 94 98 
5 3-CNC6H4 5-3q 78 93 
6 2-naphthyl 5-3r 86 96 
7 2-furyl 5-3s 83 94 
8 2-thienyl 5-3t 78 95 
a Reactions were performed with 5-1 (0.1 mmol), 5-2 (0.15 mmol)  and 5-7d (0.005 mmol) in 
Et2O (1 mL) containing 5Å molecular sieves at 0 oC for 30 min. b Isolated yield. c The ee value 
was determined by HPLC analysis on a chiral stationary phase. 
 
 
5.2.3 Derivative Synthesis 
2-Alkyl-substituted chiral 3-pyrrolines are structures of high synthetic value, 
which can potentially be elaborated into many biologically useful molecules.125 As an 
illustration, a formal synthesis of pyrrolizidine alkaloid (+)-trachelanthamidine using 
our cyclization protocol as a key step was performed (Scheme 5.3). The [3+2] 
cycloaddition between imine 5-8 and allenoate 5-2 occurred smoothly in the presence 
of 5-7d, affording functionalized pyrroline 5-9 in 82% yield and 96% ee. Treatment 
of 5-9 with boron trifluoride resulted in simultaneous removal of the DPP protection 
and cleavage of the silyloxy group, giving intermediate 5-10 in good yield. 




















which can be converted to (+)-trachelanthamidine following the procedures described 
in the literature.127 
 
 
Scheme 5.3 A formal synthesis of (+)-trachelanthamidine 
 
5.2.4 Plausible Mechanism and Transition State Model 
We propose that amide and carbamate portions of the catalyst interact with 
imines via hydrogen bonding interactions, which contribute significantly to the key 
transition state leading to the formation of the major stereoisomer (Figure 5.1). The 
preferential adoption of an s-cis conformation by DPP imines8 facilitates the 
intramolecular delivery of phosphonium enolate to the imine. The catalytic effects of 
N-methylated catalyst 5-12 were examined, and cyclization product 5-3a was 
obtained in 82% yield after 4 h, but with only 59% ee (Scheme 5.4). In comparison, 
similar catalysts with free carbamate (5-5 and 5-7d in Table 5.1) afforded products in 
excellent yields and around 90% ee in just a few minutes. These results clearly 
support the importance of the hydrogen bond donor groups in our catalytic systems. 
Thioureas are known to provide excellent activations and stereochemical controls for 
reactions involving imines, as demonstrated by Jacobsen et al. in their related report.50 
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However, dipeptide or threonine-based phosphinethiourea 5-13 or 5-14 was found to 
be completely ineffective in our reactions. Since catalysts 5-13/5-14 are 
conformationally flexible, we believe the thiourea group of the catalyst preferentially 






















t = 4 h,









t = 24 h, 5-3a: <10% yield  








In conclusion, we have developed a highly enantioselective [3+2] cyclization 
between imines and allenoates, by employing dipeptide-based chiral phosphines as 
catalysts. Notably, this is the first time that alkyl imines have been applied 
successfully in the asymmetric [3+2] cycloaddition. Moreover, such enantioselective 
cyclization is very versatile, worked equally well for aryl imines. The efficiency of 
the cyclization processes described in this report is noteworthy; in the presence of 5-5 
mol% 5-7d, all the reactions were completed within one hour, and the 2-alkyl/aryl-
substituted 3-pyrrolines could be easily prepared in nearly enantiomerically pure form. 
Synthetic value of our method has been demonstrated by using imineallene annulation 
as a key step in a concise formal synthesis of (+)-trachelanthamidine. We are 
currently investigating the reaction mechanism and applying the methodology 
described to the synthesis of biologically important molecules. 
 
5.4 Experimental Section 
5.4.1 Materials and General Methods 
All starting materials were obtained from commercial sources and were used 
without further purification unless otherwise stated. Toluene, THF and Et2O were 
dried and distilled from sodium benzophenone prior to use. CHCl3 and CH2Cl2 were 
distilled from CaH2 prior to use. All solvents used in reactions involving phosphorus-
containing compounds were degassed using N2. Melting points were determined using 
a Büchi B-540 melting point apparatus. Optical rotations were measured using a Jasco 
DIP-1000 polarimeter. 1H and 13C NMR spectra were recorded on a Bruker ACF300 
or AMX500 (500 MHz) spectrometer. Chemical shifts are reported in parts per 
million (ppm), and the residual solvent peak was used as an internal reference: proton 
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(CHCl3, δ 7.26), carbon (CHCl3, δ 77.0). Multiplicities are indicated as follows: s 
(singlet), d (doublet), t (triplet), m (multiplet). Coupling constants are reported in 
hertz (Hz). High-resolution mass spectra were obtained on a Finnigan/MAT 95XL-T 
spectrometer. TLC was accomplished using Merck pre-coated TLC plates (Merck 60 
F254), and compounds were made visual with UV light at 254 nm. Flash 
chromatographic separations were performed on Merck 60 (0.040–0.063 mm) mesh 
silica gel. Enantiomeric excesses were determined by HPLC analysis on a chiral 
stationary phase.  
All the alkyl, aryl-, heteroaryl- and alkynel-substituted aldimines were 
synthesized from the intermediates of the corresponding sulfinyl adducts according to 
literature reported methods.128,129 Catalysts 5-4, 5-5, 5-6, 5-7a and 5-7d were prepared 
following the procedures described in Chapter 3. 
 
5.4.2 Catalysts Preparation  
tert-Butyl (S)-1-((2R,3S)-3-((2,3-dimethylbutan-2-yl)dimethylsilyloxy)-1-(diphenylp- 
hosphino) butan-2-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (5-7b) 
 
 
To a solution of 3-15 (140 mg, 0.29 mmol) in anhydrous DMF (40 μL) at room 
temperature under N2 was added imidazole (39 mg, 0.58 mmol), followed by TDSCl 
(70 μL, 0.35 mmol). The resulting mixture was stirred at room temperature for 24 h, 
and then quenched by adding water (5 mL), and extracted with diethyl ether (3 x 5 




Purification by column chromatography (hexane: ethyl acetate = 20:1 to 10:1) 
afforded catalyst 5-7b (0.140 g, 77% yield) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 7.53 (t, J = 7.3 Hz, 2H), 7.40-7.33 (m, 5H), 7.32-7.28 
(m, 3H), 5.97 (d, J = 8.8 Hz, 1H), 5.30 (d, J = 8.9 Hz, 1H), 4.30 (d, J = 6.3 Hz, 1H), 
3.87-3.75 (m, 2H), 2.39 (dd, J1 = 5.1 Hz, J2 = 12.6 Hz, 1H), 2.17-2.12 (m, 1H), 1.68-
1.61 (m, 1H), 1.45 (s, 9H), 1.10 (d, J = 6.3 Hz, 3H), 1.00 (s, 9H), 0.91-0.90 (m, 6H), 
0.85 (s, 6H), 0.14 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 169.9, 155.7, 138.9 (d), 
137.4 (d), 132.7 (d), 128.6 (dd), 79.4, 68.5 (d), 63.1, 52.5 (d), 34.3 (d), 32.3 (d), 28.3, 
26.8, 24.9, 21.5, 20.3 (t), 18.7 (t), -1.5, -2.3, -2.5; 31P NMR (121 MHz, CDCl3) δ -23.7 






The catalyst 5-7c was prepared from 5-15 in 51% yield, following the same 
procedure described for the preparation of 5-7b. 
A white solid; 1H NMR (500 MHz, CDCl3) δ 7.52 (t, J = 7.3 Hz, 2H), 7.39-7.31 (m, 
5H), 7.29-7.28 (m, 3H), 5.97 (d, J = 8.9 Hz, 1H), 5.30 (d, J = 8.9 Hz, 1H), 4.44-4.40 
(m, 1H), 3.90 (t, J = 7.3 Hz, 1H), 3.76 (d, J = 8.9 Hz, 1H), 2.40- 2.27 (m, 2H), 1.67 
(m, 1H), 1.45 (s, 9H), 1.16 (d, J = 6.3 Hz, 3H), 1.06 (d, J = 7.6 Hz, 21H), 0.99 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ 170.1, 155.7, 137.8 (d), 132.9, 132.6 (d), 128.7, 128.5 
(dd), 79.4, 68.6 (d), 63.0, 52.8 (d), 34.6, 31.8 (d), 28.3, 26.8, 21.3, 18.2 (d), 17.7, 12.6; 
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31P NMR (121 MHz, CDCl3) δ -23.2 (s); HRMS (ESI) m/z calcd for C36H60N2O4PSi 
[M+H]+ = 643.3986, found = 643.3999. 
 
5.4.3 Representative Procedure for [3+2] Cycloadditions  
To a flame-dried round bottle flask with a magnetic stirring bar was added 5-1a 
(27.1 mg, 0.1 mmol), 5-7d (3.6 mg, 0.005 mmol) and 5Å molecular sieves (60 mg) 
under N2, followed by the addition of anhydrous Et2O (1 mL). The reaction mixture 
was cooled to 0 oC in an ice-bath, allenoate 2 (22 μL, 0.15 mmol) was then added, and 
the mixture was stirred at 0 oC for 30 minutes. The reaction mixture was then filtered 
(to remove molecular sieves) and concentrated under reduced pressure. The residue 
was purified by column chromatography on silica gel (hexane/EtOAc = 10:1 to 2:1) to 
afford the cycloaddtion product 5-3a (37.9 mg, 92% yield) as a colorless oil. 
 




A colorless oil; [α]26D = -23.8 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.91-
7.81 (m, 4H), 7.52-7.41 (m, 6H), 6.64 (s, 1H), 4.76 (s, 1H), 4.09-3.95 (m, 2 H), 1.61-
1.55 (m, 1H), 1.48-1.38 (m, 10H), 1.43-1.27 (m, 1H), 1.18-1.12 (m, 1H), 0.79 (t, J = 
7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 162.2, 137.8 (d), 137.1 (d), 132.4 (d), 
132.2 (d), 132.0 (d), 131.8 (d), 128.5 (dd), 81.1, 64.2 (d), 53.8 (d), 36.6, 28.1, 16.6, 




C24H30NNaO3P [M+Na]+ = 434.1856, found = 434.1873; the ee value was 96%, tR 
(major) = 16.1 min, tR (minor) = 22.5 min (Chiralcel IA-H, λ = 254 nm, 5% 
iPrOH/hexanes, flow rate = 1.0 mL/min). 
 
(R)-tert-Butyl 1-(diphenylphosphoryl)-2-methyl-2,5-dihydro-1H-pyrrole-3-carboxy- 




A colorless oil; [α]26D = -3.8 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.92-
7.82 (m, 4H), 7.51-7.41 (m, 6H), 6.60 (s, 1H), 4.64-4.63 (m, 1H), 4.11-3.99 (m, 2 H), 
1.45 (s, 9H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 162.1, 139.8 (d), 
136.2 (d), 132.4 (dd), 131.9 (d), 137.6 (d), 131.2 (d), 128.5 (dd), 81.1, 60.5 (d), 53.4 
(d), 28.1 (d), 21.9 (d); 31P NMR (202 MHz, CDCl3) δ 25.9 (s); HRMS (ESI) m/z calcd 
for C22H27NO3P [M+H]+ = 384.1723, found = 384.1739; the ee value was 95%, tR 
(major) = 24.4 min, tR (minor) = 30.1 min (Chiralcel IA-H, λ = 254 nm, 5% 
iPrOH/hexanes, flow rate = 1.0 mL/min). 
 
(R)-tert-Butyl 1-(diphenylphosphoryl)-2-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylate   
(5-3c) 
 
A colorless oil; [α]26D = -22.5 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.91-
7.81 (m, 4H), 7.54-7.41 (m, 6H), 6.68 (s, 1H), 4.79-4.78 (m, 1H), 4.11-4.05 (m, 1 H), 
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7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 162.2, 137.5 (d), 137.1, 132.4 (d), 132.2 
(d), 131.8 (d), 131.3, 128.5 (dd), 81.1, 64.9, 55.1 (d), 28.1, 27.0, 7.3; 31P NMR (202 
MHz, CDCl3) δ 26.3 (s); HRMS (ESI) m/z calcd for C23H29NO3P [M+H]+ = 398.1880, 
found = 398.1898; the ee value was 96%, tR (major) = 24.5 min, tR (minor) = 36.5 min 





A colorless oil; [α]26D = -100.3 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.91-
7.81 (m, 4H), 7.54-7.41 (m, 6H), 6.65 (s, 1H), 4.78 (d, J = 4.4 Hz, 1H), 4.11-4.01 (m, 
1 H), 4.00-3.96 (m, 1 H), 1.63-1.57 (m, 1 H), 1.45 (s, 9H), 1.41-1.34 (m, 1 H), 1.26-
1.20 (m, 3H), 1.17-1.11 (m, 3 H), 0.84 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 162.2, 137.6 (d), 137.1 (d), 132.4 (d), 132.2 (d), 131.9 (d), 131.8 (d), 131.3, 
128.5 (dd), 81.1, 64.3, 54.9 (d), 34.1, 31.8, 28.0, 22.6, 14.0; 31P NMR (202 MHz, 
CDCl3) δ 26.5 (s); HRMS (ESI) m/z calcd for C26H32NNaO3P [M+Na]+ = 460.2012, 
found = 460.2022; the ee value was 97%, tR (major) = 16.2 min, tR (minor) = 20.8 min 
(Chiralcel IA-H, λ = 254 nm, 5% iPrOH/hexanes, flow rate = 1.0 mL/min). 
 











A colorless oil; [α]26D = -45.7 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.91-
7.81 (m, 4H), 7.54-7.41 (m, 6H), 6.65 (s, 1H), 4.78 (d, J = 4.4 Hz, 1H), 4.10-4.05 (m, 
1 H), 4.01-3.95 (m, 1 H), 1.63-1.57 (m, 1 H), 1.49-1.45 (m, 10H), 1.39-1.35 (m, 1 H), 
1.28-1.23 (m, 3H), 1.20-1.17 (m, 4 H), 0.86 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 162.3, 137.8 (d), 137.1, 132.4, 132.2 (d), 131.8 (d), 131.4, 128.5 (dd), 81.0, 
64.3, 54.9 (d), 34.2, 31.7, 29.3, 28.1, 23.1, 22.5, 14.0; 31P NMR (202 MHz, CDCl3) δ 
26.5 (s); HRMS (ESI) m/z calcd for C27H37NO3P [M+H]+ = 454.2506, found = 
454.2515; the ee value was 97%, tR (major) = 42.4 min, tR (minor) = 53.5 min 










A colorless oil; [α]26D = -46.6 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.91-
7.81 (m, 4H), 7.52-7.41 (m, 6H), 6.65 (s, 1H), 4.78 (d, J = 4.4 Hz, 1H), 4.11-4.01 (m, 
1 H), 4.00-3.95 (m, 1 H), 1.63-1.45 (m, 1 H), 1.39 (s, 9H), 1.38-1.34 (m, 1H), 1.29-
1.25 (m, 4 H), 1.22-1.10 (m, 6H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 162.3, 137.8 (d), 137.1 (d), 132.4 (d), 132.2 (d), 131.9 (d), 131.7, 131.5 (d), 
128.5 (dd), 81.0, 64.4, 54.9 (d), 34.3, 31.8, 29.6, 29.1, 28.1, 23.2, 22.6, 14.0; 31P NMR 
(202 MHz, CDCl3) δ 26.5 (s); HRMS (ESI) m/z calcd for C28H39NO3P [M+H]+ = 
468.2662, found = 468.2676; the ee value was 97%, tR (major) = 12.7 min, tR (minor) 
= 16.1 min (Chiralcel IA-H, λ = 254 nm, 5% iPrOH/hexanes, flow rate = 1.0 mL/min). 
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(R)-tert-Butyl 1-(diphenylphosphoryl)-2-octyl-2,5-dihydro-1H-pyrrole-3-carboxylate   
(5-3g) 
 
A colorless oil; [α]26D = -44.2 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.91-
7.81 (m, 4H), 7.53-7.41 (m, 6H), 6.65 (s, 1H), 4.78 (d, J = 4.4 Hz, 1H), 4.11-4.05 (m, 
1 H), 4.01-3.95 (m, 1 H), 1.62-1.46 (m, 1 H), 1.39 (s, 9H), 1.39-1.34 (m, 1H), 1.29-
1.10 (m, 12H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 162.3, 137.9 
(d), 137.3 (d), 132.5 (d), 132.2 (d), 131.8 (d), 131.5, 131.5 (d), 128.5 (dd), 81.0, 64.4, 
54.9 (d), 34.3, 31.9, 29.7, 29.5, 28.1, 23.2, 22.6, 14.0; 31P NMR (202 MHz, CDCl3) δ 
26.4 (s); HRMS (ESI) m/z calcd for C29H41NO3P [M+H]+ = 482.2819, found = 
482.2832; the ee value was 96%, tR (major) = 12.1 min, tR (minor) = 15.1 min 





A colorless oil; [α]26D = -69.7 (c 0.8, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.90-
7.85 (m, 4H), 7.53-7.43 (m, 6H), 7.25-7.23 (m, 2), 7.17-7.10 (m, 3H), 6.73 (s, 1H), 
4.88 (d, J = 4.4 Hz, 1H), 4.16-4.02 (m, 2H), 2.77-2.71 (m, 1 H), 2.46-2.40 (m, 1 H), 
1.98-1.91 (m, 1 H), 1.67-1.64 (m, 1 H), 1.50 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 




125.6, 81.3, 64.3, 55.0 (d), 36.3, 29.8, 28.1; 31P NMR (202 MHz, CDCl3) δ 26.3 (s); 
HRMS (ESI) m/z calcd for C29H32NNaO3P [M+Na]+ = 496.2012, found = 496.2031; 
the ee value was 95%, tR (major) = 25.9 min, tR (minor) = 36.1 min (Chiralcel IA-H, λ 





A colorless oil; [α]26D = -35.8 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.89-
7.79 (m, 4H), 7.51-7.39 (m, 6H), 6.61 (s, 1H), 4.74-4.70 (m, 1H), 4.07-3.97 (m, 2 H), 
1.67-1.61 (m, 1H), 1.59 (s, 9H), 1.44-1.23 (m, 2H), 0.69 (d, J = 6.4 Hz, 3H), 0.66 (d, 
J = 6.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 162.3, 139.5 (d), 137.1 (d), 136.8 (d), 
132.5 (d), 132.2 (d), 132.1, 131.8 (d), 131.7 (d), 128.5 (dd), 81.0, 63.2 (d), 53.9 (d), 
44.0 (d), 28.0, 24.1, 23.3 (d); 31P NMR (202 MHz, CDCl3) δ 27.0 (s); HRMS (ESI) 
m/z calcd for C25H33NO3P [M+H]+ = 426.2193, found = 426.2183; the ee value was 
95%, tR (major) = 18.7 min, tR (minor) = 28.3 min (Chiralcel IA-H, λ = 254 nm, 5% 
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A colorless oil; [α]26D = -51.3 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.86-
7.77 (m, 4H), 7.53-7.41 (m, 6H), 6.67 (d, J = 1.3 Hz, 1H), 4.71-4.68 (m, 1H), 4.05-
3.90 (m, 2 H), 1.92-1.86 (m, 1H), 1.47 (s, 9H), 0.77 (d, J = 7.0 Hz, 3H), 0.73 (d, J = 
7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 162.9, 138.0, 137.6, 132.5 (d), 132.2 (d), 
131.9, 131.8 (d), 131.7 (d), 131.4, 131.2, 128.5 (dd), 81.1, 69.2, 55.2 (d), 34.6 (d), 
28.0, 18.1 (d); 31P NMR (202 MHz, CDCl3) δ 28.1 (s); HRMS (ESI) m/z calcd for 
C24H31NO3P [M+H]+ = 412.2036, found = 412.2044; the ee value was 99%, tR (major) 
= 20.1 min, tR (minor) = 33.1 min (Chiralcel IA-H, λ = 254 nm, 5% iPrOH/hexanes, 





A colorless oil; [α]26D = -43.3 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.87-
7.77 (m, 4H), 7.54-7.41 (m, 6H), 6.63 (d, J = 1.3 Hz, 1H), 4.63 (d, J = 5.1 Hz, 1H), 
4.04-4.00 (m, 1 H), 3.99-3.89 (m, 1 H), 1.66-1.59 (m, 4H), 1.57-1.47 (m, 13H), 1.40-
1.33 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 162.9, 138.0 (d), 137.2 (d), 132.5 (d), 
132.2 (d), 131.9 (d), 131.8 (d), 131.7 (d), 131.4, 131.2, 128.5 (dd), 81.1, 68.8, 55.1 (d), 
45.1 (d), 28.8 (d), 28.1, 26.7, 26.5 (d); 31P NMR (202 MHz, CDCl3) δ 28.2 (s); HRMS 
(ESI) m/z calcd for C27H35NO3P [M+H]+ = 452.2349, found = 452.2362; the ee value 
was 99%, tR (major) = 22.0 min, tR (minor) = 36.5 min (Chiralcel IA-H, λ = 254 nm, 








A colorless oil; [α]26D = -212.7 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.92-
7.85 (m, 4H), 7.51-7.36 (m, 6H), 7.27-7.15 (m, 5H), 6.73 (s, 1H), 5.99-5.94 (m, 1H), 
5.82-5.79 (m, 1H), 5.09-5.06 (m, 1H), 4.20-4.17 (m, 2H), 1.39 (s, 9H); 13C NMR (125 
MHz, CDCl3) δ 161.8, 137.4 (d), 137.0 (d), 136.7, 132.7 (d), 132.4 (d), 132.0, 131.9 
(d), 131.8 (d), 131.6, 131.4, 131.2, 130.6, 128.5 (dd), 128.2 (d), 127.4, 126.5, 81.2, 
67.0, 53.5 (d), 28.0; 31P NMR (202 MHz, CDCl3) δ 26.3 (s); HRMS (ESI) m/z calcd 
for C29H31NO3P [M+H]+ = 472.2036, found = 472.2047; the ee value was 96%, tR 
(major) = 14.7 min, tR (minor) = 17.7 min (Chiralcel IC-H, λ = 254 nm, 30% 





A colorless oil; [α]26D = -117.6 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.82-
7.78 (m, 2H), 7.56-7.52 (m, 2H), 7.48-7.33 (m, 4H), 7.19-7.15 (m, 2H), 7.12-7.05 (m, 
3H), 6.81-6.79 (m, 3H), 5.48-5.45 (m, 1H), 4.39-4.32 (m, 1H), 4.28-4.22 (m, 1H), 
1.22 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 161.6, 142.5 (d), 139.0 (d), 136.3 (d), 
132.4 (d), 132.2 (d),  131.9 (d), 131.8 (d), 131.5 (d), 131.0, 130.0, 128.5 (dd), 128.0 
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(d), 127.7, 127.5, 127.0, 81.2, 68.3 (d), 54.6 (d), 27.8; 31P NMR (202 MHz, CDCl3) δ 
27.1 (s); HRMS (ESI) m/z calcd for C27H29NO3P [M+H]+ = 446.1880, found = 
446.1865; the ee value was 95%, tR (minor) = 45.4 min, tR (major) = 82.6 min 





A colorless oil; [α]26D = -175.9 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.82-
7.79 (m, 2H), 7.57-7.48 (m, 3H), 7.44-7.37 (m, 3H), 7.24-7.19 (m, 4H), 6.80 (s, 1H), 
6.70 (t, J = 4.1 Hz, 2H), 5.46-5.43 (m, 1H), 4.38-4.31 (m, 1H), 4.27-4.21 (m, 1H), 
1.25 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 161.4, 141.8, 138.5 (d), 136.7 (d), 132.4 
(dd), 132.1 (d),  131.9, 131.8 (d), 131.1 (d), 130.9 (d), 129.2, 128.5 (dd), 121.0, 81.5, 
67.7 (d), 54.6 (d), 27.9; 31P NMR (202 MHz, CDCl3) δ 26.9 (s); HRMS (ESI) m/z 
calcd for C27H28NO3P81Br [M+H]+ = 526.0964, found = 526.0970; the ee value was 
95%, tR (major) = 28.4 min, tR (minor) = 40.2 min (Chiralcel IC-H, λ = 254 nm, 15% 















A colorless oil; [α]26D = -83.4 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.83-
7.79 (m, 2H), 7.57-7.49 (m, 3H), 7.45-7.39 (m, 3H), 7.25-7.21 (m, 3H), 7.00 (t, J = 
7.9 Hz, 1H), 6.87-6.83 (m, 2H), 6.74 (t, J = 1.9 Hz, 1H), 5.43-5.39 (m, 1H), 4.39-4.33 
(m, 1H), 4.28-4.22 (m, 1H), 1.24 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 161.3, 144.9, 
138.4 (d), 136.7 (d), 137.0 (d), 132.4 (d), 132.1 (d), 131.9 (d), 131.8, 130.8 (d), 130.7, 
130.1, 129.9, 129.4, 128.7 (d), 128.1 (d), 125.9, 121.6, 81.5, 67.8 (d), 54.6 (d), 27.8; 
31P NMR (202 MHz, CDCl3) δ 26.9 (s); HRMS (ESI) m/z calcd for C27H28NO3P79Br 
[M+H]+ = 524.0985, found = 524.0972; C27H28NO3P81Br [M+H]+ = 526.0964, found 
= 526.0954; the ee value was 96%, tR (major) = 35.6 min, tR (minor) = 40.9 min 





A colorless oil; [α]26D = -136.0 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.81-
7.77 (m, 2H), 7.58-7.45 (m, 2H), 7.42-7.34 (m, 4H), 7.23-7.19 (m, 2H), 6.76 (s, 1H), 
6.72-6.70 (m, 2H), 6.62-6.60 (m, 2H), 5.44-5.41 (m, 1H), 4.35-4.29 (m, 1H), 4.26-
4.20 (m, 1H), 3.75 (s, 3H), 1.24 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 161.6, 158.7, 
139.0 (d), 136.0 (d), 134.7 (d), 132.4 (d), 132.3 (d), 131.9 (d), 131.5 (d), 131.2 (d), 
130.2, 128.5 (dd), 127.9, 113.0, 81.1, 67.8 (d), 55.2, 54.3 (d), 27.8; 31P NMR (202 
MHz, CDCl3) δ 26.8 (s); HRMS (ESI) m/z calcd for C28H31NO4P [M+H]+ = 476.1985, 
found = 476.1989; the ee value was 98%, tR (minor) = 82.2 min, tR (major) = 85.9 min 
(Chiralcel IC-H, λ = 254 nm, 3% iPrOH/hexanes, flow rate = 0.5 mL/min). 






A colorless oil; [α]26D = -116.3 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.81-
7.77 (m, 2H), 7.57-7.51 (m, 3H), 7.46-7.40 (m, 4H), 7.26-7.16 (m, 4H), 6.95 (s, 1H), 
6.85 (s, 1H), 5.53-5.49 (m, 1H), 4.39-4.26 (m, 2H), 1.25 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 161.0, 144.3, 137.8 (d), 137.4 (d), 132.3 (d), 132.2 (d), 131.9 (d), 131.8, 
131.4, 131.2, 131.0, 130.7, 130.3, 130.0, 128.6 (dd), 128.2, 118.6, 111.7, 81.7, 67.6 
(d), 54.8, 27.8; 31P NMR (202 MHz, CDCl3) δ 26.8 (s); HRMS (ESI) m/z calcd for 
C28H28N2O3P [M+H]+ = 471.1832, found = 471.1839; the ee value was 93%, tR 
(major) = 26.7 min, tR (minor) = 40.9 min (Chiralcel IC-H, λ = 254 nm, 30% 





A colorless oil; [α]26D = -127.1 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.81-
7.79 (m, 3H), 7.78-7.52 (m, 1H), 7.68-7.36 (m, 8H), 7.27-7.24 (m, 1H), 7.16-7.14 (m, 
1H), 7.07-7.03 (m, 2H), 6.96 (s, 1H), 6.87 (s, 1H), 5.65-5.62 (m, 1H), 4.46-4.42 (m, 




138.7 (d), 136.6 (d), 132.7 (d), 132.4 (d), 132.3, 132.1, 131.9 (d), 131.6 (d), 130.0 (d), 
128.5 (d), 128.0, 127.9 (d), 127.5 (d), 127.4, 126.9, 125.6 (d), 124.9, 81.2, 68.5 (d), 
54.6 (d), 27.8; 31P NMR (202 MHz, CDCl3) δ 27.1 (s); HRMS (ESI) m/z calcd for 
C31H31NO3P [M+H]+ = 496.2036, found = 496.2051; the ee value was 96%, tR (minor) 
= 21.5 min, tR (major) = 30.0 min (Chiralcel IC-H, λ = 254 nm, 30% iPrOH/hexanes, 







A colorless oil; [α]26D = -99.4 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.84-
7.80 (m, 2H), 7.66-7.61 (m, 2H), 7.50-7.47 (m, 1H), 7.44-7.40 (m, 3H), 7.32-7.28 (m, 
2H), 7.21 (d, J = 1.3 Hz, 1H), 6.81 (s, 1H), 6.11-6.10 (m, 1H), 5.63-5.59 (m, 2H), 
4.22-4.19 (m, 1H), 1.30 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 161.4, 153.5 (d), 
141.3, 137.7 (d), 135.8 (d), 132.3 (dd), 131.9 (d), 131.6 (d), 131.2, 130.5, 128.6 (d), 
128.1 (d), 110.2, 107.4, 81.2, 60.9 (d), 54.2 (d), 27.8; 31P NMR (202 MHz, CDCl3) δ 
26.8 (s); HRMS (ESI) m/z calcd for C25H27NO4P [M+H]+ = 436.1672, found = 
436.1678; the ee value was 94%, tR (minor) = 27.4 min, tR (major) = 59.9 min 
(Chiralcel IC-H, λ = 254 nm, 20% iPrOH/hexanes, flow rate = 1.0 mL/min).  
 
(S)-tert-Butyl 1-(diphenylphosphoryl)-2-(thiophen-2-yl)-2,5-dihydro-1H-pyrrole-3-











A colorless oil; [α]26D = -106.8 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.90-
7.86 (m, 2H), 7.67-7.62 (m, 2H), 7.51-7.43 (m, 4H), 7.40-7.23 (m, 2H), 7.10 (d, J = 
5.1 Hz, 1H), 6.75 (s, 1H), 6.66-6.65 (m, 1H), 6.26 (d, J = 3.2, 1H), 5.85-5.81 (m, 1H), 
4.32-4.16 (m, 2H), 1.30 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 161.4, 146.5 (d), 
137.7 (d), 138.6 (d), 136.5 (d), 132.4 (d), 132.3 (d), 131.2 (d), 130.0 (d), 131.6 (d), 
131.0 (d), 130.0, 128.6 (d), 128.1 (d), 126.0, 125.4, 124.3, 81.3, 63.2 (d), 53.7 (d), 
27.8; 31P NMR (202 MHz, CDCl3) δ 27.5 (s); HRMS (ESI) m/z calcd for 
C25H27NO3PS [M+H]+ = 452.1444, found = 452.1449; the ee value was 95%, tR 
(minor) = 31.8 min, tR (major) = 53.5 min (Chiralcel IC-H, λ = 254 nm, 20% 
iPrOH/hexanes, flow rate = 1.0 mL/min). 
 
5.4.5 A Formal Synthesis of (+)-Trachelanthamidine  
 (R)-tert-Butyl 2-(3-(tert-butyldiphenylsilyloxy)propyl)-1-(diphenylphosphoryl)-2,5-
dihy- 1H-pyrrole-3-carboxylate (5-11) 
 
The cyclization product 5-9 (0.164 g, 82%) was prepared from imine 5-8 (0.158 
g, 0.3 mmol) and allene 5-2 (63 μL, 0.45 mmol), following the representative 
procedure described for the [3+2] annulation reaction. 
A  colorless oil; [α]26D = -38.4 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.90-




4.08 (m, 1H), 3.95-3.89 (m, 1H), 3.57 (t, J = 5.7 Hz, 2H), 1.73-1.69 (m, 2H), 1.44 (s, 
9H), 1.31-1.26 (m, 2H), 1.04 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 162.1, 137.5, 
135.5, 134.0 (d), 132.4 (d), 132.3 (d), 132.2, 132.0, 131.8, 131.3, 131.0, 129.5, 128.6 
(d), 128.4 (d), 127.5 (d), 81.1, 64.2, 63.9, 54.8 (d), 30.7, 28.0, 26.9, 26.5, 19.2; 31P 
NMR (202 MHz, CDCl3) δ 27.1 (s); HRMS (ESI) m/z calcd for C40H49NO4PSi 
[M+H]+ = 666.3163, found = 666.3180; the ee value was 96%, tR (minor) = 26.2 min, 






To a solution of 5-9 (0.164 g, 0.25 mmol) in CH2Cl2 (2 mL) at 0 °C were added 
successively MeOH (2 mL) and BF3·OEt2 (0.55 mL, 2.5 mmol). The mixture was 
stirred at 0 °C for 30 min and then at room temperature for 4 h. The aqueous layer 
was then separated, and the pH of which was adjusted to around 10 by with the 
addition of aqueous K2CO3. The aqueous layer was extracted with CH2Cl2 several 
times (3 x 8 mL), and the combined organic extracts were washed with brine, and 
dried over Na2SO4. Purification by column chromatography (hexane: ethyl acetate = 2: 
1) afforded 5-10 (56.7 mg, 76%) as a colorless oil. 
[α]26D = +12.3 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.73 (d, J = 1.9 Hz, 
1H), 4.19 (s, 1H), 3.86-3.82 (m, 4H), 3.65-3.55 (m, 2H), 1.97-1.92 (m, 1H), 1.71-1.64 
(m, 3H), 1.48 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 162.9, 139.6, 80.9, 63.9, 62.6, 
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52.1, 32.1, 29.1, 28.1; HRMS (ESI) m/z calcd for C12H22NO3 [M+H]+ = 228.1525, 





To a solution of 5-10 (30 mg, 0.13 mmol) in anhydrous CH2Cl2 (3 mL) at 0 oC 
was added triethylamine (22 μL, 0.16 mmol), followed by a slow addition of TsCl 
(25.2 mg, 0.13 mmol) in CH2Cl2 (0.5 mL) under N2. The resulting mixture was stirred 
at 0 oC for 2 hrs. The reaction was then quenched by the addition of H2O (5 mL), and 
the mixture was extracted with CH2Cl2 (3 × 8 mL). The combined organic extracts 
were washed with brine (10 mL), dried over Na2SO4, and purified by column 
chromatography (hexane: ethyl acetate = 2 : 1) to afford 5-11 (45.1 mg, 91%) as a 
white solid. 
[α]26D = -119.3 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.70 (d, J = 8.2 Hz, 
2H), 7.30 (d, J = 7.6 Hz, 2H), 6.46 (d, J = 1.3 Hz,  1H), 4.78 (d, J = 3.8 Hz, 1H), 4.20 
(t, J = 2.5 Hz, 2H), 3.65 (t, J = 6.0 Hz, 2H), 2.41 (s, 3H), 2.07-2.00 (m, 1H), 1.72-1.50 
(m, 3H), 1.44 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 161.5, 143.7, 136.3, 135.4, 
134.4, 129.8, 127.4, 81.7, 65.7, 62.7, 55.1, 30.0, 28.0, 27.0, 21.5; HRMS (ESI) m/z 
calcd for C19H27NNaO5S [M+Na]+ = 404.1502, found = 404.1508. 
 
5.4.6 Determination of Absolute Configurations of [3+2] 




5.4.6.1   Determination of Absolute Configurations of [3+2] Cyclization Adducts 




(R)-tert-Butyl 2-isopropyl-2,5-dihydro-1H-pyrrole-3-carboxylate (5-15) 
Compound 5-15 (30.8 mg, 73%) was prepared from 5-3j (0.082 g, 0.2 mmol), 
following the procedure described for the preparation of 5-10. 
[α]26D = -27.0 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.78-6.76 (m, 1H), 4.17 
(d, J = 2.5 Hz, 1H), 3.84 (t, J = 3.5 Hz, 2H), 2.24-2.18 (m, 2H), 1.51 (s, 9H), 1.00 (d, 
J = 6.3 Hz, 3H), 0.79 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 163.5, 140.1, 
138.5, 80.5, 69.3, 53.9, 30.9, 28.1, 20.3, 15.4; HRMS (ESI) m/z calcd for C12H22NO2 
[M+H]+ = 212.2576, found = 212.2568. 
 
(R)-tert-Butyl 2-isopropyl-1-tosyl-2,5-dihydro-1H-pyrrole-3-carboxylate (5-16) 
Compound 5-16 (34.3 mg, 93%) was prepared from 5-15 (0.021 g, 0.1 mmol), 
following the procedure described for the preparation of 5-11. 
[α]26D = -165.1 (c 1.00, CHCl3), (lit.6 [α] D = +105.6 (c 0.63, CHCl3)); 1H NMR (500 
MHz, CDCl3) δ 7.68 (d, J = 8.2 Hz, 2H), 7.26 (d, J = 7.6 Hz, 2H), 6.38 (s,  1H), 4.68 
(t, J = 3.4 Hz, 1H), 4.21-4.17 (m, 1H), 4.09-4.04 (m, 1H), 2.40 (s, H), 2.17-2.10 (m, 
1H), 1.42 (s, 9H), 1.06 (d, J = 7.0 Hz, 3H), 0.88 (d, J = 7.0 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 61.9, 143.5, 137.1, 135.6, 134.7, 129.6, 127.5, 81.4, 71.5, 65.8, 33.2, 
21.5, 19.3, 17.2; HRMS (ESI) m/z calcd for C19H28NO4S [M+H]+ = 366.1734, found 
= 366.1741. 
Chapter 5 [3+2] Cycloaddtion of Imines with Allenoates 
167 
 
The absolute configuration of 5-3j was determined as R, by comparing the 
optical rotation of 5-16 with the value reported in the literature.131 The absolute 
configurations of other [3+2] products derived from aliphatic DPP imines were 
assigned by analogy. 
 
5.4.6.2 Determination of Absolute Configurations of [3+2] Cyclization Adducts 

























(R)-Ethyl 2-phenyl-2,5-dihydro-1H-pyrrole-3-carboxylate (5-18) 
Compound 5-17 was prepared from 5-3m (0.15 g, 0.34 mmol), following the 
procedure described for the preparation of 5-10. After quickly passing through 
column, the crude 5-3m was used directly in the next step. 
Compound 5-3m from the previous step was dissolved in EtOH (3 mL), treated 
with aqueous HCl (0.6 mL, 12 N), and the mixture was heated to reflux for 3 h. The 
solvent was then removed, and the residue was diluted with water (4 mL). The 
aqueous mixture was extracted with EtOAc, the pH was adjusted to 10 with aqueous 
NaOH solution.  The combined extracts were concentrated and further dired over the 




























[α]26D = -65.3 (c 0.6, CHCl3); 1H NMR (500 MHz, D2O) δ 7.42-7.31 (m, 5H), 7.16 (d, 
J = 1.9 Hz, 1H), 5.30-5.29 (m, 1H), 4.12-4.04 (m, 3H), 3.99-3.95 (m, 1H), 1.10 (t, J = 












The compound 5-20 (67 mg, 80%) was prepared from imine 5-1m (0.061 g, 0.2 
mmol) and allene 5-19 (33 μL, 0.3 mmol), following the representative procedure 
described for the [3+2] annulation reaction. 
A colorless oil; [α]26D = -136.4 (c 1.00, CHCl3) (lit.7: [α] D = +161 (c 0.94, CHCl3)); 
1H NMR (500 MHz, CDCl3) δ 7.82-7.77 (m, 2H), 7.57-7.53 (m, 2H), 7.45 (t, J = 3.8 
Hz, 1H), 7.41-7.34 (m, 3H), 7.20-7.12 (m, 2H), 7.11-7.09 (m, 3H), 6.86-6.85 (m, 3H), 
5.53-5.49 (m, 1H), 4.44-4.37 (m, 1H), 4.34-4.28 (m, 1H), 4.06-3.93 (m, 2H), 1.08 (t, J 
= 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 162.2, 142.4 (d), 137.6 (d), 137.0 (d), 
132.4 (d), 132.0, 131.9 (d), 131.6 (d), 130.9, 130.0, 128.6 (d), 128.1 (d), 127.8, 127.4, 
127.2, 68.4 (d), 60.5, 54.7 (d), 13.9; 31P NMR (202 MHz, CDCl3) δ 27.2 (s); HRMS 
(ESI) m/z calcd for C25H25NO3P [M+H]+ = 418.1567, found = 418.1574; the ee value 
was 85%, tR (minor) = 39.1 min, tR (major) = 69.2 min (Chiralcel IC-H, λ = 254 nm, 
30% iPrOH/hexanes, flow rate = 1.0 mL/min). 
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The absolute configuration of 5-20 was was determined as R, by comparing its 
optical rotation with the value reported in the literature.50 Compound 5-20 was 
deprotected to afford 5-18 (a colorless oil, [α]26D = -52.6 (c 0.6, CHCl3)), which had 
same configuration as that was prepared from 5-3m. Thus, the configuration of 5-3m 
was assigned as R, and the absolute configurations of other [3+2] products derived 
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